[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"blog-posts-zh":3},[4,574,1807,2363,3263,3752,4076,4307,4604,4839,7166],{"_path":5,"_dir":6,"_draft":7,"_partial":7,"_locale":8,"title":9,"description":10,"cat":11,"icon":12,"accent":13,"date":14,"dateLabel":15,"read":16,"author":17,"image":18,"body":19,"_type":568,"_id":569,"_source":570,"_file":571,"_stem":572,"_extension":573},"\u002Fblog\u002Fzh\u002Fsemaglutide-lifespan-mice","zh",false,"","司美格鲁肽让老年小鼠多活 92 天：这项 Nature 研究说明了什么，又没说明什么","下面是一般性的科普内容，不是医疗建议，也不是鼓励你去弄点什么来用。我们要讲的这项研究是在小鼠身上做的。动物用量推不出人的用量，我们这里也不给任何用量。","研究","tabler:hourglass","#3F8A9B","2026-09-03","2026年9月","10 分钟","myPeptides Team","\u002Fassets\u002Fsema_ageing_hero.png",{"type":20,"children":21,"toc":555},"root",[22,29,34,40,45,125,130,135,140,146,151,156,169,174,201,206,211,216,228,233,238,250,260,281,287,292,304,309,314,319,331,336,371,377,382,387,392,397,402,407,419,424,429,442,462,467],{"type":23,"tag":24,"props":25,"children":26},"element","p",{},[27],{"type":28,"value":10},"text",{"type":23,"tag":24,"props":30,"children":31},{},[32],{"type":28,"value":33},"先说结论：2026 年 9 月 2 日，Nature 上线了一项研究——老年小鼠每天注射司美格鲁肽，中位寿命比对照组长了 92 天，也就是大约 12%。这项工作出自大学实验室，经费来自 NIH 的几笔资助，不是诺和诺德掏的钱。它拿出了一个“少吃就会瘦”解释不了的发现；同时它也有好几个地方，是从小鼠跳到人身上会断掉的。",{"type":23,"tag":35,"props":36,"children":38},"h2",{"id":37},"这项研究测的是什么",[39],{"type":28,"value":37},{"type":23,"tag":24,"props":41,"children":42},{},[43],{"type":28,"value":44},"加州大学伯克利分校 Danica Chen 的团队选的是 20 月龄的雌性小鼠——换算到人身上，大概相当于六十出头。从那时起，这些小鼠每天都要在皮下挨一针：要么是司美格鲁肽，要么是生理盐水。也就是说，对照组同样天天被抓出来扎一下，两组受到的操作应激是一样的。",{"type":23,"tag":46,"props":47,"children":48},"table",{},[49,68],{"type":23,"tag":50,"props":51,"children":52},"thead",{},[53],{"type":23,"tag":54,"props":55,"children":56},"tr",{},[57,63],{"type":23,"tag":58,"props":59,"children":60},"th",{},[61],{"type":28,"value":62},"指标",{"type":23,"tag":58,"props":64,"children":65},{},[66],{"type":28,"value":67},"结果",{"type":23,"tag":69,"props":70,"children":71},"tbody",{},[72,86,99,112],{"type":23,"tag":54,"props":73,"children":74},{},[75,81],{"type":23,"tag":76,"props":77,"children":78},"td",{},[79],{"type":28,"value":80},"中位寿命，对照组（39 只）",{"type":23,"tag":76,"props":82,"children":83},{},[84],{"type":28,"value":85},"742 天",{"type":23,"tag":54,"props":87,"children":88},{},[89,94],{"type":23,"tag":76,"props":90,"children":91},{},[92],{"type":28,"value":93},"中位寿命，司美格鲁肽组（40 只）",{"type":23,"tag":76,"props":95,"children":96},{},[97],{"type":28,"value":98},"834 天",{"type":23,"tag":54,"props":100,"children":101},{},[102,107],{"type":23,"tag":76,"props":103,"children":104},{},[105],{"type":28,"value":106},"差值",{"type":23,"tag":76,"props":108,"children":109},{},[110],{"type":28,"value":111},"92 天，约 12%",{"type":23,"tag":54,"props":113,"children":114},{},[115,120],{"type":23,"tag":76,"props":116,"children":117},{},[118],{"type":28,"value":119},"司美格鲁肽组的进食量",{"type":23,"tag":76,"props":121,"children":122},{},[123],{"type":28,"value":124},"−24%",{"type":23,"tag":24,"props":126,"children":127},{},[128],{"type":28,"value":129},"这个差距在统计上非常明确（P = 5.7 × 10⁻⁶），偶然这个解释基本可以排除。分析里没有剔掉任何一只动物。减掉的体重主要是脂肪，去脂体重的占比还上升了。",{"type":23,"tag":24,"props":131,"children":132},{},[133],{"type":28,"value":134},"你在媒体上有时看到 11%、有时看到 12%，两个都没错：92 天占 742 天是 12.4%，占 834 天是 11.0%——同一个数字，换了个分母而已。新闻稿里说的是“大约 100 天”；准确的数是 92，而且是中位数，不是平均数。",{"type":23,"tag":24,"props":136,"children":137},{},[138],{"type":28,"value":139},"还有一件事几乎所有报道都漏了：研究里其实是三组彼此独立的动物。寿命组那 79 只小鼠，从来没做过运动能力、记忆或干细胞的检测——那几项是另外的队列做的。“活得更久的小鼠同时也更硬朗”这句听着顺理成章的话，研究里一个字都没有，因为没有任何一只动物身上同时量过这两件事。",{"type":23,"tag":35,"props":141,"children":143},{"id":142},"真正的看点和节食比一比",[144],{"type":28,"value":145},"真正的看点：和节食比一比",{"type":23,"tag":24,"props":147,"children":148},{},[149],{"type":28,"value":150},"少喂食能让啮齿动物活得更久，这事从 1930 年代就知道了。所以最直白的解释应该是：司美格鲁肽压住了食欲，小鼠少吃了 24%，说白了就是用针管做的热量限制。",{"type":23,"tag":24,"props":152,"children":153},{},[154],{"type":28,"value":155},"作者恰恰查的就是这一点。他们另设了一组，把一部分动物的口粮精确减到和司美格鲁肽组自己少吃的一样多——同样是 24%，只不过一个靠食盆控制，一个靠食欲。在随后的五个月里，研究者对这两组加上一个对照组反复做了测试。",{"type":23,"tag":24,"props":157,"children":158},{},[159,161,167],{"type":28,"value":160},"在自发活动量、转棒平衡、倒挂悬吊和跑台耐力这几项上，司美格鲁肽和节食",{"type":23,"tag":162,"props":163,"children":164},"strong",{},[165],{"type":28,"value":166},"打成平手",{"type":28,"value":168},"——两组都守住了各自的起始水平，而对照组一路下滑。但在另外三项上，司美格鲁肽比节食更好，而且好过了起始水平：陌生环境里的探索行为、迷宫里的空间记忆，以及葡萄糖耐量。两组的体重和脂肪减少幅度相当，所以这几项差别不可能只是省下那点热量造成的。",{"type":23,"tag":24,"props":170,"children":171},{},[172],{"type":28,"value":173},"这是整篇论文里最有意思的发现。而它要打三处折扣，这三处得跟发现本身摆在一起说：",{"type":23,"tag":175,"props":176,"children":177},"ul",{},[178,191,196],{"type":23,"tag":179,"props":180,"children":181},"li",{},[182,184,189],{"type":28,"value":183},"节食组是整项研究里",{"type":23,"tag":162,"props":185,"children":186},{},[187],{"type":28,"value":188},"唯一没有设盲",{"type":28,"value":190},"的部分——喂多喂少，一看就知道。偏偏被引用最多的那个结论，就出自这个最容易受实验者影响的组，用的还是依赖行为观察的终点。",{"type":23,"tag":179,"props":192,"children":193},{},[194],{"type":28,"value":195},"终点有九个左右，每组十只动物，却没有针对这一整族终点做多重比较校正。三个“命中”只能算提出假设，不算优效性的证明。",{"type":23,"tag":179,"props":197,"children":198},{},[199],{"type":28,"value":200},"寿命这一项，压根就没有节食对照。这项研究没法回答司美格鲁肽延长寿命是不是比节食更强。",{"type":23,"tag":35,"props":202,"children":204},{"id":203},"身体里发生了什么",[205],{"type":28,"value":203},{"type":23,"tag":24,"props":207,"children":208},{},[209],{"type":28,"value":210},"作者查了司美格鲁肽是不是拨动了和热量限制同样的那些开关——大方向上是对的：肝脏和肌肉里的 NAD⁺ 升高，多个 Sirtuin 蛋白上调，血里的促生长因子 IGF1 下降，一个受 FOXO 调控的长寿基因转录增强。在肝组织里，炎症和脂代谢相关的程序走低，蛋白质质量控制和胰岛素应答走高。",{"type":23,"tag":24,"props":212,"children":213},{},[214],{"type":28,"value":215},"关于这一段，有两点要说清楚。第一，这不是一次严丝合缝的验证。七种 Sirtuin 并没有全部起反应，而且肝脏和肌肉里起反应的还不是同一批。这里很多结果测的是基因转录层面，每组只有五到六只动物——机制这部分的分量，明显比那条生存曲线要虚。第二，如果你一直在追长寿这条线的讨论：mTOR、AMPK 和雷帕霉素在这篇论文里根本没有出现过。谁要是从这项研究里读出了这几样，那是他自己加进去的。",{"type":23,"tag":24,"props":217,"children":218},{},[219,221,226],{"type":28,"value":220},"还有一个细节很容易被讲反：骨髓里造血干细胞的数量在司美格鲁肽组是",{"type":23,"tag":162,"props":222,"children":223},{},[224],{"type":28,"value":225},"下降",{"type":28,"value":227},"的，不是上升。这被视为好消息，因为这类细胞在衰老过程中会变多、质量却变差。把这个发现说成“干细胞更多了”，就是说反了。",{"type":23,"tag":35,"props":229,"children":231},{"id":230},"肌肉这一问",[232],{"type":28,"value":230},{"type":23,"tag":24,"props":234,"children":235},{},[236],{"type":28,"value":237},"对大多数读者来说，这才是最要紧的问题：它对肌肉、尤其是上了年纪之后的肌肉，到底做了什么？",{"type":23,"tag":24,"props":239,"children":240},{},[241,243,248],{"type":28,"value":242},"老实说，这项研究只回答了一半。",{"type":23,"tag":162,"props":244,"children":245},{},[246],{"type":28,"value":247},"表现",{"type":28,"value":249},"确实更好了——转棒上、倒挂网格的悬吊上、跑台上都是。前两项在按体重校正之后优势依然在；体重轻的动物本来就更容易吊住，这一点已经被扣掉了。",{"type":23,"tag":24,"props":251,"children":252},{},[253,258],{"type":23,"tag":162,"props":254,"children":255},{},[256],{"type":28,"value":257},"没有",{"type":28,"value":259},"测的是：以克为单位的去脂体重。文中只报告了它占体重的百分比——而只要总体重因为掉脂肪而下降，这个比例就必然上升。没有握力测量，没有单块肌肉的重量，也没有组织切片。想从这篇论文里论证“肌肉量保住了”，跟论证相反的结论一样，都缺料。",{"type":23,"tag":24,"props":261,"children":262},{},[263,265,270,272,279],{"type":28,"value":264},"另外还摆着一项方向相反的研究：Karasawa 等人 2025 年在 Cell Metabolism 上报告，用了司美格鲁肽的小鼠肌肉力量输出下降，而且这个下降",{"type":23,"tag":162,"props":266,"children":267},{},[268],{"type":28,"value":269},"不能",{"type":28,"value":271},"只用肌肉量流失来解释。研究设计不同，问的问题也不同——但方向是反着的。把两边同时摆在桌面上，比挑一边站队要诚实。这个问题在人身上的那一面，我们在",{"type":23,"tag":273,"props":274,"children":276},"a",{"href":275},"\u002Fblog\u002Fretatrutide-liver-damage-myths",[277],{"type":28,"value":278},"瑞它鲁肽与肝脏的事实核查",{"type":28,"value":280},"里聊得更细。",{"type":23,"tag":35,"props":282,"children":284},{"id":283},"大脑以及人身上的那次对照检验",[285],{"type":28,"value":286},"大脑——以及人身上的那次对照检验",{"type":23,"tag":24,"props":288,"children":289},{},[290],{"type":28,"value":291},"作者自己特别强调的一个发现和大脑有关：在齿状回——成年大脑里仍会长出新神经元的那个区域——司美格鲁肽组的神经新生明显更活跃。",{"type":23,"tag":24,"props":293,"children":294},{},[295,297,302],{"type":28,"value":296},"不过这条最适合当标题的结论，在人身上已经检验过一次了，结果是阴性。在 EVOKE 和 EVOKE+ 两项研究里，3,808 名早期阿尔茨海默病患者连续两年每天服用司美格鲁肽片剂。主要终点",{"type":23,"tag":162,"props":298,"children":299},{},[300],{"type":28,"value":301},"没有达到",{"type":28,"value":303},"，两项研究都差得明显；原计划的延长期也被中止了。部分炎症和 tau 标志物有轻微改善，另一些标志物甚至变差了。",{"type":23,"tag":24,"props":305,"children":306},{},[307],{"type":28,"value":308},"这并不推翻小鼠那边的发现——两边问的不是同一个问题：人体研究问的是司美格鲁肽能不能刹住已经发病的阿尔茨海默病，而不是它在健康的老化大脑里能做成什么。但这是最顺理成章的一次外推，它在迄今同类规模最大的试验里接受了检验，而且没有成功。",{"type":23,"tag":24,"props":310,"children":311},{},[312],{"type":28,"value":313},"还有一个更朴素的解释，不该被轻轻放过。神经科学家 Tara Spires-Jones 在英国科学媒体中心（Science Media Centre）提醒说，用了药的动物本来就动得更多——而运动对大脑的好处是有据可查的，路子还相当接近，中间根本不需要一个 GLP-1 药物。这项研究没办法排除这种可能。",{"type":23,"tag":35,"props":315,"children":317},{"id":316},"剂量为什么搬不过来",[318],{"type":28,"value":316},{"type":23,"tag":24,"props":320,"children":321},{},[322,324,329],{"type":28,"value":323},"小鼠拿到的是每公斤 10 nmol，",{"type":23,"tag":162,"props":325,"children":326},{},[327],{"type":28,"value":328},"每天",{"type":28,"value":330},"一针，打在皮下，一直打到生命结束。人是每周一针，通常打上几个月到几年，而且大多远不到 60 岁。",{"type":23,"tag":24,"props":332,"children":333},{},[334],{"type":28,"value":335},"你可以试着换算，只是不同的算法给出的答案并不一样。按监管机构惯用的体表面积折算，落到的是已获批维持剂量的那个量级；直接按每公斤体重硬折，小鼠拿到的就是八到十二倍。两个数都没错，只是它们回答的不是同一个问题——真正能比的，是血液里的药物暴露量，而这项研究没有测。司美格鲁肽在人体内大约能停留一周，在啮齿动物体内则要短上几个数量级；正因为如此，动物实验必须天天打。也就是说，小鼠经历的是每天一次的波峰和波谷，而每周一针的人身上是一条基本平坦的血药曲线。这两种模式究竟是哪一种造出了那个效应，没人知道——这项研究根本没测血药浓度。",{"type":23,"tag":24,"props":337,"children":338},{},[339,341,346,348,353,355,361,363,369],{"type":28,"value":340},"这里站得住的说法是：",{"type":23,"tag":162,"props":342,"children":343},{},[344],{"type":28,"value":345},"效应量级可比",{"type":28,"value":347},"——小鼠少吃了 24%，掉的主要是脂肪，这和人身上的量级差不多；",{"type":23,"tag":162,"props":349,"children":350},{},[351],{"type":28,"value":352},"剂量可比",{"type":28,"value":354},"则不成立。想搞明白单位和毫克为什么这么容易搞混，可以看",{"type":23,"tag":273,"props":356,"children":358},{"href":357},"\u002Fmg-ml-iu",[359],{"type":28,"value":360},"毫克、毫升和 IU",{"type":28,"value":362},"；搞错了会发生什么，看",{"type":23,"tag":273,"props":364,"children":366},{"href":365},"\u002Fblog\u002Fglp1-dosing-errors",[367],{"type":28,"value":368},"GLP-1 用药差错",{"type":28,"value":370},"。",{"type":23,"tag":35,"props":372,"children":374},{"id":373},"_12-算多吗",[375],{"type":28,"value":376},"12% 算多吗",{"type":23,"tag":24,"props":378,"children":379},{},[380],{"type":28,"value":381},"要给它找个参照，最合适的是这个领域里被研究得最透的那种抗衰老药物。雷帕霉素在与这项研究相同的生命阶段开始给药，把雌性小鼠的中位寿命延长了大约 15%。所以这里的 12% 属于同一个量级——扎实，但不是往上冒尖的异类。",{"type":23,"tag":24,"props":383,"children":384},{},[385],{"type":28,"value":386},"真正关键的是接下来这点：雷帕霉素是在干预测试计划（Interventions Testing Program）里测出来的。这是美国国立衰老研究所主持的项目，每种化合物都要在三个彼此独立的实验点同时测试，用的是遗传背景各异的小鼠，而且两种性别都测——之所以这么办，恰恰是因为这个领域里单个实验室的结果常常重复不出来。司美格鲁肽不在这些名单上，原因很朴素：那个项目里的化合物是掺在饲料里给的，而一种需要天天注射的肽，塞不进这套流程。",{"type":23,"tag":24,"props":388,"children":389},{},[390],{"type":28,"value":391},"所以这项研究是一个单实验点的结果，用的是单一品系、单一性别的小鼠，每组不到 40 只。寿命变长了，这在统计上很清楚；至于正好是 12%，那只是一个粗略的估计。而选用雌性动物是有意为之，为的是避开雄鼠之间的争斗——雄性那边，干脆就没有数据。",{"type":23,"tag":24,"props":393,"children":394},{},[395],{"type":28,"value":396},"还有一点对这批读者格外要紧，而且没有一篇报道提到：这些小鼠并不胖。它不是肥胖模型，动物吃的是普通饲料，上了年纪也守住了体重。也就是说，这个效应是在没有既往肥胖的前提下出现的。人这边恰好反过来——关于司美格鲁肽的证据，几乎全部来自超重人群。一个六十岁、身材偏瘦的人能不能得到同样的好处，还是说掉体重对他反而成了麻烦，眼下完全没有答案。",{"type":23,"tag":35,"props":398,"children":400},{"id":399},"这项研究是谁出的钱",[401],{"type":28,"value":399},{"type":23,"tag":24,"props":403,"children":404},{},[405],{"type":28,"value":406},"经费来自美国国立卫生研究院的三笔资助，不是厂家出的。诺和诺德的名字在文中一处也没出现。",{"type":23,"tag":24,"props":408,"children":409},{},[410,412,417],{"type":28,"value":411},"但有一条藏在附注里的信息还是得说，而且我们看到的所有报道都没提：加州大学就“GLP-1 受体激动剂用于健康衰老”提交了一份",{"type":23,"tag":162,"props":413,"children":414},{},[415],{"type":28,"value":416},"专利申请",{"type":28,"value":418},"。也就是说，通讯作者所在的机构，对这项研究考察的这个用途本身有经济利益。这不会让数据失效——但你读新闻稿里那些措辞的时候，得把这个背景放进去。",{"type":23,"tag":35,"props":420,"children":422},{"id":421},"结论",[423],{"type":28,"value":421},{"type":23,"tag":24,"props":425,"children":426},{},[427],{"type":28,"value":428},"这是一项好研究，里面有一个真实的发现：一种 GLP-1 药物在生命晚期才开始给药，让老年小鼠活得更久，也放慢了它们的衰退——在大约九项测量指标里的三项上，比省下同样热量的节食做得更好。对衰老研究来说，这是个值得认真对待的结果。",{"type":23,"tag":24,"props":430,"children":431},{},[432,434,440],{"type":28,"value":433},"对你来说，它什么也没有改变。关于司美格鲁肽和人类寿命，眼下没有任何人体数据；最顺理成章的那条大脑外推刚刚失败；肌肉的问题悬着；而这里真正起作用的那套“治疗”，是一天一针打到生命结束。司美格鲁肽是处方药，获批用于治疗肥胖症和 2 型糖尿病——还有哪些肽拿到了批准，可以看我们的 ",{"type":23,"tag":273,"props":435,"children":437},{"href":436},"\u002Ffda-approved-peptides",[438],{"type":28,"value":439},"FDA 已批准肽类清单",{"type":28,"value":441},"。“活得更久”不在其中，而这项研究里也没有任何一处，能当作为此用药的理由。",{"type":23,"tag":24,"props":443,"children":444},{},[445,447,453,455,461],{"type":28,"value":446},"想先搞懂这一类药物到底怎么起作用，从",{"type":23,"tag":273,"props":448,"children":450},{"href":449},"\u002Fwhat-are-peptides",[451],{"type":28,"value":452},"什么是肽",{"type":28,"value":454},"看起；至于这个具体药物的背景，看",{"type":23,"tag":273,"props":456,"children":458},{"href":457},"\u002Fglp1\u002Fsemaglutide",[459],{"type":28,"value":460},"司美格鲁肽",{"type":28,"value":370},{"type":23,"tag":35,"props":463,"children":465},{"id":464},"参考来源",[466],{"type":28,"value":464},{"type":23,"tag":175,"props":468,"children":469},{},[470,483,495,507,519,531,543],{"type":23,"tag":179,"props":471,"children":472},{},[473,475],{"type":28,"value":474},"Feng 等，Nature 2026，",{"type":23,"tag":273,"props":476,"children":480},{"href":477,"rel":478},"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41586-026-10940-7",[479],"nofollow",[481],{"type":28,"value":482},"Late-life semaglutide treatment slows ageing and extends lifespan in female mice",{"type":23,"tag":179,"props":484,"children":485},{},[486,488],{"type":28,"value":487},"Strong 等，Aging Cell 2020，",{"type":23,"tag":273,"props":489,"children":492},{"href":490,"rel":491},"https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002F10.1111\u002Facel.13269",[479],[493],{"type":28,"value":494},"Rapamycin-mediated mouse lifespan extension: Late-life dosage regimes with sex-specific effects",{"type":23,"tag":179,"props":496,"children":497},{},[498,500],{"type":28,"value":499},"Karasawa 等，Cell Metabolism 2025，",{"type":23,"tag":273,"props":501,"children":504},{"href":502,"rel":503},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F40769122\u002F",[479],[505],{"type":28,"value":506},"Unexpected effects of semaglutide on skeletal muscle mass and force-generating capacity in mice",{"type":23,"tag":179,"props":508,"children":509},{},[510,512],{"type":28,"value":511},"Cummings 等，The Lancet 2026，",{"type":23,"tag":273,"props":513,"children":516},{"href":514,"rel":515},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F41865758\u002F",[479],[517],{"type":28,"value":518},"Efficacy and safety of oral semaglutide in early-stage symptomatic Alzheimer's disease (evoke and evoke+)",{"type":23,"tag":179,"props":520,"children":521},{},[522,524],{"type":28,"value":523},"Lincoff 等，New England Journal of Medicine 2023，",{"type":23,"tag":273,"props":525,"children":528},{"href":526,"rel":527},"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2307563",[479],[529],{"type":28,"value":530},"Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)",{"type":23,"tag":179,"props":532,"children":533},{},[534,536],{"type":28,"value":535},"Di Francesco 等，Nature 2024，",{"type":23,"tag":273,"props":537,"children":540},{"href":538,"rel":539},"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41586-024-08026-3",[479],[541],{"type":28,"value":542},"Dietary restriction impacts health and lifespan of genetically diverse mice",{"type":23,"tag":179,"props":544,"children":545},{},[546,548],{"type":28,"value":547},"Harrison 等，Nature 2009，",{"type":23,"tag":273,"props":549,"children":552},{"href":550,"rel":551},"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fnature08221",[479],[553],{"type":28,"value":554},"Rapamycin fed late in life extends lifespan in genetically heterogeneous mice",{"title":8,"searchDepth":556,"depth":556,"links":557},2,[558,559,560,561,562,563,564,565,566,567],{"id":37,"depth":556,"text":37},{"id":142,"depth":556,"text":145},{"id":203,"depth":556,"text":203},{"id":230,"depth":556,"text":230},{"id":283,"depth":556,"text":286},{"id":316,"depth":556,"text":316},{"id":373,"depth":556,"text":376},{"id":399,"depth":556,"text":399},{"id":421,"depth":556,"text":421},{"id":464,"depth":556,"text":464},"markdown","content:blog:zh:semaglutide-lifespan-mice.md","content","blog\u002Fzh\u002Fsemaglutide-lifespan-mice.md","blog\u002Fzh\u002Fsemaglutide-lifespan-mice","md",{"_path":575,"_dir":6,"_draft":7,"_partial":7,"_locale":8,"title":576,"description":577,"cat":11,"icon":578,"accent":579,"date":580,"dateLabel":581,"read":582,"author":17,"image":583,"body":584,"_type":568,"_id":1804,"_source":570,"_file":1805,"_stem":1806,"_extension":573},"\u002Fblog\u002Fzh\u002Fnisotirostide-ly3457263","Nisotirostide（LY3457263）：一款只以「叠加」形式存在的 PYY 药物，以及数据真正说了什么","这里讲的是通识科普，不是医疗建议，也不是叫你去弄或者去用任何东西。Nisotirostide 是在研药物，全球任何地方都未获批准，既不能合法购买，也开不出处方。剂量我们一个字都不给——因为压根就没有公开的剂量，原因下文会说。文中的数字来自不同试验，人群和时长都不一样，不是头对头比较。","tabler:flask-2","#2E9E8F","2026-08-05","2026年8月","12 min","\u002Fassets\u002Fnisotirostide_hero.png",{"type":20,"children":585,"toc":1792},[586,590,609,614,620,639,677,694,706,711,716,879,897,902,907,913,922,947,964,969,981,987,992,1004,1016,1028,1033,1104,1109,1127,1139,1144,1150,1161,1192,1202,1302,1314,1319,1324,1547,1552,1558,1563,1568,1573,1591,1596,1608,1613,1618,1647,1651,1656,1660],{"type":23,"tag":24,"props":587,"children":588},{},[589],{"type":28,"value":577},{"type":23,"tag":24,"props":591,"children":592},{},[593,595,600,602,607],{"type":28,"value":594},"最近几个月论坛上冒出一个新名字，说法几乎千篇一律：",{"type":23,"tag":162,"props":596,"children":597},{},[598],{"type":28,"value":599},"Nisotirostide",{"type":28,"value":601},"，「加在替尔泊肽或司美格鲁肽上面的那个东西」。它的代号是 ",{"type":23,"tag":162,"props":603,"children":604},{},[605],{"type":28,"value":606},"LY3457263",{"type":28,"value":608},"，公司是礼来。和绝大多数灰市新词不同，这套说法里有一部分是真的：这个分子确实就是按「加在别人上面」设计的。没有任何一项试验让它在肥胖人群里单独对照安慰剂——组合不是生物黑客的自行发挥，而是试验方案本身。",{"type":23,"tag":24,"props":610,"children":611},{},[612],{"type":28,"value":613},"只是同一轮查证还翻出了第二个发现，很不好听，而它在这篇文章里的分量和第一个一样重。",{"type":23,"tag":35,"props":615,"children":617},{"id":616},"nisotirostide-到底是什么",[618],{"type":28,"value":619},"Nisotirostide 到底是什么",{"type":23,"tag":24,"props":621,"children":622},{},[623,625,630,632,637],{"type":28,"value":624},"Nisotirostide 是一种",{"type":23,"tag":162,"props":626,"children":627},{},[628],{"type":28,"value":629},"激活 Y2 受体的合成肽",{"type":28,"value":631},"（Y2 受体也写作 NPY2R），说白了就是长效的 ",{"type":23,"tag":162,"props":633,"children":634},{},[635],{"type":28,"value":636},"PYY",{"type":28,"value":638}," 类似物，每周皮下注射一次。",{"type":23,"tag":24,"props":640,"children":641},{},[642,644,650,652,661,663,669,671,675],{"type":28,"value":643},"PYY 是人体自己的饱腹信号。小肠下段和结肠里的 L 细胞在进食后把它释放出来——和 GLP-1 一起，出自同一批细胞。进入血液后，释放出来的 PYY",{"type":23,"tag":645,"props":646,"children":647},"sub",{},[648],{"type":28,"value":649},"1-36",{"type":28,"value":651}," 会被剪短成 ",{"type":23,"tag":162,"props":653,"children":654},{},[655,656],{"type":28,"value":636},{"type":23,"tag":645,"props":657,"children":658},{},[659],{"type":28,"value":660},"3-36",{"type":28,"value":662},"，这一剪就换了收件人：长的那一版还会结合 Y1 和 Y5，而这两个受体是",{"type":23,"tag":664,"props":665,"children":666},"em",{},[667],{"type":28,"value":668},"促进",{"type":28,"value":670},"食欲的；PYY",{"type":23,"tag":645,"props":672,"children":673},{},[674],{"type":28,"value":660},{"type":28,"value":676}," 则几乎只找 Y2，而 Y2 是把饥饿感往下压的。所以肥胖研究从来只关心短的那一版。",{"type":23,"tag":24,"props":678,"children":679},{},[680,682,686,688,692],{"type":28,"value":681},"它一直没能变成药，卡在两点上：天然 PYY",{"type":23,"tag":645,"props":683,"children":684},{},[685],{"type":28,"value":660},{"type":28,"value":687}," 的半衰期只有大约 ",{"type":23,"tag":162,"props":689,"children":690},{},[691],{"type":28,"value":16},{"type":28,"value":693},"，而能让人明显有饱腹感的剂量又会引起恶心。治疗窗窄到这个地步，很难再窄了。整个现代 PYY 类似物家族——包括 Nisotirostide——干的都是同一件事：把这扇窗撑开。把肽改造成能维持几天而不是几分钟，同时让它尽可能只认 Y2，免得顺手激活了那些反而开胃的亲戚。",{"type":23,"tag":24,"props":695,"children":696},{},[697,699,704],{"type":28,"value":698},"有一点要拎清楚：它",{"type":23,"tag":162,"props":700,"children":701},{},[702],{"type":28,"value":703},"不是肠促胰素",{"type":28,"value":705},"。Nisotirostide 不是 GLP-1，不是 GIP，也不是胰高血糖素激动剂，而是一根完全不同的杠杆——这恰恰是它作为搭配对象有意思的地方。两个 GLP-1 叠在一起，无非是把同一个受体打两遍；把 Y2 激动剂放在 GLP-1 旁边，才是真的开了第二条路。",{"type":23,"tag":35,"props":707,"children":709},{"id":708},"大多数文章写到这里就停了",[710],{"type":28,"value":708},{"type":23,"tag":24,"props":712,"children":713},{},[714],{"type":28,"value":715},"真去翻试验登记，会看到一个异常整齐的规律。这就是 LY3457263 全部公开的临床项目：",{"type":23,"tag":46,"props":717,"children":718},{},[719,750],{"type":23,"tag":50,"props":720,"children":721},{},[722],{"type":23,"tag":54,"props":723,"children":724},{},[725,730,735,740,745],{"type":23,"tag":58,"props":726,"children":727},{},[728],{"type":28,"value":729},"试验",{"type":23,"tag":58,"props":731,"children":732},{},[733],{"type":28,"value":734},"期别",{"type":23,"tag":58,"props":736,"children":737},{},[738],{"type":28,"value":739},"人群",{"type":23,"tag":58,"props":741,"children":742},{},[743],{"type":28,"value":744},"测的是什么",{"type":23,"tag":58,"props":746,"children":747},{},[748],{"type":28,"value":749},"状态",{"type":23,"tag":69,"props":751,"children":752},{},[753,786,818,848],{"type":23,"tag":54,"props":754,"children":755},{},[756,761,766,771,781],{"type":23,"tag":76,"props":757,"children":758},{},[759],{"type":28,"value":760},"NCT04641312",{"type":23,"tag":76,"props":762,"children":763},{},[764],{"type":28,"value":765},"1",{"type":23,"tag":76,"props":767,"children":768},{},[769],{"type":28,"value":770},"健康人 + 2 型糖尿病，n = 67",{"type":23,"tag":76,"props":772,"children":773},{},[774,776],{"type":28,"value":775},"单次给药，单用",{"type":23,"tag":162,"props":777,"children":778},{},[779],{"type":28,"value":780},"以及与度拉糖肽合用",{"type":23,"tag":76,"props":782,"children":783},{},[784],{"type":28,"value":785},"2021\u002F12 完成",{"type":23,"tag":54,"props":787,"children":788},{},[789,794,798,803,813],{"type":23,"tag":76,"props":790,"children":791},{},[792],{"type":28,"value":793},"NCT05377333",{"type":23,"tag":76,"props":795,"children":796},{},[797],{"type":28,"value":765},{"type":23,"tag":76,"props":799,"children":800},{},[801],{"type":28,"value":802},"2 型糖尿病，n = 94",{"type":23,"tag":76,"props":804,"children":805},{},[806,808],{"type":28,"value":807},"多次给药，单用",{"type":23,"tag":162,"props":809,"children":810},{},[811],{"type":28,"value":812},"以及与 GLP‑1 受体激动剂合用",{"type":23,"tag":76,"props":814,"children":815},{},[816],{"type":28,"value":817},"2023\u002F11 完成",{"type":23,"tag":54,"props":819,"children":820},{},[821,826,830,835,843],{"type":23,"tag":76,"props":822,"children":823},{},[824],{"type":28,"value":825},"NCT05582096",{"type":23,"tag":76,"props":827,"children":828},{},[829],{"type":28,"value":765},{"type":23,"tag":76,"props":831,"children":832},{},[833],{"type":28,"value":834},"超重\u002F肥胖，n = 38",{"type":23,"tag":76,"props":836,"children":837},{},[838],{"type":23,"tag":162,"props":839,"children":840},{},[841],{"type":28,"value":842},"仅与替尔泊肽联用",{"type":23,"tag":76,"props":844,"children":845},{},[846],{"type":28,"value":847},"2023\u002F06 完成",{"type":23,"tag":54,"props":849,"children":850},{},[851,856,861,866,874],{"type":23,"tag":76,"props":852,"children":853},{},[854],{"type":28,"value":855},"NCT06897475",{"type":23,"tag":76,"props":857,"children":858},{},[859],{"type":28,"value":860},"2",{"type":23,"tag":76,"props":862,"children":863},{},[864],{"type":28,"value":865},"2 型糖尿病，n = 240",{"type":23,"tag":76,"props":867,"children":868},{},[869],{"type":23,"tag":162,"props":870,"children":871},{},[872],{"type":28,"value":873},"加在司美格鲁肽或替尔泊肽之上",{"type":23,"tag":76,"props":875,"children":876},{},[877],{"type":28,"value":878},"招募中，2027\u002F01 结束",{"type":23,"tag":24,"props":880,"children":881},{},[882,884,890,892],{"type":28,"value":883},"四项试验，每一项里都坐着一个 GLP-1。唯一一项在肥胖人群里做的——NCT05582096——只测了与",{"type":23,"tag":273,"props":885,"children":887},{"href":886},"\u002Fglp1\u002Ftirzepatide",[888],{"type":28,"value":889},"替尔泊肽",{"type":28,"value":891},"的组合，做了十一周，38 个人，主要终点是耐受性而不是体重。",{"type":23,"tag":162,"props":893,"children":894},{},[895],{"type":28,"value":896},"而且到今天都没有公布结果。",{"type":23,"tag":24,"props":898,"children":899},{},[900],{"type":28,"value":901},"第二个发现就在这儿，也是难听的那个。那项肥胖试验 2023 年 6 月结束，之后并没有跟上任何一个减重的二期。2025 年 3 月启动的那个，是糖尿病试验。药物数据库现在已经把 Nisotirostide 的肥胖适应症标为「非活跃」，最高只走到一期。真正在推进的路线是 2 型糖尿病。",{"type":23,"tag":24,"props":903,"children":904},{},[905],{"type":28,"value":906},"也别过度解读：公司搁置项目的理由多得很，礼来在代谢管线的投资者材料里也仍然放着这个分子。但「Nisotirostide 减肥针即将上市」这幅图，跟档案一对就散了。",{"type":23,"tag":35,"props":908,"children":910},{"id":909},"正在做的那项试验究竟在测什么",[911],{"type":28,"value":912},"正在做的那项试验，究竟在测什么",{"type":23,"tag":24,"props":914,"children":915},{},[916,920],{"type":23,"tag":162,"props":917,"children":918},{},[919],{"type":28,"value":855},{"type":28,"value":921}," 是眼下正在跑的研究，值得逐条读，因为它被引用错的次数实在太多。",{"type":23,"tag":24,"props":923,"children":924},{},[925,927,932,934,938,940,945],{"type":28,"value":926},"入组的是",{"type":23,"tag":162,"props":928,"children":929},{},[930],{"type":28,"value":931},"2 型糖尿病",{"type":28,"value":933},"成人，HbA1c 在 7.5% 到 10.5% 之间，BMI 不低于 27，已经稳定使用",{"type":23,"tag":273,"props":935,"children":936},{"href":457},[937],{"type":28,"value":460},{"type":28,"value":939},"或替尔泊肽至少三个月，",{"type":23,"tag":162,"props":941,"children":942},{},[943],{"type":28,"value":944},"血糖却仍然没达标",{"type":28,"value":946},"。这些人在原有治疗之上，每周再加一针 Nisotirostide 或安慰剂，共三个盲态剂量组。240 人，双盲，研究中心分布在美国、加拿大、德国、波兰、波多黎各和英国。",{"type":23,"tag":24,"props":948,"children":949},{},[950,955,957,962],{"type":23,"tag":162,"props":951,"children":952},{},[953],{"type":28,"value":954},"主要终点是第 24 周的 HbA1c 降幅",{"type":28,"value":956},"，体重变化是",{"type":23,"tag":664,"props":958,"children":959},{},[960],{"type":28,"value":961},"次要",{"type":28,"value":963},"终点。这不是咬文嚼字：试验的样本量是按主要终点算的，入组标准也跟着它走。这里挑的是血糖失控的人，不是想把体重减到最多的人。",{"type":23,"tag":24,"props":965,"children":966},{},[967],{"type":28,"value":968},"至于剂量：三个组的名字就直接叫「Dose 1」「Dose 2」「Dose 3」，具体毫克数没有公开。所以谁要是给你报一个 Nisotirostide 的剂量，那不是从试验里读来的——试验里根本没写。",{"type":23,"tag":24,"props":970,"children":971},{},[972,974,979],{"type":28,"value":973},"最早可能出结果的时间点是 ",{"type":23,"tag":162,"props":975,"children":976},{},[977],{"type":28,"value":978},"2026 年 12 月",{"type":28,"value":980},"的主要完成日，整项研究到 2027 年 1 月收尾。",{"type":23,"tag":35,"props":982,"children":984},{"id":983},"一个-pyy-类似物叠上去实际能换来多少",[985],{"type":28,"value":986},"一个 PYY 类似物叠上去，实际能换来多少",{"type":23,"tag":24,"props":988,"children":989},{},[990],{"type":28,"value":991},"关于 Nisotirostide 本身，没有已发表的疗效数据。但关于这一类药物有——而且有一项记录得异常干净的实验，问的恰好就是我们关心的问题：在已经用着司美格鲁肽的基础上，加一个每周一次的 Y2 类似物，会怎样？",{"type":23,"tag":24,"props":993,"children":994},{},[995,997,1002],{"type":28,"value":996},"诺和诺德用它自己的分子 ",{"type":23,"tag":162,"props":998,"children":999},{},[1000],{"type":28,"value":1001},"PYY1875",{"type":28,"value":1003}," 把这件事从大鼠一路做到二期，2025 年整套发表。分子和 Nisotirostide 不同，原理一模一样：选择性 Y2 激动剂，半衰期约 10 天，每周一针。",{"type":23,"tag":24,"props":1005,"children":1006},{},[1007,1009,1014],{"type":28,"value":1008},"**动物实验里效果相当惊人。**肥胖大鼠单用司美格鲁肽掉了 12.5% 的体重，司美格鲁肽加 PYY1875 则掉了 ",{"type":23,"tag":162,"props":1010,"children":1011},{},[1012],{"type":28,"value":1013},"24.6%",{"type":28,"value":1015},"，进食量从 389 克降到 215 克。顺带一提，PYY1875 单用什么也没干成，那组动物反而还长胖了。效果只存在于组合之中——教科书式的协同。",{"type":23,"tag":24,"props":1017,"children":1018},{},[1019,1021,1026],{"type":28,"value":1020},"**到了人身上，剩下的就没多少了。**二期的设计是严丝合缝对着「叠加」这个问题来的：先开放标签用 32 周司美格鲁肽 2.4 mg 打底，这一段受试者平均减掉 14.3%，从 102.1 公斤降到 87.5 公斤；",{"type":23,"tag":664,"props":1022,"children":1023},{},[1024],{"type":28,"value":1025},"然后",{"type":28,"value":1027},"才随机分组，在继续用司美格鲁肽的前提下加 PYY1875 或安慰剂。",{"type":23,"tag":24,"props":1029,"children":1030},{},[1031],{"type":28,"value":1032},"再走 16 周之后的结果：",{"type":23,"tag":46,"props":1034,"children":1035},{},[1036,1050],{"type":23,"tag":50,"props":1037,"children":1038},{},[1039],{"type":23,"tag":54,"props":1040,"children":1041},{},[1042,1045],{"type":23,"tag":58,"props":1043,"children":1044},{},[],{"type":23,"tag":58,"props":1046,"children":1047},{},[1048],{"type":28,"value":1049},"第 32 周之后额外减掉的体重",{"type":23,"tag":69,"props":1051,"children":1052},{},[1053,1066,1079],{"type":23,"tag":54,"props":1054,"children":1055},{},[1056,1061],{"type":23,"tag":76,"props":1057,"children":1058},{},[1059],{"type":28,"value":1060},"PYY1875 1.0 mg + 司美格鲁肽 2.4 mg",{"type":23,"tag":76,"props":1062,"children":1063},{},[1064],{"type":28,"value":1065},"−5.6%",{"type":23,"tag":54,"props":1067,"children":1068},{},[1069,1074],{"type":23,"tag":76,"props":1070,"children":1071},{},[1072],{"type":28,"value":1073},"安慰剂 + 司美格鲁肽 2.4 mg",{"type":23,"tag":76,"props":1075,"children":1076},{},[1077],{"type":28,"value":1078},"−3.1%",{"type":23,"tag":54,"props":1080,"children":1081},{},[1082,1089],{"type":23,"tag":76,"props":1083,"children":1084},{},[1085],{"type":23,"tag":162,"props":1086,"children":1087},{},[1088],{"type":28,"value":106},{"type":23,"tag":76,"props":1090,"children":1091},{},[1092,1097,1099],{"type":23,"tag":162,"props":1093,"children":1094},{},[1095],{"type":28,"value":1096},"−2.2 个百分点",{"type":28,"value":1098},"（95% CI −4.2 至 −0.1），约合 ",{"type":23,"tag":162,"props":1100,"children":1101},{},[1102],{"type":28,"value":1103},"2.2 公斤",{"type":23,"tag":24,"props":1105,"children":1106},{},[1107],{"type":28,"value":1108},"两公斤。统计学上勉强站住，置信区间的下缘几乎贴到零。",{"type":23,"tag":24,"props":1110,"children":1111},{},[1112,1114,1119,1121,1126],{"type":28,"value":1113},"代价却不小。",{"type":23,"tag":162,"props":1115,"children":1116},{},[1117],{"type":28,"value":1118},"联合组有 68% 的人出现胃肠道不良反应",{"type":28,"value":1120},"，而司美格鲁肽加安慰剂那组是 29%。重度事件：15% 对 4%。因不良反应停药：21.3% 对 10.7%。47 名受试者里只有 30 人曾经加到目标剂量，到治疗结束时还留在目标剂量上的仅剩 ",{"type":23,"tag":162,"props":1122,"children":1123},{},[1124],{"type":28,"value":1125},"20 人，也就是 42.6%",{"type":28,"value":370},{"type":23,"tag":24,"props":1128,"children":1129},{},[1130,1132,1137],{"type":28,"value":1131},"更高的那个剂量组干脆没做完：八个人里有",{"type":23,"tag":162,"props":1133,"children":1134},{},[1135],{"type":28,"value":1136},"七个",{"type":28,"value":1138},"在第 3 到第 12 周之间因为胃肠道反应退出。作者的结论原文是：作为司美格鲁肽的加药，疗效有限，「但耐受性并不好」。",{"type":23,"tag":24,"props":1140,"children":1141},{},[1142],{"type":28,"value":1143},"这不是脚注，而是关于这个思路目前最有信息量的一个数据点。它不代表 Nisotirostide 注定失败——分子不同、选择性不同、爬坡方案不同，而且礼来用替尔泊肽证明过自己是把耐受性当回事的。但它把举证责任挪了个位置。谁要说 PYY 类似物是你 GLP-1 方案的大幅增效器，就得解释清楚这次凭什么不一样。",{"type":23,"tag":35,"props":1145,"children":1147},{"id":1146},"竞争对手以及这场比赛为什么已经换了场地",[1148],{"type":28,"value":1149},"竞争对手——以及这场比赛为什么已经换了场地",{"type":23,"tag":24,"props":1151,"children":1152},{},[1153,1155,1160],{"type":28,"value":1154},"就在 PYY 上着这一课的同时，另一类药物把「GLP-1 上面该加什么」回答得相当有说服力：",{"type":23,"tag":162,"props":1156,"children":1157},{},[1158],{"type":28,"value":1159},"胰淀素",{"type":28,"value":370},{"type":23,"tag":24,"props":1162,"children":1163},{},[1164,1169,1171,1176,1178,1183,1185,1190],{"type":23,"tag":162,"props":1165,"children":1166},{},[1167],{"type":28,"value":1168},"CagriSema",{"type":28,"value":1170},"（卡格列奈肽 + 司美格鲁肽，诺和诺德）是已经做完的那份答卷。三期试验 REDEFINE 1 纳入 3417 名无 2 型糖尿病的成人，第 68 周平均减重 ",{"type":23,"tag":162,"props":1172,"children":1173},{},[1174],{"type":28,"value":1175},"20.4%",{"type":28,"value":1177},"；在完整坚持治疗的人群中是 ",{"type":23,"tag":162,"props":1179,"children":1180},{},[1181],{"type":28,"value":1182},"22.7%",{"type":28,"value":1184},"，其中 40.4% 减掉了至少四分之一的体重。同一项试验里作对照：卡格列奈肽单用 11.5%，司美格鲁肽单用 14.9%，安慰剂 3%。在",{"type":23,"tag":162,"props":1186,"children":1187},{},[1188],{"type":28,"value":1189},"合并",{"type":28,"value":1191},"2 型糖尿病人群的 REDEFINE 2 中，是 13.7% 对安慰剂 3.4%，并有 74% 的人把 HbA1c 降到 6.5% 及以下。",{"type":23,"tag":24,"props":1193,"children":1194},{},[1195,1200],{"type":23,"tag":162,"props":1196,"children":1197},{},[1198],{"type":28,"value":1199},"Eloralintide",{"type":28,"value":1201},"（LY3841136）是礼来自家的胰淀素——它的数字也解释了公司内部的注意力在往哪儿挪。2025 年 11 月公布的 48 周二期，263 名无糖尿病成人：",{"type":23,"tag":46,"props":1203,"children":1204},{},[1205,1221],{"type":23,"tag":50,"props":1206,"children":1207},{},[1208],{"type":23,"tag":54,"props":1209,"children":1210},{},[1211,1216],{"type":23,"tag":58,"props":1212,"children":1213},{},[1214],{"type":28,"value":1215},"Eloralintide，每周一次",{"type":23,"tag":58,"props":1217,"children":1218},{},[1219],{"type":28,"value":1220},"48 周减重",{"type":23,"tag":69,"props":1222,"children":1223},{},[1224,1237,1250,1263,1276,1289],{"type":23,"tag":54,"props":1225,"children":1226},{},[1227,1232],{"type":23,"tag":76,"props":1228,"children":1229},{},[1230],{"type":28,"value":1231},"1 mg",{"type":23,"tag":76,"props":1233,"children":1234},{},[1235],{"type":28,"value":1236},"−9.5%",{"type":23,"tag":54,"props":1238,"children":1239},{},[1240,1245],{"type":23,"tag":76,"props":1241,"children":1242},{},[1243],{"type":28,"value":1244},"3 mg",{"type":23,"tag":76,"props":1246,"children":1247},{},[1248],{"type":28,"value":1249},"−12.4%",{"type":23,"tag":54,"props":1251,"children":1252},{},[1253,1258],{"type":23,"tag":76,"props":1254,"children":1255},{},[1256],{"type":28,"value":1257},"6 mg",{"type":23,"tag":76,"props":1259,"children":1260},{},[1261],{"type":28,"value":1262},"−17.6%",{"type":23,"tag":54,"props":1264,"children":1265},{},[1266,1271],{"type":23,"tag":76,"props":1267,"children":1268},{},[1269],{"type":28,"value":1270},"9 mg",{"type":23,"tag":76,"props":1272,"children":1273},{},[1274],{"type":28,"value":1275},"−20.1%",{"type":23,"tag":54,"props":1277,"children":1278},{},[1279,1284],{"type":23,"tag":76,"props":1280,"children":1281},{},[1282],{"type":28,"value":1283},"6\u002F9 mg 爬坡",{"type":23,"tag":76,"props":1285,"children":1286},{},[1287],{"type":28,"value":1288},"−19.9%",{"type":23,"tag":54,"props":1290,"children":1291},{},[1292,1297],{"type":23,"tag":76,"props":1293,"children":1294},{},[1295],{"type":28,"value":1296},"安慰剂",{"type":23,"tag":76,"props":1298,"children":1299},{},[1300],{"type":28,"value":1301},"−0.4%",{"type":23,"tag":24,"props":1303,"children":1304},{},[1305,1307,1312],{"type":28,"value":1306},"二十个百分点——而且是",{"type":23,"tag":162,"props":1308,"children":1309},{},[1310],{"type":28,"value":1311},"单药",{"type":28,"value":1313},"，旁边没有任何肠促胰素。真正值得注意的是耐受性：以轻到中度的胃肠道症状和乏力为主，1 mg 和 3 mg 组与安慰剂相当，爬坡放慢之后还明显更少。礼来已经宣布启动单药三期，同时在并行测试与替尔泊肽的组合。",{"type":23,"tag":24,"props":1315,"children":1316},{},[1317],{"type":28,"value":1318},"把这两张图并排放着看。Y2 激动剂加在司美格鲁肽上，买到大约两个百分点，代价是三分之二的人不舒服；胰淀素激动剂自己就买到二十个百分点，而且耐受良好。钱会往哪边流，没什么悬念。",{"type":23,"tag":24,"props":1320,"children":1321},{},[1322],{"type":28,"value":1323},"其余的赛道，一并列全：",{"type":23,"tag":46,"props":1325,"children":1326},{},[1327,1352],{"type":23,"tag":50,"props":1328,"children":1329},{},[1330],{"type":23,"tag":54,"props":1331,"children":1332},{},[1333,1338,1343,1348],{"type":23,"tag":58,"props":1334,"children":1335},{},[1336],{"type":28,"value":1337},"药物",{"type":23,"tag":58,"props":1339,"children":1340},{},[1341],{"type":28,"value":1342},"是什么",{"type":23,"tag":58,"props":1344,"children":1345},{},[1346],{"type":28,"value":1347},"自家试验的最好成绩",{"type":23,"tag":58,"props":1349,"children":1350},{},[1351],{"type":28,"value":749},{"type":23,"tag":69,"props":1353,"children":1354},{},[1355,1380,1405,1431,1457,1483,1513],{"type":23,"tag":54,"props":1356,"children":1357},{},[1358,1365,1370,1375],{"type":23,"tag":76,"props":1359,"children":1360},{},[1361],{"type":23,"tag":162,"props":1362,"children":1363},{},[1364],{"type":28,"value":1168},{"type":23,"tag":76,"props":1366,"children":1367},{},[1368],{"type":28,"value":1369},"胰淀素 + GLP‑1（诺和诺德）",{"type":23,"tag":76,"props":1371,"children":1372},{},[1373],{"type":28,"value":1374},"68 周 22.7%",{"type":23,"tag":76,"props":1376,"children":1377},{},[1378],{"type":28,"value":1379},"三期已完成",{"type":23,"tag":54,"props":1381,"children":1382},{},[1383,1390,1395,1400],{"type":23,"tag":76,"props":1384,"children":1385},{},[1386],{"type":23,"tag":162,"props":1387,"children":1388},{},[1389],{"type":28,"value":1199},{"type":23,"tag":76,"props":1391,"children":1392},{},[1393],{"type":28,"value":1394},"选择性胰淀素（礼来）",{"type":23,"tag":76,"props":1396,"children":1397},{},[1398],{"type":28,"value":1399},"48 周 20.1%，单药",{"type":23,"tag":76,"props":1401,"children":1402},{},[1403],{"type":28,"value":1404},"三期启动中",{"type":23,"tag":54,"props":1406,"children":1407},{},[1408,1416,1421,1426],{"type":23,"tag":76,"props":1409,"children":1410},{},[1411],{"type":23,"tag":162,"props":1412,"children":1413},{},[1414],{"type":28,"value":1415},"Petrelintide",{"type":23,"tag":76,"props":1417,"children":1418},{},[1419],{"type":28,"value":1420},"胰淀素（Zealand\u002F罗氏）",{"type":23,"tag":76,"props":1422,"children":1423},{},[1424],{"type":28,"value":1425},"42 周 10.7%",{"type":23,"tag":76,"props":1427,"children":1428},{},[1429],{"type":28,"value":1430},"二期阳性（2026\u002F03）",{"type":23,"tag":54,"props":1432,"children":1433},{},[1434,1442,1447,1452],{"type":23,"tag":76,"props":1435,"children":1436},{},[1437],{"type":23,"tag":162,"props":1438,"children":1439},{},[1440],{"type":28,"value":1441},"Amycretin",{"type":23,"tag":76,"props":1443,"children":1444},{},[1445],{"type":28,"value":1446},"GLP‑1 + 胰淀素合一（诺和诺德）",{"type":23,"tag":76,"props":1448,"children":1449},{},[1450],{"type":28,"value":1451},"36 周 24.3%",{"type":23,"tag":76,"props":1453,"children":1454},{},[1455],{"type":28,"value":1456},"1b\u002F2a 期",{"type":23,"tag":54,"props":1458,"children":1459},{},[1460,1468,1473,1478],{"type":23,"tag":76,"props":1461,"children":1462},{},[1463],{"type":23,"tag":162,"props":1464,"children":1465},{},[1466],{"type":28,"value":1467},"MariTide",{"type":23,"tag":76,"props":1469,"children":1470},{},[1471],{"type":28,"value":1472},"GLP‑1 激动 + GIP 阻断，每月一次（安进）",{"type":23,"tag":76,"props":1474,"children":1475},{},[1476],{"type":28,"value":1477},"52 周约 20%",{"type":23,"tag":76,"props":1479,"children":1480},{},[1481],{"type":28,"value":1482},"二期",{"type":23,"tag":54,"props":1484,"children":1485},{},[1486,1498,1503,1508],{"type":23,"tag":76,"props":1487,"children":1488},{},[1489],{"type":23,"tag":162,"props":1490,"children":1491},{},[1492],{"type":23,"tag":273,"props":1493,"children":1495},{"href":1494},"\u002Fglp1\u002Fretatrutide",[1496],{"type":28,"value":1497},"Retatrutide",{"type":23,"tag":76,"props":1499,"children":1500},{},[1501],{"type":28,"value":1502},"GLP‑1 + GIP + 胰高血糖素（礼来）",{"type":23,"tag":76,"props":1504,"children":1505},{},[1506],{"type":28,"value":1507},"48 周约 24%",{"type":23,"tag":76,"props":1509,"children":1510},{},[1511],{"type":28,"value":1512},"三期",{"type":23,"tag":54,"props":1514,"children":1515},{},[1516,1523,1531,1539],{"type":23,"tag":76,"props":1517,"children":1518},{},[1519],{"type":23,"tag":162,"props":1520,"children":1521},{},[1522],{"type":28,"value":599},{"type":23,"tag":76,"props":1524,"children":1525},{},[1526],{"type":23,"tag":162,"props":1527,"children":1528},{},[1529],{"type":28,"value":1530},"Y2\u002FPYY 激动剂（礼来）",{"type":23,"tag":76,"props":1532,"children":1533},{},[1534],{"type":23,"tag":162,"props":1535,"children":1536},{},[1537],{"type":28,"value":1538},"无公开数据",{"type":23,"tag":76,"props":1540,"children":1541},{},[1542],{"type":23,"tag":162,"props":1543,"children":1544},{},[1545],{"type":28,"value":1546},"二期，糖尿病",{"type":23,"tag":24,"props":1548,"children":1549},{},[1550],{"type":28,"value":1551},"最后那一行，就是整篇文章浓缩成的一行。",{"type":23,"tag":35,"props":1553,"children":1555},{"id":1554},"回到最初那个问题老实回答",[1556],{"type":28,"value":1557},"回到最初那个问题，老实回答",{"type":23,"tag":24,"props":1559,"children":1560},{},[1561],{"type":28,"value":1562},"能不能把 Nisotirostide 当成一款和替尔泊肽或司美格鲁肽叠着用的减肥针？",{"type":23,"tag":24,"props":1564,"children":1565},{},[1566],{"type":28,"value":1567},"**从概念上：能，而且它本来就是这么设计的。**它不是肠促胰素，走的是另一条饱腹通路，所有试验把它和 GLP-1 配在一起正是出于这个理由。药理逻辑是站得住的。",{"type":23,"tag":24,"props":1569,"children":1570},{},[1571],{"type":28,"value":1572},"**从证据上：不能，至少今天不能。**关于这个分子的已发表疗效数字是零。唯一一项肥胖试验是 38 人、十一周的耐受性研究，而且没有公布结果。在推进的开发路线冲的是血糖不是体重。而这一类药物唯一完整发表的人体实验，换来大约两公斤，代价是把五分之一的受试者赶出了研究。",{"type":23,"tag":24,"props":1574,"children":1575},{},[1576,1578,1584,1586,1590],{"type":28,"value":1577},"再加上那条永远不变的：眼下以「Nisotirostide」名义流通的东西，按定义就是未获批准、身份和纯度都不明的灰市货。一个 NCT 编号不为陌生人寄给你的那支西林瓶背书——在这件事上它甚至连剂量都背书不了，因为试验剂量是盲的。完整的法律图景见我们的基础文章",{"type":23,"tag":273,"props":1579,"children":1581},{"href":1580},"\u002Fare-peptides-legal",[1582],{"type":28,"value":1583},"肽类合法吗？",{"type":28,"value":1585},"；想从头看起，就是",{"type":23,"tag":273,"props":1587,"children":1588},{"href":449},[1589],{"type":28,"value":452},{"type":28,"value":370},{"type":23,"tag":35,"props":1592,"children":1594},{"id":1593},"值得盯住的时间点",[1595],{"type":28,"value":1593},{"type":23,"tag":24,"props":1597,"children":1598},{},[1599,1601,1606],{"type":28,"value":1600},"这个故事还有没有下文，只由一个日期决定：",{"type":23,"tag":162,"props":1602,"children":1603},{},[1604],{"type":28,"value":1605},"NCT06897475 在 2026 年 12 月的主要完成",{"type":28,"value":1607},"。到那时才第一次会有关于这个分子本身的数字——HbA1c 为主、体重为辅，对照安慰剂，叠在司美格鲁肽或替尔泊肽之上。如果体重曲线明显往下走、脱落率又还过得去，那条被搁置的肥胖路线会很快回来；如果曲线是平的，或者胃肠道那一幕重演，这个问题也就到此为止。",{"type":23,"tag":24,"props":1609,"children":1610},{},[1611],{"type":28,"value":1612},"在那之前，Nisotirostide 是一个用来观察的分子，不是用来搞到手的。",{"type":23,"tag":35,"props":1614,"children":1616},{"id":1615},"这对今天的你意味着什么",[1617],{"type":28,"value":1615},{"type":23,"tag":24,"props":1619,"children":1620},{},[1621,1623,1629,1631,1637,1639,1645],{"type":28,"value":1622},"对于人们实际在用的那些药，中立的部分是算账。要记录自己手上有什么、浓度多少、什么时候用的，",{"type":23,"tag":273,"props":1624,"children":1626},{"href":1625},"\u002Fpeptides-list",[1627],{"type":28,"value":1628},"我们的肽类追踪器",{"type":28,"value":1630},"就是为这件事做的。如果复溶是那个让你心里没底的步骤，",{"type":23,"tag":273,"props":1632,"children":1634},{"href":1633},"\u002Fcalculator",[1635],{"type":28,"value":1636},"我们的计算器",{"type":28,"value":1638},"能在你知道西林瓶浓度和加进去的抑菌注射用水之后，把目标剂量换算成注射器上的刻度。而既然是每周一针、血药水平在两针之间起起落落，",{"type":23,"tag":273,"props":1640,"children":1642},{"href":1641},"\u002Fplotter",[1643],{"type":28,"value":1644},"血药水平曲线图",{"type":28,"value":1646},"会把这条曲线画出来。这些都不是在建议你去用什么——只是把账算清楚而已。",{"type":23,"tag":35,"props":1648,"children":1649},{"id":421},[1650],{"type":28,"value":421},{"type":23,"tag":24,"props":1652,"children":1653},{},[1654],{"type":28,"value":1655},"Nisotirostide（LY3457263）是礼来那款作用于 Y2 受体、每周一次的 PYY 类似物，它确实是按搭配用药设计的，也从来没被别的方式试过——论坛叙事里这一半是真的。另一半不成立：没有公开的疗效数据，唯一的肥胖试验只是一项没有结果的小型耐受性研究，在推进的开发路线是 2 型糖尿病，而这一类药物最好的已发表实验换来大约两公斤外加 68% 的胃肠道不良反应。与此同时，胰淀素已经把组合这道题答完了：CagriSema 的 22.7%，以及 eloralintide 单枪匹马的 20.1% 且耐受良好。想看下一代减重药往哪儿走，就看胰淀素。Nisotirostide 是一条有意思的脚注，附带一个 2026 年 12 月的日期——还算不上答案。",{"type":23,"tag":35,"props":1657,"children":1658},{"id":464},[1659],{"type":28,"value":464},{"type":23,"tag":175,"props":1661,"children":1662},{},[1663,1675,1686,1697,1708,1720,1732,1744,1756,1768,1780],{"type":23,"tag":179,"props":1664,"children":1665},{},[1666,1668],{"type":28,"value":1667},"ClinicalTrials.gov，",{"type":23,"tag":273,"props":1669,"children":1672},{"href":1670,"rel":1671},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT06897475",[479],[1673],{"type":28,"value":1674},"NCT06897475 — LY3457263 加在司美格鲁肽或替尔泊肽之上治疗 2 型糖尿病（二期）",{"type":23,"tag":179,"props":1676,"children":1677},{},[1678,1679],{"type":28,"value":1667},{"type":23,"tag":273,"props":1680,"children":1683},{"href":1681,"rel":1682},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT05582096",[479],[1684],{"type":28,"value":1685},"NCT05582096 — LY3457263 与替尔泊肽联用于超重\u002F肥胖（一期）",{"type":23,"tag":179,"props":1687,"children":1688},{},[1689,1690],{"type":28,"value":1667},{"type":23,"tag":273,"props":1691,"children":1694},{"href":1692,"rel":1693},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT05377333",[479],[1695],{"type":28,"value":1696},"NCT05377333 — LY3457263 单用及与 GLP-1 受体激动剂合用于 2 型糖尿病（一期）",{"type":23,"tag":179,"props":1698,"children":1699},{},[1700,1701],{"type":28,"value":1667},{"type":23,"tag":273,"props":1702,"children":1705},{"href":1703,"rel":1704},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT04641312",[479],[1706],{"type":28,"value":1707},"NCT04641312 — 首次人体单次递增剂量研究（一期）",{"type":23,"tag":179,"props":1709,"children":1710},{},[1711,1713],{"type":28,"value":1712},"Wulff 等，Obesity 2025，",{"type":23,"tag":273,"props":1714,"children":1717},{"href":1715,"rel":1716},"https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002F10.1002\u002Foby.24329",[479],[1718],{"type":28,"value":1719},"Long-acting PYY3−36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies",{"type":23,"tag":179,"props":1721,"children":1722},{},[1723,1725],{"type":28,"value":1724},"Østergaard 等，Science Translational Medicine 2025，",{"type":23,"tag":273,"props":1726,"children":1729},{"href":1727,"rel":1728},"https:\u002F\u002Fwww.science.org\u002Fdoi\u002F10.1126\u002Fscitranslmed.adq6392",[479],[1730],{"type":28,"value":1731},"Variant screening of PYY3–36 leads to potent long-acting PYY analogs with superior Y2 receptor selectivity",{"type":23,"tag":179,"props":1733,"children":1734},{},[1735,1737],{"type":28,"value":1736},"礼来，",{"type":23,"tag":273,"props":1738,"children":1741},{"href":1739,"rel":1740},"https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Flillys-selective-amylin-agonist-eloralintide-demonstrated-meaningful-weight-loss-and-favorable-tolerability-in-a-phase-2-study-of-adults-with-obesity-or-overweight-302607061.html",[479],[1742],{"type":28,"value":1743},"Eloralintide：选择性胰淀素激动剂的二期结果",{"type":23,"tag":179,"props":1745,"children":1746},{},[1747,1749],{"type":28,"value":1748},"诺和诺德 \u002F NEJM，",{"type":23,"tag":273,"props":1750,"children":1753},{"href":1751,"rel":1752},"https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fcagrisema-2-4-mg--2-4-mg-demonstrated-22-7-mean-weight-reduction-in-adults-with-overweight-or-obesity-in-redefine-1--published-in-nejm-302487770.html",[479],[1754],{"type":28,"value":1755},"CagriSema 2.4 mg\u002F2.4 mg 在 REDEFINE 1 中平均减重 22.7%",{"type":23,"tag":179,"props":1757,"children":1758},{},[1759,1761],{"type":28,"value":1760},"NEJM 2025，",{"type":23,"tag":273,"props":1762,"children":1765},{"href":1763,"rel":1764},"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Fabs\u002F10.1056\u002FNEJMoa2502082",[479],[1766],{"type":28,"value":1767},"Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes（REDEFINE 2）",{"type":23,"tag":179,"props":1769,"children":1770},{},[1771,1773],{"type":28,"value":1772},"罗氏，",{"type":23,"tag":273,"props":1774,"children":1777},{"href":1775,"rel":1776},"https:\u002F\u002Fwww.roche.com\u002Fmedia\u002Freleases\u002Fmed-cor-2026-03-05",[479],[1778],{"type":28,"value":1779},"胰淀素类似物 petrelintide 的二期阳性结果",{"type":23,"tag":179,"props":1781,"children":1782},{},[1783,1785],{"type":28,"value":1784},"安进，",{"type":23,"tag":273,"props":1786,"children":1789},{"href":1787,"rel":1788},"https:\u002F\u002Fwww.amgen.com\u002Fnewsroom\u002Fpress-releases\u002F2024\u002F11\u002Famgen-announces-robust-weight-loss-with-maritide-in-people-living-with-obesity-or-overweight-at-52-weeks-in-a-phase-2-study",[479],[1790],{"type":28,"value":1791},"MariTide 二期 52 周结果",{"title":8,"searchDepth":556,"depth":556,"links":1793},[1794,1795,1796,1797,1798,1799,1800,1801,1802,1803],{"id":616,"depth":556,"text":619},{"id":708,"depth":556,"text":708},{"id":909,"depth":556,"text":912},{"id":983,"depth":556,"text":986},{"id":1146,"depth":556,"text":1149},{"id":1554,"depth":556,"text":1557},{"id":1593,"depth":556,"text":1593},{"id":1615,"depth":556,"text":1615},{"id":421,"depth":556,"text":421},{"id":464,"depth":556,"text":464},"content:blog:zh:nisotirostide-ly3457263.md","blog\u002Fzh\u002Fnisotirostide-ly3457263.md","blog\u002Fzh\u002Fnisotirostide-ly3457263",{"_path":1808,"_dir":6,"_draft":7,"_partial":7,"_locale":8,"title":1809,"description":1810,"cat":1811,"icon":1812,"accent":1813,"date":1814,"dateLabel":581,"read":1815,"author":17,"image":1816,"body":1817,"_type":568,"_id":2360,"_source":570,"_file":2361,"_stem":2362,"_extension":573},"\u002Fblog\u002Fzh\u002Fparadigm-peptides-coa-fraud-sentence","伪造检测报告获刑70个月：Paradigm Peptides案","本文是一则刑事案件报道，不是医疗或法律建议，更不是让你去弄任何物质。下文内容均出自起诉书、检方通报和媒体报道，来源列在文末。","安全","tabler:file-certificate","#E0533D","2026-08-01","8 min","\u002Fassets\u002Fparadigm_coa_hero.png",{"type":20,"children":1818,"toc":2349},[1819,1823,1855,1867,1873,1915,1920,1932,1937,1942,1965,1970,1975,1980,1999,2004,2016,2021,2032,2037,2042,2061,2066,2071,2152,2158,2163,2227,2239,2244,2264,2269,2274],{"type":23,"tag":24,"props":1820,"children":1821},{},[1822],{"type":28,"value":1810},{"type":23,"tag":24,"props":1824,"children":1825},{},[1826,1828,1833,1835,1840,1842,1847,1849,1854],{"type":28,"value":1827},"2026年7月30日（周四），联邦法官Cristal C. Brisco在印第安纳州南本德判处",{"type":23,"tag":162,"props":1829,"children":1830},{},[1831],{"type":28,"value":1832},"48岁的Matthew J. Kawa 70个月监禁",{"type":28,"value":1834},"——将近六年，刑满后还有一年监督释放。Kawa经营的",{"type":23,"tag":162,"props":1836,"children":1837},{},[1838],{"type":28,"value":1839},"Paradigm Peptides",{"type":28,"value":1841},"，是网上那片「仅供研究」地带里颇有名气的一家店。他32岁的妹妹",{"type":23,"tag":162,"props":1843,"children":1844},{},[1845],{"type":28,"value":1846},"Jennifer L. Stechkober",{"type":28,"value":1848},"是店里的主要员工，被判",{"type":23,"tag":162,"props":1850,"children":1851},{},[1852],{"type":28,"value":1853},"16个月",{"type":28,"value":370},{"type":23,"tag":24,"props":1856,"children":1857},{},[1858,1860,1865],{"type":28,"value":1859},"对一个卖肽的商家来说，这样的刑期并不常见。但真正值得注意的不是刑期长短，而是Kawa认下的那件事：他",{"type":23,"tag":162,"props":1861,"children":1862},{},[1863],{"type":28,"value":1864},"伪造检测报告",{"type":28,"value":1866},"——正是行业里一半人拿来证明自己品质的那种文件。",{"type":23,"tag":35,"props":1868,"children":1870},{"id":1869},"paradigm是家什么店",[1871],{"type":28,"value":1872},"Paradigm是家什么店",{"type":23,"tag":24,"props":1874,"children":1875},{},[1876,1878,1883,1885,1892,1894,1899,1901,1906,1908,1913],{"type":28,"value":1877},"从",{"type":23,"tag":162,"props":1879,"children":1880},{},[1881],{"type":28,"value":1882},"2019年4月到2024年3月",{"type":28,"value":1884},"，Paradigm Peptides通过",{"type":23,"tag":1886,"props":1887,"children":1889},"code",{"className":1888},[],[1890],{"type":28,"value":1891},"paradigmpeptides.com",{"type":28,"value":1893},"销售肽、SARM和HCG，货从印第安纳州密歇根城发出。检方估计，客户约有",{"type":23,"tag":162,"props":1895,"children":1896},{},[1897],{"type":28,"value":1898},"54,000人，遍及全美50个州和80个国家",{"type":28,"value":1900},"；起诉书认定，流入市场的未获批准药品价值",{"type":23,"tag":162,"props":1902,"children":1903},{},[1904],{"type":28,"value":1905},"超过300万美元",{"type":28,"value":1907},"。Kawa同意没收",{"type":23,"tag":162,"props":1909,"children":1910},{},[1911],{"type":28,"value":1912},"500万美元",{"type":28,"value":1914},"收益，两名被告另需支付78,317.52美元赔偿。",{"type":23,"tag":24,"props":1916,"children":1917},{},[1918],{"type":28,"value":1919},"那个网站读起来跟今天很多店铺没什么两样：美国制造、纯度99%、第三方实验室检测——页面下方再加一句，这些东西仅供研究使用。",{"type":23,"tag":24,"props":1921,"children":1922},{},[1923,1925,1930],{"type":28,"value":1924},"没有一条是真的。Kawa把原料从",{"type":23,"tag":162,"props":1926,"children":1927},{},[1928],{"type":28,"value":1929},"中国、印度等国",{"type":28,"value":1931},"进口到印第安纳州和伊利诺伊州的地址，在密歇根城分装，再当作自家生产的产品卖出去。从来没有做过检测。他在认罪材料里写得很清楚：他「没有检测过我的公司卖给客户的SARM产品」。",{"type":23,"tag":35,"props":1933,"children":1935},{"id":1934},"水印上的手脚",[1936],{"type":28,"value":1934},{"type":23,"tag":24,"props":1938,"children":1939},{},[1940],{"type":28,"value":1941},"起诉书列出了兄妹俩误导监管机构和客户的六种做法。其中一条，凡是下载过COA的人都值得看一眼：",{"type":23,"tag":1943,"props":1944,"children":1945},"blockquote",{},[1946],{"type":23,"tag":24,"props":1947,"children":1948},{},[1949,1951,1956,1958,1963],{"type":28,"value":1950},"通过修改",{"type":23,"tag":162,"props":1952,"children":1953},{},[1954],{"type":28,"value":1955},"其他公司",{"type":28,"value":1957},"检测报告上的信息",{"type":23,"tag":162,"props":1959,"children":1960},{},[1961],{"type":28,"value":1962},"以及水印",{"type":28,"value":1964},"，伪造与Paradigm产品相关的检测报告",{"type":23,"tag":24,"props":1966,"children":1967},{},[1968],{"type":28,"value":1969},"这不是马虎，而是有意为之的手艺活。拿一份真实验室的PDF——抬头、排版、水印，凡是让人觉得「独立第三方」的元素一应俱全——换掉化合物名称和数值，再把水印修成指向自家店铺的样子。客户看到的，就是一份怎么看都像外部核验的文件。",{"type":23,"tag":24,"props":1971,"children":1972},{},[1973],{"type":28,"value":1974},"另外五条补全了整幅图景：把产品谎称为不供人服用的研究试剂；声称Paradigm已获FDA许可并完成注册；声称在自家美国实验室生产并检测；虚报SARM的成分；以及把发往国外的包裹在海关申报为**「化妆品样品」**，以躲开查验。",{"type":23,"tag":35,"props":1976,"children":1978},{"id":1977},"西林瓶里到底装了什么",[1979],{"type":28,"value":1977},{"type":23,"tag":24,"props":1981,"children":1982},{},[1983,1985,1990,1992,1997],{"type":28,"value":1984},"当调查人员检测六种以「模拟睾酮作用」名义销售的产品时，",{"type":23,"tag":162,"props":1986,"children":1987},{},[1988],{"type":28,"value":1989},"六种全都含有真正的睾酮",{"type":28,"value":1991},"——一种处方类甾体激素，在美国属于管制物质。起诉书举了2023年9月1日的两个例子：以",{"type":23,"tag":162,"props":1993,"children":1994},{},[1995],{"type":28,"value":1996},"YK-11",{"type":28,"value":1998},"名义卖出的是睾酮，以**奥斯他林（MK-2866）**名义卖出的也是睾酮。",{"type":23,"tag":24,"props":2000,"children":2001},{},[2002],{"type":28,"value":2003},"标签造假到这一步，就变成了健康问题。一个以为自己在用SARM的人，不会想到自己吃下的是完整剂量的雄激素——不会预期它的作用，不会预期它的副作用，更不会预期一场没通过的兴奋剂检测。",{"type":23,"tag":24,"props":2005,"children":2006},{},[2007,2009,2014],{"type":28,"value":2008},"HCG那边如出一辙。2020年到2024年3月，Kawa持续从境外进货。",{"type":23,"tag":162,"props":2010,"children":2011},{},[2012],{"type":28,"value":2013},"至少有十五次",{"type":28,"value":2015},"，他被告知寄给他的HCG包裹在边境被扣，理由是标示不实的药品。他照做不误。第二项指控针对的正是这样一个包裹，日期为2024年1月16日。",{"type":23,"tag":35,"props":2017,"children":2019},{"id":2018},"一个付出代价的客户",[2020],{"type":28,"value":2018},{"type":23,"tag":24,"props":2022,"children":2023},{},[2024,2026,2031],{"type":28,"value":2025},"Dan Murphy当时三十出头，做市场咨询。2023年，他为了增肌开始用Paradigm的SARM。几个月后，失眠、疼痛的囊肿型痤疮、夸大的念头接踵而至，随后是被害妄想——他认定妻子在合谋对付他——以及反复出现的自杀念头。医生给出的判断是：",{"type":23,"tag":162,"props":2027,"children":2028},{},[2029],{"type":28,"value":2030},"类固醇诱发的精神病",{"type":28,"value":370},{"type":23,"tag":24,"props":2033,"children":2034},{},[2035],{"type":28,"value":2036},"直到2025年2月，一封来自调查人员的信才让他明白原因：他吃下去的东西里有睾酮。他后来说：「我失去了朋友、家人、同事和客户，差点连命都没了。」Brisco法官在庭上总结道，Kawa「只顾着自己想建立什么，却没有想过那些人」，留下了「一道令人难以置信的伤害痕迹」。",{"type":23,"tag":35,"props":2038,"children":2040},{"id":2039},"警告从2020年就开始了",[2041],{"type":28,"value":2039},{"type":23,"tag":24,"props":2043,"children":2044},{},[2045,2047,2052,2054,2059],{"type":28,"value":2046},"这个案子还有一点值得注意：其中没有任何意外。FDA",{"type":23,"tag":162,"props":2048,"children":2049},{},[2050],{"type":28,"value":2051},"从2020年起",{"type":28,"value":2053},"就在发警告。",{"type":23,"tag":162,"props":2055,"children":2056},{},[2057],{"type":28,"value":2058},"2022年3月30日",{"type":28,"value":2060},"是一封正式的警告信：Paradigm宣传SARM和肽时，声称可以预防、治疗、治愈癌症、糖尿病、心血管疾病、骨质疏松、莱姆病等疾病，这恰恰使它们成为未获批准的药品。信中还特别点名LGD-4033、奥斯他林、GW-501516和MK-677的已知风险：危及生命的反应、肝毒性、心梗和中风风险升高。",{"type":23,"tag":24,"props":2062,"children":2063},{},[2064],{"type":28,"value":2065},"店铺在那之后又开了两年。2023年9月，FDA查扣产品送检——睾酮的结果就是这么来的。2024年3月20日，一切结束。",{"type":23,"tag":35,"props":2067,"children":2069},{"id":2068},"判决存档",[2070],{"type":28,"value":2068},{"type":23,"tag":175,"props":2072,"children":2073},{},[2074,2098,2108,2132,2142],{"type":23,"tag":179,"props":2075,"children":2076},{},[2077,2082,2084,2089,2091,2096],{"type":23,"tag":162,"props":2078,"children":2079},{},[2080],{"type":28,"value":2081},"案件：",{"type":28,"value":2083}," ",{"type":23,"tag":664,"props":2085,"children":2086},{},[2087],{"type":28,"value":2088},"United States of America v. Kawa et al.",{"type":28,"value":2090},"，案号 ",{"type":23,"tag":162,"props":2092,"children":2093},{},[2094],{"type":28,"value":2095},"3:25-cr-00091",{"type":28,"value":2097},"，美国联邦地区法院印第安纳北区南本德分庭",{"type":23,"tag":179,"props":2099,"children":2100},{},[2101,2106],{"type":23,"tag":162,"props":2102,"children":2103},{},[2104],{"type":28,"value":2105},"指控：",{"type":28,"value":2107}," 以欺骗和误导为目的，将未获批准的药品投入州际贸易（21 U.S.C. §§ 331(d)、333(a)(2)）；Kawa另有欺诈进口一项（18 U.S.C. § 545）",{"type":23,"tag":179,"props":2109,"children":2110},{},[2111,2116,2118,2123,2125,2130],{"type":23,"tag":162,"props":2112,"children":2113},{},[2114],{"type":28,"value":2115},"认罪：",{"type":28,"value":2117}," 2025年12月10日 · ",{"type":23,"tag":162,"props":2119,"children":2120},{},[2121],{"type":28,"value":2122},"宣判：",{"type":28,"value":2124}," 2026年7月30日 · ",{"type":23,"tag":162,"props":2126,"children":2127},{},[2128],{"type":28,"value":2129},"主审：",{"type":28,"value":2131}," Cristal C. Brisco法官",{"type":23,"tag":179,"props":2133,"children":2134},{},[2135,2140],{"type":23,"tag":162,"props":2136,"children":2137},{},[2138],{"type":28,"value":2139},"刑罚：",{"type":28,"value":2141}," Kawa 70个月监禁加1年监督释放；Stechkober 16个月加1年；没收500万美元，赔偿78,317.52美元",{"type":23,"tag":179,"props":2143,"children":2144},{},[2145,2150],{"type":23,"tag":162,"props":2146,"children":2147},{},[2148],{"type":28,"value":2149},"侦办：",{"type":28,"value":2151}," FDA刑事调查办公室与美国邮政监察局",{"type":23,"tag":35,"props":2153,"children":2155},{"id":2154},"怎么看一份coa",[2156],{"type":28,"value":2157},"怎么看一份COA",{"type":23,"tag":24,"props":2159,"children":2160},{},[2161],{"type":28,"value":2162},"检测报告是某一批次的一张快照——不多，但也不少。它值不值钱，取决于几件可以核实的事：",{"type":23,"tag":2164,"props":2165,"children":2166},"ol",{},[2167,2177,2187,2197,2207,2217],{"type":23,"tag":179,"props":2168,"children":2169},{},[2170,2175],{"type":23,"tag":162,"props":2171,"children":2172},{},[2173],{"type":28,"value":2174},"是谁出具的？",{"type":28,"value":2176}," 一家有名称、有地址、能联系上的独立实验室。一份查不到出具方的PDF只是一张图，不是证据。",{"type":23,"tag":179,"props":2178,"children":2179},{},[2180,2185],{"type":23,"tag":162,"props":2181,"children":2182},{},[2183],{"type":28,"value":2184},"有没有批号，和你手里西林瓶上的是否一致？",{"type":28,"value":2186}," 没有这层对应，报告说的是某个批次，未必是你的那批。",{"type":23,"tag":179,"props":2188,"children":2189},{},[2190,2195],{"type":23,"tag":162,"props":2191,"children":2192},{},[2193],{"type":28,"value":2194},"日期对得上批次吗？",{"type":28,"value":2196}," 一份两年前的COA配一件上周才发出的货，说不通。",{"type":23,"tag":179,"props":2198,"children":2199},{},[2200,2205],{"type":23,"tag":162,"props":2201,"children":2202},{},[2203],{"type":28,"value":2204},"用的什么方法？",{"type":28,"value":2206}," HPLC回答「有多纯」，质谱回答「是哪个分子」。Paradigm钻的正是这道缝：再漂亮的纯度数字，也说明不了西林瓶里装的是不是标签上写的东西。",{"type":23,"tag":179,"props":2208,"children":2209},{},[2210,2215],{"type":23,"tag":162,"props":2211,"children":2212},{},[2213],{"type":28,"value":2214},"实验室能确认吗？",{"type":28,"value":2216}," 正经的检测机构会回应关于报告编号的询问。仅这一步，就足以让那些伪造件现形。",{"type":23,"tag":179,"props":2218,"children":2219},{},[2220,2225],{"type":23,"tag":162,"props":2221,"children":2222},{},[2223],{"type":28,"value":2224},"危险信号：",{"type":28,"value":2226}," 整个产品线纯度数字一模一样、缺批号、水印与所称实验室对不上、报告以截图而非PDF形式给出。",{"type":23,"tag":24,"props":2228,"children":2229},{},[2230,2232,2237],{"type":28,"value":2231},"还有那句在法庭上最不值钱的话：**「仅供研究使用」**谁也保护不了——既保护不了卖家免于起诉，也保护不了你免于瓶里的东西。法律层面的情况，见我们的",{"type":23,"tag":273,"props":2233,"children":2234},{"href":1580},[2235],{"type":28,"value":2236},"肽合法吗",{"type":28,"value":2238},"一文。",{"type":23,"tag":35,"props":2240,"children":2242},{"id":2241},"最后一点讽刺",[2243],{"type":28,"value":2241},{"type":23,"tag":24,"props":2245,"children":2246},{},[2247,2249,2254,2256,2262],{"type":28,"value":2248},"Kawa起诉书列出的未获批准药品里，有一个是",{"type":23,"tag":162,"props":2250,"children":2251},{},[2252],{"type":28,"value":2253},"BPC-157",{"type":28,"value":2255},"。就在宣判前一周，FDA的一个咨询委员会建议放开这个肽的药房配制——与该机构自己科学家的意见相反。我们在",{"type":23,"tag":273,"props":2257,"children":2259},{"href":2258},"\u002Fblog\u002Ffda-peptides-503a-vote",[2260],{"type":28,"value":2261},"这里",{"type":28,"value":2263},"做过梳理。",{"type":23,"tag":24,"props":2265,"children":2266},{},[2267],{"type":28,"value":2268},"同一个分子，两个世界。一个世界里，人们争论配方、纯度标准和监管；另一个世界里，一份改过颜色的PDF被发到你邮箱。两者之间的差别不在化学，而在于有没有人为卖出去的东西负责，以及你能不能查得到。",{"type":23,"tag":35,"props":2270,"children":2272},{"id":2271},"来源",[2273],{"type":28,"value":2271},{"type":23,"tag":175,"props":2275,"children":2276},{},[2277,2289,2301,2313,2325,2337],{"type":23,"tag":179,"props":2278,"children":2279},{},[2280,2282],{"type":28,"value":2281},"美国印第安纳北区联邦检察官办公室，2026年7月30日，",{"type":23,"tag":273,"props":2283,"children":2286},{"href":2284,"rel":2285},"https:\u002F\u002Fwww.justice.gov\u002Fusao-ndin\u002Fpr\u002Fillinois-man-and-indiana-woman-sentenced-respectively-70-months-and-16-months-prison",[479],[2287],{"type":28,"value":2288},"Illinois Man and Indiana Woman Sentenced Respectively to 70 Months and 16 Months in Prison For Selling Unapproved Drugs in Interstate Commerce",{"type":23,"tag":179,"props":2290,"children":2291},{},[2292,2294],{"type":28,"value":2293},"美国印第安纳北区联邦检察官办公室，",{"type":23,"tag":273,"props":2295,"children":2298},{"href":2296,"rel":2297},"https:\u002F\u002Fwww.justice.gov\u002Fusao-ndin\u002Funited-states-v-matthew-kawa",[479],[2299],{"type":28,"value":2300},"United States v. Matthew Kawa — 受害者信息",{"type":23,"tag":179,"props":2302,"children":2303},{},[2304,2306,2311],{"type":28,"value":2305},"起诉书（Information），",{"type":23,"tag":664,"props":2307,"children":2308},{},[2309],{"type":28,"value":2310},"United States v. Kawa et al.",{"type":28,"value":2312},"，案号 3:25-cr-00091（N.D. Ind.）",{"type":23,"tag":179,"props":2314,"children":2315},{},[2316,2318],{"type":28,"value":2317},"CBS News，2026年7月30日，",{"type":23,"tag":273,"props":2319,"children":2322},{"href":2320,"rel":2321},"https:\u002F\u002Fwww.cbsnews.com\u002Fnews\u002Fpeptides-seller-prison-sentence-unapproved-drugs\u002F",[479],[2323],{"type":28,"value":2324},"Judge sentences peptide vendor to nearly 6 years in prison for \"an incredible trail of harm\"",{"type":23,"tag":179,"props":2326,"children":2327},{},[2328,2330],{"type":28,"value":2329},"BBC News，2026年7月31日，",{"type":23,"tag":273,"props":2331,"children":2334},{"href":2332,"rel":2333},"https:\u002F\u002Fwww.bbc.co.uk\u002Fnews\u002Farticles\u002Fc4gd82vvvdno",[479],[2335],{"type":28,"value":2336},"He bought a fitness supplement online to bulk up, but ended up losing his mind",{"type":23,"tag":179,"props":2338,"children":2339},{},[2340,2342],{"type":28,"value":2341},"The Times of Northwest Indiana，2026年7月31日，",{"type":23,"tag":273,"props":2343,"children":2346},{"href":2344,"rel":2345},"https:\u002F\u002Fnwitimes.com\u002Fnews\u002Flocal\u002Flaporte\u002Fmichigan-city\u002Farticle_7fc64142-b21b-4974-a410-bd572f84b84a.html",[479],[2347],{"type":28,"value":2348},"Michigan City woman, Illinois man sentenced for fraud",{"title":8,"searchDepth":556,"depth":556,"links":2350},[2351,2352,2353,2354,2355,2356,2357,2358,2359],{"id":1869,"depth":556,"text":1872},{"id":1934,"depth":556,"text":1934},{"id":1977,"depth":556,"text":1977},{"id":2018,"depth":556,"text":2018},{"id":2039,"depth":556,"text":2039},{"id":2068,"depth":556,"text":2068},{"id":2154,"depth":556,"text":2157},{"id":2241,"depth":556,"text":2241},{"id":2271,"depth":556,"text":2271},"content:blog:zh:paradigm-peptides-coa-fraud-sentence.md","blog\u002Fzh\u002Fparadigm-peptides-coa-fraud-sentence.md","blog\u002Fzh\u002Fparadigm-peptides-coa-fraud-sentence",{"_path":2364,"_dir":6,"_draft":7,"_partial":7,"_locale":8,"title":2365,"description":2366,"cat":11,"icon":578,"accent":2367,"date":2368,"dateLabel":2369,"read":2370,"author":17,"image":2371,"body":2372,"_type":568,"_id":3260,"_source":570,"_file":3261,"_stem":3262,"_extension":573},"\u002Fblog\u002Fzh\u002Fenicepatide-ct-388-roche","Enicepatide（罗氏的 CT-388）：它到底是什么，又和司美格鲁肽、替尔泊肽、Retatrutide 及胰淀素类药物怎么比","本文属于一般性科普，不是医疗建议，也不是鼓励你去获取或使用任何物质。Enicepatide 是一款在研药物，全球任何地方都尚未获批，无法合法购买，也开不出处方。文中没有任何剂量、叠加或购买指导；下面那些跨试验的数字来自各自独立的研究，并不是头对头比较。","#6D5FC7","2026-07-24","2026年7月","11 min","\u002Fassets\u002Fenicepatide_hero.png",{"type":20,"children":2373,"toc":3251},[2374,2378,2397,2403,2422,2447,2491,2496,2501,2520,2573,2585,2604,2609,2621,2837,2842,2922,2934,2940,2945,2954,2986,2991,3076,3088,3092,3117,3142,3147,3165,3169],{"type":23,"tag":24,"props":2375,"children":2376},{},[2377],{"type":28,"value":2366},{"type":23,"tag":24,"props":2379,"children":2380},{},[2381,2383,2388,2390,2395],{"type":28,"value":2382},"如果你一直盯着减肥药的研发管线，2026 年美国糖尿病协会（ADA）在新奥尔良的年会上冒出了一个新名字，之后就赖在头条上不走了：",{"type":23,"tag":162,"props":2384,"children":2385},{},[2386],{"type":28,"value":2387},"enicepatide",{"type":28,"value":2389},"。它是罗氏的，注射剂，每周一次；在二期试验里做出了 ",{"type":23,"tag":162,"props":2391,"children":2392},{},[2393],{"type":28,"value":2394},"48 周减重约 22.5%",{"type":28,"value":2396}," 的成绩——这种数字，此前只有替尔泊肽和 Retatrutide 摸到过。这篇就是大白话版：enicepatide 是什么，它在司美格鲁肽、替尔泊肽、Retatrutide、Cagrilintide 和 Eloralintide 之间站在哪个位置，研究到底走到了哪一步，以及把它和别的东西凑一起到底有没有道理——也就是 CagriSema 那个问题，还有生物黑客论坛上“reta + cagri”那个问题。",{"type":23,"tag":35,"props":2398,"children":2400},{"id":2399},"enicepatide-到底是什么",[2401],{"type":28,"value":2402},"Enicepatide 到底是什么",{"type":23,"tag":24,"props":2404,"children":2405},{},[2406,2408,2413,2415,2420],{"type":28,"value":2407},"Enicepatide 是一个你也许早就认识的分子的新名字——它的代号是 ",{"type":23,"tag":162,"props":2409,"children":2410},{},[2411],{"type":28,"value":2412},"CT-388",{"type":28,"value":2414},"（也写作 RO7795068）。它随着罗氏 2023 年 12 月以约 27 亿美元收购 ",{"type":23,"tag":162,"props":2416,"children":2417},{},[2418],{"type":28,"value":2419},"Carmot Therapeutics",{"type":28,"value":2421}," 一起进了门，此后罗氏／基因泰克一直在大力推进它。",{"type":23,"tag":24,"props":2423,"children":2424},{},[2425,2427,2432,2434,2438,2440,2445],{"type":28,"value":2426},"从机制上说，它是一款 ",{"type":23,"tag":162,"props":2428,"children":2429},{},[2430],{"type":28,"value":2431},"每周一次皮下注射的 GLP-1\u002FGIP 双受体激动剂",{"type":28,"value":2433},"——一个分子同时打开两种与食欲和血糖有关的肠道激素受体。这一点它和 ",{"type":23,"tag":273,"props":2435,"children":2436},{"href":886},[2437],{"type":28,"value":889},{"type":28,"value":2439}," 是一样的。真正让它与众不同的，是它",{"type":23,"tag":664,"props":2441,"children":2442},{},[2443],{"type":28,"value":2444},"怎么",{"type":28,"value":2446},"作用于这些受体：",{"type":23,"tag":175,"props":2448,"children":2449},{},[2450,2467],{"type":23,"tag":179,"props":2451,"children":2452},{},[2453,2458,2460,2465],{"type":23,"tag":162,"props":2454,"children":2455},{},[2456],{"type":28,"value":2457},"均衡，而不是偏科。",{"type":28,"value":2459}," 替尔泊肽对 GIP 受体的偏重远远大过 GLP-1。Enicepatide 则被设计成对两者的激活大致",{"type":23,"tag":664,"props":2461,"children":2462},{},[2463],{"type":28,"value":2464},"相当",{"type":28,"value":2466},"——这是一种真正不同的药理特征，而不只是同一个东西加了个强化版。",{"type":23,"tag":179,"props":2468,"children":2469},{},[2470,2475,2477,2482,2484,2489],{"type":23,"tag":162,"props":2471,"children":2472},{},[2473],{"type":28,"value":2474},"信号偏向（signalling-biased）。",{"type":28,"value":2476}," 这是最技术性的那个卖点。Enicepatide 的设计意图，是在细胞内触发有用的“cAMP”信号，同时几乎不去招募 ",{"type":23,"tag":162,"props":2478,"children":2479},{},[2480],{"type":28,"value":2481},"β-抑制蛋白（β-arrestin）",{"type":28,"value":2483},"——正是这个蛋白，平时会把受体拽回细胞内部、再把它关掉。这种“内化”少了，受体就能更久地保持响应；罗氏正是拿这个机制来解释这款药效果持久，以及减重曲线 ",{"type":23,"tag":162,"props":2485,"children":2486},{},[2487],{"type":28,"value":2488},"到 48 周都还没触顶",{"type":28,"value":2490}," 这件事。",{"type":23,"tag":24,"props":2492,"children":2493},{},[2494],{"type":28,"value":2495},"你不用真懂这些生物化学，也能记住结论：enicepatide 是一款精修过的双重激动剂，主打每一针都尽量把药效撑得更久，而不是一个全新的药物门类。",{"type":23,"tag":35,"props":2497,"children":2499},{"id":2498},"二期数据",[2500],{"type":28,"value":2498},{"type":23,"tag":24,"props":2502,"children":2503},{},[2504,2506,2511,2513,2518],{"type":28,"value":2505},"让所有人都为之一动的数据，来自一项二期研究（CT388-103），受试者是 ",{"type":23,"tag":162,"props":2507,"children":2508},{},[2509],{"type":28,"value":2510},"469 名",{"type":28,"value":2512}," 超重或肥胖的成年人，在 48 周里用 ",{"type":23,"tag":162,"props":2514,"children":2515},{},[2516],{"type":28,"value":2517},"4 mg 到 24 mg",{"type":28,"value":2519}," 五个剂量对比安慰剂。结果给出了一条漂亮的剂量-反应曲线，在最高剂量下：",{"type":23,"tag":175,"props":2521,"children":2522},{},[2523,2540],{"type":23,"tag":179,"props":2524,"children":2525},{},[2526,2531,2533,2538],{"type":23,"tag":162,"props":2527,"children":2528},{},[2529],{"type":28,"value":2530},"48 周经安慰剂校正的减重约 22.5%",{"type":28,"value":2532},"（疗效估计目标），而且",{"type":23,"tag":162,"props":2534,"children":2535},{},[2536],{"type":28,"value":2537},"还没到平台期",{"type":28,"value":2539},"——试验窗口关闭时，曲线仍在往下走。",{"type":23,"tag":179,"props":2541,"children":2542},{},[2543,2545,2550,2552,2557,2559,2564,2566,2571],{"type":28,"value":2544},"在 48 周仍用 24 mg 剂量的人里，",{"type":23,"tag":162,"props":2546,"children":2547},{},[2548],{"type":28,"value":2549},"95.7%",{"type":28,"value":2551}," 至少减掉了 5% 的体重，",{"type":23,"tag":162,"props":2553,"children":2554},{},[2555],{"type":28,"value":2556},"87%",{"type":28,"value":2558}," 减掉了 ≥10%，",{"type":23,"tag":162,"props":2560,"children":2561},{},[2562],{"type":28,"value":2563},"47.8%",{"type":28,"value":2565}," 减掉了 ≥20%，",{"type":23,"tag":162,"props":2567,"children":2568},{},[2569],{"type":28,"value":2570},"26.1%",{"type":28,"value":2572}," 减掉了 ≥30%。",{"type":23,"tag":24,"props":2574,"children":2575},{},[2576,2578,2583],{"type":28,"value":2577},"它并非没有副作用。和这一类药里的每一款一样，麻烦主要出在胃肠道——恶心、呕吐、腹泻——",{"type":23,"tag":162,"props":2579,"children":2580},{},[2581],{"type":28,"value":2582},"因不良事件而停药的比例为 5.9%",{"type":28,"value":2584},"，安慰剂组则是 1.3%。这是个实打实的数字，但落在强效肠促胰素类药物的正常区间之内。",{"type":23,"tag":24,"props":2586,"children":2587},{},[2588,2590,2595,2597,2602],{"type":28,"value":2589},"凭着这份成绩，罗氏在 2026 年初启动了三期项目 ",{"type":23,"tag":162,"props":2591,"children":2592},{},[2593],{"type":28,"value":2594},"ENITH",{"type":28,"value":2596},"，比较现实的上市时间大约在 ",{"type":23,"tag":162,"props":2598,"children":2599},{},[2600],{"type":28,"value":2601},"2030 年",{"type":28,"value":2603}," 前后。换句话说：疗效信号很强，时间线很长。",{"type":23,"tag":35,"props":2605,"children":2607},{"id":2606},"它和你已经认识的那些药差在哪",[2608],{"type":28,"value":2606},{"type":23,"tag":24,"props":2610,"children":2611},{},[2612,2614,2619],{"type":28,"value":2613},"先把整个格局摆出来。这里最有用的一点认知是：这些分子并不是在干同一件事。有些作用于肠促胰素受体（GLP-1、GIP、胰高血糖素）；另一些则模拟 ",{"type":23,"tag":162,"props":2615,"children":2616},{},[2617],{"type":28,"value":2618},"胰淀素（amylin）",{"type":28,"value":2620},"——一种完全不同的饱腹感激素。",{"type":23,"tag":46,"props":2622,"children":2623},{},[2624,2649],{"type":23,"tag":50,"props":2625,"children":2626},{},[2627],{"type":23,"tag":54,"props":2628,"children":2629},{},[2630,2634,2639,2644],{"type":23,"tag":58,"props":2631,"children":2632},{},[2633],{"type":28,"value":1337},{"type":23,"tag":58,"props":2635,"children":2636},{},[2637],{"type":28,"value":2638},"它是什么",{"type":23,"tag":58,"props":2640,"children":2641},{},[2642],{"type":28,"value":2643},"各自试验中的峰值减重",{"type":23,"tag":58,"props":2645,"children":2646},{},[2647],{"type":28,"value":2648},"进展",{"type":23,"tag":69,"props":2650,"children":2651},{},[2652,2685,2717,2746,2775,2807],{"type":23,"tag":54,"props":2653,"children":2654},{},[2655,2663,2675,2680],{"type":23,"tag":76,"props":2656,"children":2657},{},[2658],{"type":23,"tag":162,"props":2659,"children":2660},{},[2661],{"type":28,"value":2662},"Enicepatide（CT-388）",{"type":23,"tag":76,"props":2664,"children":2665},{},[2666,2668,2673],{"type":28,"value":2667},"均衡、信号偏向的 ",{"type":23,"tag":162,"props":2669,"children":2670},{},[2671],{"type":28,"value":2672},"GLP-1\u002FGIP",{"type":28,"value":2674}," 双重激动剂（罗氏）",{"type":23,"tag":76,"props":2676,"children":2677},{},[2678],{"type":28,"value":2679},"48 周约 22.5%",{"type":23,"tag":76,"props":2681,"children":2682},{},[2683],{"type":28,"value":2684},"三期（ENITH）",{"type":23,"tag":54,"props":2686,"children":2687},{},[2688,2695,2707,2712],{"type":23,"tag":76,"props":2689,"children":2690},{},[2691],{"type":23,"tag":162,"props":2692,"children":2693},{},[2694],{"type":28,"value":460},{"type":23,"tag":76,"props":2696,"children":2697},{},[2698,2700,2705],{"type":28,"value":2699},"纯 ",{"type":23,"tag":162,"props":2701,"children":2702},{},[2703],{"type":28,"value":2704},"GLP-1",{"type":28,"value":2706}," 激动剂（诺和诺德——Wegovy\u002FOzempic）",{"type":23,"tag":76,"props":2708,"children":2709},{},[2710],{"type":28,"value":2711},"68 周约 15%",{"type":23,"tag":76,"props":2713,"children":2714},{},[2715],{"type":28,"value":2716},"已获批",{"type":23,"tag":54,"props":2718,"children":2719},{},[2720,2727,2737,2742],{"type":23,"tag":76,"props":2721,"children":2722},{},[2723],{"type":23,"tag":162,"props":2724,"children":2725},{},[2726],{"type":28,"value":889},{"type":23,"tag":76,"props":2728,"children":2729},{},[2730,2735],{"type":23,"tag":162,"props":2731,"children":2732},{},[2733],{"type":28,"value":2734},"GIP\u002FGLP-1",{"type":28,"value":2736}," 双重激动剂，偏重 GIP（礼来——Zepbound\u002FMounjaro）",{"type":23,"tag":76,"props":2738,"children":2739},{},[2740],{"type":28,"value":2741},"约 20–25%",{"type":23,"tag":76,"props":2743,"children":2744},{},[2745],{"type":28,"value":2716},{"type":23,"tag":54,"props":2747,"children":2748},{},[2749,2756,2766,2771],{"type":23,"tag":76,"props":2750,"children":2751},{},[2752],{"type":23,"tag":162,"props":2753,"children":2754},{},[2755],{"type":28,"value":1497},{"type":23,"tag":76,"props":2757,"children":2758},{},[2759,2764],{"type":23,"tag":162,"props":2760,"children":2761},{},[2762],{"type":28,"value":2763},"GLP-1\u002FGIP\u002F胰高血糖素",{"type":28,"value":2765}," 三重激动剂（礼来）",{"type":23,"tag":76,"props":2767,"children":2768},{},[2769],{"type":28,"value":2770},"最高约 24%+",{"type":23,"tag":76,"props":2772,"children":2773},{},[2774],{"type":28,"value":1512},{"type":23,"tag":54,"props":2776,"children":2777},{},[2778,2786,2797,2802],{"type":23,"tag":76,"props":2779,"children":2780},{},[2781],{"type":23,"tag":162,"props":2782,"children":2783},{},[2784],{"type":28,"value":2785},"Cagrilintide",{"type":23,"tag":76,"props":2787,"children":2788},{},[2789,2791,2795],{"type":28,"value":2790},"长效 ",{"type":23,"tag":162,"props":2792,"children":2793},{},[2794],{"type":28,"value":1159},{"type":28,"value":2796}," 类似物（诺和诺德）",{"type":23,"tag":76,"props":2798,"children":2799},{},[2800],{"type":28,"value":2801},"单用效果一般；与司美格鲁肽搭配即 CagriSema",{"type":23,"tag":76,"props":2803,"children":2804},{},[2805],{"type":28,"value":2806},"三期（作为 CagriSema）",{"type":23,"tag":54,"props":2808,"children":2809},{},[2810,2817,2828,2833],{"type":23,"tag":76,"props":2811,"children":2812},{},[2813],{"type":23,"tag":162,"props":2814,"children":2815},{},[2816],{"type":28,"value":1199},{"type":23,"tag":76,"props":2818,"children":2819},{},[2820,2822,2826],{"type":28,"value":2821},"选择性 ",{"type":23,"tag":162,"props":2823,"children":2824},{},[2825],{"type":28,"value":1159},{"type":28,"value":2827}," 激动剂（礼来）",{"type":23,"tag":76,"props":2829,"children":2830},{},[2831],{"type":28,"value":2832},"48 周约 9.5–20.1%",{"type":23,"tag":76,"props":2834,"children":2835},{},[2836],{"type":28,"value":1512},{"type":23,"tag":24,"props":2838,"children":2839},{},[2840],{"type":28,"value":2841},"再老实补几句，因为一张表会把真实的差异抹平：",{"type":23,"tag":175,"props":2843,"children":2844},{},[2845,2860,2882,2906],{"type":23,"tag":179,"props":2846,"children":2847},{},[2848,2852,2854,2859],{"type":23,"tag":162,"props":2849,"children":2850},{},[2851],{"type":28,"value":460},{"type":28,"value":2853}," 是那个单受体的原型。之后所有更新的药，某种意义上都是在回答一个问题：“我们能不能打赢纯 GLP-1？”背景可以看我们的 ",{"type":23,"tag":273,"props":2855,"children":2856},{"href":457},[2857],{"type":28,"value":2858},"司美格鲁肽资料页",{"type":28,"value":370},{"type":23,"tag":179,"props":2861,"children":2862},{},[2863,2867,2869,2874,2876,2881],{"type":23,"tag":162,"props":2864,"children":2865},{},[2866],{"type":28,"value":889},{"type":28,"value":2868}," 第一个证明了两个受体强过一个。Enicepatide 的说法是，它对同样这两个受体的作用",{"type":23,"tag":664,"props":2870,"children":2871},{},[2872],{"type":28,"value":2873},"更均衡、也更持久",{"type":28,"value":2875},"——它要对标的那位在位者，见 ",{"type":23,"tag":273,"props":2877,"children":2878},{"href":886},[2879],{"type":28,"value":2880},"替尔泊肽资料页",{"type":28,"value":370},{"type":23,"tag":179,"props":2883,"children":2884},{},[2885,2889,2891,2897,2899,2904],{"type":23,"tag":162,"props":2886,"children":2887},{},[2888],{"type":28,"value":1497},{"type":28,"value":2890}," 加上了第三个受体——胰高血糖素，目前在所有肠促胰素类药里减重数字最高。它最新的三期读数，我们在 ",{"type":23,"tag":273,"props":2892,"children":2894},{"href":2893},"\u002Fblog\u002Fretatrutide-triumph-2-3-results",[2895],{"type":28,"value":2896},"Retatrutide TRIUMPH-2 与 TRIUMPH-3",{"type":28,"value":2898}," 里讲过，完整图景则在 ",{"type":23,"tag":273,"props":2900,"children":2901},{"href":1494},[2902],{"type":28,"value":2903},"Retatrutide 资料页",{"type":28,"value":2905},"。Enicepatide 并不想在力气上压过它，而是想用一套更干净的双受体设计，做出相近的效果。",{"type":23,"tag":179,"props":2907,"children":2908},{},[2909,2914,2916,2920],{"type":23,"tag":162,"props":2910,"children":2911},{},[2912],{"type":28,"value":2913},"Cagrilintide 和 Eloralintide",{"type":28,"value":2915}," 根本不是肠促胰素——它们是 ",{"type":23,"tag":162,"props":2917,"children":2918},{},[2919],{"type":28,"value":1159},{"type":28,"value":2921}," 药物，走的是另一条独立的饱腹通路。正是这个区别，才有了下一节的存在。",{"type":23,"tag":24,"props":2923,"children":2924},{},[2925,2927,2932],{"type":28,"value":2926},"有一句提醒，请你从头到尾记着：",{"type":23,"tag":162,"props":2928,"children":2929},{},[2930],{"type":28,"value":2931},"这些数字没有一个是头对头得来的。",{"type":28,"value":2933}," 不同的试验、不同的时长、不同的人群。一项研究里的 22.5% 和另一项里的 24%，并不能断定哪款药“更强”——只有一场直接对照的试验才能，而这类试验大多还没做过。",{"type":23,"tag":35,"props":2935,"children":2937},{"id":2936},"它能叠加吗cagrisemareta-cagri以及罗氏自己的答案",[2938],{"type":28,"value":2939},"它能叠加吗？CagriSema、“reta + cagri”，以及罗氏自己的答案",{"type":23,"tag":24,"props":2941,"children":2942},{},[2943],{"type":28,"value":2944},"这是把论坛塞满的那个问题，值得好好答一答，因为流行的说法里有点乱。",{"type":23,"tag":24,"props":2946,"children":2947},{},[2948],{"type":23,"tag":2949,"props":2950,"children":2953},"img",{"alt":2951,"src":2952},"一条肠促胰素式的缎带和一个小小的胰淀素环，一起汇入同一支注射笔——肠促胰素叠加胰淀素的组合思路","\u002Fassets\u002Fenicepatide_combo.png",[],{"type":23,"tag":24,"props":2955,"children":2956},{},[2957,2959,2964,2966,2970,2972,2977,2979,2984],{"type":28,"value":2958},"先把分类捋清楚。",{"type":23,"tag":162,"props":2960,"children":2961},{},[2962],{"type":28,"value":2963},"CagriSema 并不是两款 GLP-1 药物",{"type":28,"value":2965},"——它是一款 GLP-1 药物（司美格鲁肽）加一款 ",{"type":23,"tag":162,"props":2967,"children":2968},{},[2969],{"type":28,"value":1159},{"type":28,"value":2971}," 药物（cagrilintide），装在同一支笔里，作用于两套",{"type":23,"tag":664,"props":2973,"children":2974},{},[2975],{"type":28,"value":2976},"不同",{"type":28,"value":2978},"的激素系统。这才是关键的套路：整个行业都在朝 ",{"type":23,"tag":162,"props":2980,"children":2981},{},[2982],{"type":28,"value":2983},"“肠促胰素 + 胰淀素”",{"type":28,"value":2985}," 这个下一步汇拢，因为这两条通路是以互补的方式抑制食欲，而不是往同一个受体上死磕。",{"type":23,"tag":24,"props":2987,"children":2988},{},[2989],{"type":28,"value":2990},"看懂了这一点，叠加这个问题就不言自明了：",{"type":23,"tag":175,"props":2992,"children":2993},{},[2994,3016,3053],{"type":23,"tag":179,"props":2995,"children":2996},{},[2997,3002,3004,3008,3010,3014],{"type":23,"tag":162,"props":2998,"children":2999},{},[3000],{"type":28,"value":3001},"把两款肠促胰素药叠在一起，基本没意义。",{"type":28,"value":3003}," Enicepatide 已经把 GLP-1 和 GIP 都覆盖了。再加 ",{"type":23,"tag":273,"props":3005,"children":3006},{"href":457},[3007],{"type":28,"value":460},{"type":28,"value":3009},"（更多 GLP-1）或 ",{"type":23,"tag":273,"props":3011,"children":3012},{"href":886},[3013],{"type":28,"value":889},{"type":28,"value":3015},"（同样这两个受体加码），并不会打开一条新机制——只是把你本来就在打的受体又加了一倍，往往是副作用涨了、好处却没多多少。这也是为什么没有哪个正经项目会去研发“GLP-1 再加一个 GLP-1”。",{"type":23,"tag":179,"props":3017,"children":3018},{},[3019,3024,3026,3031,3033,3038,3040,3044,3046,3051],{"type":23,"tag":162,"props":3020,"children":3021},{},[3022],{"type":28,"value":3023},"理性的搭档是胰淀素。",{"type":28,"value":3025}," 而真正露馅的地方就在这儿：罗氏正是这么干的。在 enicepatide 之外，它还在研发 ",{"type":23,"tag":162,"props":3027,"children":3028},{},[3029],{"type":28,"value":3030},"petrelintide",{"type":28,"value":3032},"，一款胰淀素类似物（单用时 42 周减重约 9%）；并在 ",{"type":23,"tag":162,"props":3034,"children":3035},{},[3036],{"type":28,"value":3037},"2026 年年中启动了一项把两者合用的二期试验",{"type":28,"value":3039},"——固定剂量的 enicepatide + petrelintide，摆明了就是要在更好耐受的前提下追更多减重。诺和诺德那一版思路叫 ",{"type":23,"tag":162,"props":3041,"children":3042},{},[3043],{"type":28,"value":1168},{"type":28,"value":3045},"；礼来那一版是 ",{"type":23,"tag":162,"props":3047,"children":3048},{},[3049],{"type":28,"value":3050},"替尔泊肽 + eloralintide",{"type":28,"value":3052},"；罗氏这一版是 enicepatide + petrelintide。同一个菜谱，三家厨房。",{"type":23,"tag":179,"props":3054,"children":3055},{},[3056,3061,3063,3067,3069,3074],{"type":23,"tag":162,"props":3057,"children":3058},{},[3059],{"type":28,"value":3060},"生物黑客那套“reta + cagri”叠加",{"type":28,"value":3062},"——",{"type":23,"tag":273,"props":3064,"children":3065},{"href":1494},[3066],{"type":28,"value":1497},{"type":28,"value":3068}," 加 cagrilintide——是同一套逻辑在灰色市场的回声：一款三重肠促胰素加一款胰淀素。从机制上说，它和那几家公司在试的东西押着同一个韵。但实际上，它完全是另一回事：",{"type":23,"tag":162,"props":3070,"children":3071},{},[3072],{"type":28,"value":3073},"这种自己动手的版本没有任何受控的人体安全数据",{"type":28,"value":3075},"，副作用（恶心、呕吐、脱水，以及随之而来的停药）也会一起叠加，而这种场景下的每一支西林瓶，都是身份和纯度都没保证的不受监管原料。一种组合在申办方的试验里药理上讲得通，并不能让自己配的那一版变得安全、剂量正确，或者合法。",{"type":23,"tag":24,"props":3077,"children":3078},{},[3079,3081,3086],{"type":28,"value":3080},"所以：enicepatide 能叠加吗？纸面上，合理的组合是 enicepatide ",{"type":23,"tag":162,"props":3082,"children":3083},{},[3084],{"type":28,"value":3085},"配一款胰淀素",{"type":28,"value":3087},"，而不是再配一款 GLP-1——而这个组合，罗氏自己正在临床监督下搭建，比任何人能买到其中任何一块，都要早上好几年。",{"type":23,"tag":35,"props":3089,"children":3090},{"id":1615},[3091],{"type":28,"value":1615},{"type":23,"tag":24,"props":3093,"children":3094},{},[3095,3097,3102,3104,3109,3111,3115],{"type":28,"value":3096},"对时间线要看得清醒。Enicepatide 还处在 ",{"type":23,"tag":162,"props":3098,"children":3099},{},[3100],{"type":28,"value":3101},"在研阶段",{"type":28,"value":3103},"。它在任何地方都没有获批，你开不到它的处方，三期项目指向的可能上市时间在 2030 年前后。眼下网上任何打着“enicepatide”或“CT-388”名号卖的东西，按定义就是身份和纯度不明的、未获批的灰色市场货——一份委员会的幻灯片、一项临床试验，替不了某个陌生人寄给你的那支西林瓶背书。想了解更大的法律图景，我们那篇讲",{"type":23,"tag":273,"props":3105,"children":3106},{"href":1580},[3107],{"type":28,"value":3108},"肽是否合法",{"type":28,"value":3110},"的总览文把各个类别都梳了一遍，而",{"type":23,"tag":273,"props":3112,"children":3113},{"href":449},[3114],{"type":28,"value":452},{"type":28,"value":3116},"则是从零讲起的入门。",{"type":23,"tag":24,"props":3118,"children":3119},{},[3120,3122,3127,3129,3133,3135,3140],{"type":28,"value":3121},"至于人们今天真正在追踪的那些药，中立的那部分就是算术。如果你想记录自己手上有什么、什么浓度、什么时候用的，",{"type":23,"tag":273,"props":3123,"children":3124},{"href":1625},[3125],{"type":28,"value":3126},"我们的肽追踪器",{"type":28,"value":3128},"正是为这个而做；如果让你犯难的是复溶这一步，",{"type":23,"tag":273,"props":3130,"children":3131},{"href":1633},[3132],{"type":28,"value":1636},{"type":28,"value":3134},"会在你知道西林瓶规格、又加了多少抑菌注射用水之后，把目标剂量换算成注射器上的单位数；又因为这些是每周一次的注射、药物水平会在两针之间起起落落，",{"type":23,"tag":273,"props":3136,"children":3137},{"href":1641},[3138],{"type":28,"value":3139},"血药浓度曲线图",{"type":28,"value":3141},"会把这条曲线画出来。这些都不是在推荐你去用任何东西——只是算术，老老实实的算术。",{"type":23,"tag":35,"props":3143,"children":3145},{"id":3144},"一句话总结",[3146],{"type":28,"value":3144},{"type":23,"tag":24,"props":3148,"children":3149},{},[3150,3152,3156,3158,3163],{"type":28,"value":3151},"Enicepatide（CT-388）是罗氏那款均衡、信号偏向的 GLP-1\u002FGIP 激动剂，它二期约 22.5% 的减重，让它在替尔泊肽和 Retatrutide 旁边挣到了一个实打实的座位——设计上是更干净的双受体，通往市场的路却更长。更有意思的其实是组合这条线：整个领域已经走到了 ",{"type":23,"tag":162,"props":3153,"children":3154},{},[3155],{"type":28,"value":2983},{"type":28,"value":3157},"，而罗氏自己的答案是 enicepatide ",{"type":23,"tag":162,"props":3159,"children":3160},{},[3161],{"type":28,"value":3162},"加 petrelintide",{"type":28,"value":3164},"，不是 enicepatide 再加一款 GLP-1。把两款肠促胰素叠在一起是多余的；自己动手那版“reta + cagri”借走了对的思路，却一点安全数据都没借来。就目前而言，enicepatide 是一款值得盯着看的药，而不是一款能弄到手的药——因为你弄不到，而论坛卖给你的那一版，也不是做出这些数字的那一版。",{"type":23,"tag":35,"props":3166,"children":3167},{"id":464},[3168],{"type":28,"value":464},{"type":23,"tag":175,"props":3170,"children":3171},{},[3172,3183,3194,3204,3216,3228,3239],{"type":23,"tag":179,"props":3173,"children":3174},{},[3175,3176],{"type":28,"value":1772},{"type":23,"tag":273,"props":3177,"children":3180},{"href":3178,"rel":3179},"https:\u002F\u002Fwww.roche.com\u002Fmedia\u002Freleases\u002Fmed-cor-2026-01-27",[479],[3181],{"type":28,"value":3182},"Positive Phase II results for its dual GLP-1\u002FGIP receptor agonist CT-388 (enicepatide)",{"type":23,"tag":179,"props":3184,"children":3185},{},[3186,3187],{"type":28,"value":1772},{"type":23,"tag":273,"props":3188,"children":3191},{"href":3189,"rel":3190},"https:\u002F\u002Fwww.roche.com\u002Fmedia\u002Freleases\u002Fmed-cor-2026-06-01",[479],[3192],{"type":28,"value":3193},"New data advancing its obesity portfolio at the ADA 2026 Scientific Sessions",{"type":23,"tag":179,"props":3195,"children":3196},{},[3197,3198],{"type":28,"value":1772},{"type":23,"tag":273,"props":3199,"children":3201},{"href":1775,"rel":3200},[479],[3202],{"type":28,"value":3203},"Positive Phase II results for petrelintide, an amylin analog",{"type":23,"tag":179,"props":3205,"children":3206},{},[3207,3209],{"type":28,"value":3208},"Medical Dialogues，",{"type":23,"tag":273,"props":3210,"children":3213},{"href":3211,"rel":3212},"https:\u002F\u002Fmedicaldialogues.in\u002Fnews\u002Findustry\u002Fpharma\u002Froche-obesity-drug-enicepatide-delivers-227-weight-loss-in-mid-stage-trial-challenges-wegovy-zepbound-172251",[479],[3214],{"type":28,"value":3215},"Roche obesity drug enicepatide delivers 22.7% weight loss in mid-stage trial",{"type":23,"tag":179,"props":3217,"children":3218},{},[3219,3221],{"type":28,"value":3220},"PMC／同行评审文献，",{"type":23,"tag":273,"props":3222,"children":3225},{"href":3223,"rel":3224},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC12771327\u002F",[479],[3226],{"type":28,"value":3227},"Effects of CT-388, a once-weekly signaling-biased dual GLP-1\u002FGIP receptor agonist",{"type":23,"tag":179,"props":3229,"children":3230},{},[3231,3232],{"type":28,"value":1736},{"type":23,"tag":273,"props":3233,"children":3236},{"href":3234,"rel":3235},"https:\u002F\u002Flilly.gcs-web.com\u002Fnews-releases\u002Fnews-release-details\u002Flillys-selective-amylin-agonist-eloralintide-demonstrated",[479],[3237],{"type":28,"value":3238},"Selective amylin agonist eloralintide — Phase 2 results",{"type":23,"tag":179,"props":3240,"children":3241},{},[3242,3244],{"type":28,"value":3243},"HCPLive，",{"type":23,"tag":273,"props":3245,"children":3248},{"href":3246,"rel":3247},"https:\u002F\u002Fwww.hcplive.com\u002Fview\u002Fcagrisema-achieves-22-7-weight-loss-in-phase-3-redefine-1-trial",[479],[3249],{"type":28,"value":3250},"CagriSema achieves 22.7% weight loss in Phase 3 REDEFINE 1",{"title":8,"searchDepth":556,"depth":556,"links":3252},[3253,3254,3255,3256,3257,3258,3259],{"id":2399,"depth":556,"text":2402},{"id":2498,"depth":556,"text":2498},{"id":2606,"depth":556,"text":2606},{"id":2936,"depth":556,"text":2939},{"id":1615,"depth":556,"text":1615},{"id":3144,"depth":556,"text":3144},{"id":464,"depth":556,"text":464},"content:blog:zh:enicepatide-ct-388-roche.md","blog\u002Fzh\u002Fenicepatide-ct-388-roche.md","blog\u002Fzh\u002Fenicepatide-ct-388-roche",{"_path":3264,"_dir":6,"_draft":7,"_partial":7,"_locale":8,"title":3265,"description":3266,"cat":3267,"icon":3268,"accent":3269,"date":2368,"dateLabel":2369,"read":3270,"author":17,"image":3271,"body":3272,"_type":568,"_id":3749,"_source":570,"_file":3750,"_stem":3751,"_extension":573},"\u002Fblog\u002Fzh\u002Ffda-peptides-503a-vote","FDA专家委员会投票支持BPC-157和TB-500：这改变了什么，又没改变什么","以下内容属于一般性科普，不构成医疗建议，也不是在建议你去获取或使用任何物质。它只是在解释一个监管流程。下文提到的肽都不是经FDA批准的药物，咨询委员会的一次投票不会让其中任何一种变得可以合法购买，本文也不含任何剂量或购买建议。","监管","tabler:building-bank","#3E7BB6","9 min","\u002Fassets\u002Ffda_peptides_hero.png",{"type":20,"children":3273,"toc":3739},[3274,3278,3298,3303,3308,3491,3496,3504,3510,3522,3527,3532,3537,3542,3547,3552,3557,3563,3568,3593,3603,3608,3613,3618,3650,3655,3660,3664],{"type":23,"tag":24,"props":3275,"children":3276},{},[3277],{"type":28,"value":3266},{"type":23,"tag":24,"props":3279,"children":3280},{},[3281,3283,3288,3290,3296],{"type":28,"value":3282},"一句话概括：2026年7月23日，FDA的药房配制咨询委员会（PCAC）投票，建议把四种肽——BPC-157、KPV、TB-500和MOTS-c——纳入那份清单，使配制药房可以合法制备它们。几场投票都很接近，而且结果",{"type":23,"tag":162,"props":3284,"children":3285},{},[3286],{"type":28,"value":3287},"与FDA自己的科学家意见相反",{"type":28,"value":3289},"——后者曾建议对受审的全部七种肽都说\"不\"。这是最大的看点，也确实值得关注。但热闹之下被跳过的那部分才是关键：委员会投票是一项建议，而非决定。它不批准这些肽，不会把它们摆上药房货架，投票当天也没有改动一个字的法律。最终仍要由FDA拍板，而那要等到以后。这场会议为何召开，我们在投票前已在",{"type":23,"tag":273,"props":3291,"children":3293},{"href":3292},"\u002Fblog\u002Ffda-peptide-review-2026",[3294],{"type":28,"value":3295},"对2026年7月FDA听证会的解读",{"type":28,"value":3297},"中写过。",{"type":23,"tag":35,"props":3299,"children":3301},{"id":3300},"到底决定了什么",[3302],{"type":28,"value":3300},{"type":23,"tag":24,"props":3304,"children":3305},{},[3306],{"type":28,"value":3307},"PCAC在FDA位于银泉市的总部开了两天会。第一天（7月23日）审议BPC-157、KPV、TB-500和MOTS-c；第二天（7月24日）审议艾米地肽（DSIP）、Semax和Epitalon。每种肽单独投票，只回答一个问题：是否有足够依据把它列入503A条款下的\"原料药清单\"——一种物质必须先进入这份清单，药师才能合法用它进行配制。",{"type":23,"tag":46,"props":3309,"children":3310},{},[3311,3337],{"type":23,"tag":50,"props":3312,"children":3313},{},[3314],{"type":23,"tag":54,"props":3315,"children":3316},{},[3317,3322,3327,3332],{"type":23,"tag":58,"props":3318,"children":3319},{},[3320],{"type":28,"value":3321},"肽",{"type":23,"tag":58,"props":3323,"children":3324},{},[3325],{"type":28,"value":3326},"委员会审议的背景",{"type":23,"tag":58,"props":3328,"children":3329},{},[3330],{"type":28,"value":3331},"投票（赞成–反对–弃权）",{"type":23,"tag":58,"props":3333,"children":3334},{},[3335],{"type":28,"value":3336},"建议",{"type":23,"tag":69,"props":3338,"children":3339},{},[3340,3362,3383,3404,3426,3449,3470],{"type":23,"tag":54,"props":3341,"children":3342},{},[3343,3347,3352,3357],{"type":23,"tag":76,"props":3344,"children":3345},{},[3346],{"type":28,"value":2253},{"type":23,"tag":76,"props":3348,"children":3349},{},[3350],{"type":28,"value":3351},"肠道与组织修复（溃疡性结肠炎）",{"type":23,"tag":76,"props":3353,"children":3354},{},[3355],{"type":28,"value":3356},"8–6–1",{"type":23,"tag":76,"props":3358,"children":3359},{},[3360],{"type":28,"value":3361},"列入清单",{"type":23,"tag":54,"props":3363,"children":3364},{},[3365,3370,3375,3379],{"type":23,"tag":76,"props":3366,"children":3367},{},[3368],{"type":28,"value":3369},"KPV",{"type":23,"tag":76,"props":3371,"children":3372},{},[3373],{"type":28,"value":3374},"创面愈合、炎症",{"type":23,"tag":76,"props":3376,"children":3377},{},[3378],{"type":28,"value":3356},{"type":23,"tag":76,"props":3380,"children":3381},{},[3382],{"type":28,"value":3361},{"type":23,"tag":54,"props":3384,"children":3385},{},[3386,3391,3396,3400],{"type":23,"tag":76,"props":3387,"children":3388},{},[3389],{"type":28,"value":3390},"TB-500",{"type":23,"tag":76,"props":3392,"children":3393},{},[3394],{"type":28,"value":3395},"创面与组织修复",{"type":23,"tag":76,"props":3397,"children":3398},{},[3399],{"type":28,"value":3356},{"type":23,"tag":76,"props":3401,"children":3402},{},[3403],{"type":28,"value":3361},{"type":23,"tag":54,"props":3405,"children":3406},{},[3407,3412,3417,3422],{"type":23,"tag":76,"props":3408,"children":3409},{},[3410],{"type":28,"value":3411},"MOTS-c",{"type":23,"tag":76,"props":3413,"children":3414},{},[3415],{"type":28,"value":3416},"代谢、体重",{"type":23,"tag":76,"props":3418,"children":3419},{},[3420],{"type":28,"value":3421},"7–5–2",{"type":23,"tag":76,"props":3423,"children":3424},{},[3425],{"type":28,"value":3361},{"type":23,"tag":54,"props":3427,"children":3428},{},[3429,3434,3439,3444],{"type":23,"tag":76,"props":3430,"children":3431},{},[3432],{"type":28,"value":3433},"艾米地肽（DSIP）",{"type":23,"tag":76,"props":3435,"children":3436},{},[3437],{"type":28,"value":3438},"睡眠",{"type":23,"tag":76,"props":3440,"children":3441},{},[3442],{"type":28,"value":3443},"第二天——截稿时尚无最终结果",{"type":23,"tag":76,"props":3445,"children":3446},{},[3447],{"type":28,"value":3448},"待定",{"type":23,"tag":54,"props":3450,"children":3451},{},[3452,3457,3462,3466],{"type":23,"tag":76,"props":3453,"children":3454},{},[3455],{"type":28,"value":3456},"Semax",{"type":23,"tag":76,"props":3458,"children":3459},{},[3460],{"type":28,"value":3461},"认知",{"type":23,"tag":76,"props":3463,"children":3464},{},[3465],{"type":28,"value":3443},{"type":23,"tag":76,"props":3467,"children":3468},{},[3469],{"type":28,"value":3448},{"type":23,"tag":54,"props":3471,"children":3472},{},[3473,3478,3483,3487],{"type":23,"tag":76,"props":3474,"children":3475},{},[3476],{"type":28,"value":3477},"Epitalon",{"type":23,"tag":76,"props":3479,"children":3480},{},[3481],{"type":28,"value":3482},"长寿",{"type":23,"tag":76,"props":3484,"children":3485},{},[3486],{"type":28,"value":3443},{"type":23,"tag":76,"props":3488,"children":3489},{},[3490],{"type":28,"value":3448},{"type":23,"tag":24,"props":3492,"children":3493},{},[3494],{"type":28,"value":3495},"第一天的四种肽都过了，但请看票差：8比6、外加一票弃权，距离平局只差一票。这不是众口一词的信任，而是一群意见分歧的委员勉强倒向了\"放开\"。第二天的三种肽在本文付印时仍在讨论；结果一旦公开，我们会补进表格，而不是在这里瞎猜。",{"type":23,"tag":24,"props":3497,"children":3498},{},[3499],{"type":23,"tag":2949,"props":3500,"children":3503},{"alt":3501,"src":3502},"七个多肽西林瓶旁边放着一张核对清单，其中四个已打勾","\u002Fassets\u002Ffda_peptides_seven.png",[],{"type":23,"tag":35,"props":3505,"children":3507},{"id":3506},"为什么fda自己的科学家说不",[3508],{"type":28,"value":3509},"为什么FDA自己的科学家说\"不\"",{"type":23,"tag":24,"props":3511,"children":3512},{},[3513,3515,3520],{"type":28,"value":3514},"正是这一点，让故事比\"委员会放行肽类\"更有意思。FDA的审评人员建议驳回",{"type":23,"tag":162,"props":3516,"children":3517},{},[3518],{"type":28,"value":3519},"全部七种",{"type":28,"value":3521},"，而他们给出的理由不是小题大做，是证据。",{"type":23,"tag":24,"props":3523,"children":3524},{},[3525],{"type":28,"value":3526},"说白了，他们的核心意思是：这些物质表征不清，关于它们到底有没有效的人体数据少得可怜，甚至根本没有。就BPC-157而言，审评人员说他们基本上只找到一篇小型试验的摘要——大约46人，而且是以灌肠方式给药，并非人们实际使用的注射。就KPV而言，他们没有找到任何人体试验。安全性数据有限，免疫原性风险——即身体对注射进来的肽产生免疫反应的可能——在很大程度上未经评估；而对溃疡性结肠炎这类疾病，已经有越过这道门槛的获批药物。再叠加配制本身的隐忧：配制产品的差错率高于工业化生产的产品，而2025年一项针对药房配制GLP-1药物的分析发现，其不良反应多于已获批的对应产品。这些都不是在说这些肽有害——而是在说，放行所需的证据眼下根本还不够。",{"type":23,"tag":24,"props":3528,"children":3529},{},[3530],{"type":28,"value":3531},"委员会成员之一、UT MD安德森癌症中心的麻醉医生Elizabeth Rebello直言不讳地道出反对意见：\"我担心我们是在回应市场制造出来的需求，而不是在做一个建立在扎实科学之上的决定。\"这正是反对票的关键：不是说这些肽已被证明有害，而是说流行本身并不构成证据。",{"type":23,"tag":35,"props":3533,"children":3535},{"id":3534},"利益冲突这道坎",[3536],{"type":28,"value":3534},{"type":23,"tag":24,"props":3538,"children":3539},{},[3540],{"type":28,"value":3541},"不了解谁坐在会议室里，就无法公允地读这次投票。委员会在会前不久被大改：十二名成员中有八名是2026年6月底任命的，而据STAT等媒体报道，这些新任命者中除一人外，都与销售或注射肽类的企业存在财务往来。被点名的例子包括：一名医生担任某男性健康连锁诊所的医务主管，而该诊所出售肽类注射；一名医生对肽类咨询收费并推广BPC-157；还有一名药师在自家的配制药房工作。",{"type":23,"tag":24,"props":3543,"children":3544},{},[3545],{"type":28,"value":3546},"这可不是无关紧要的细节。当投票放开某种产品的人，在不少情况下正是从这种放开中获利的人，这次投票就该受到和任何游说一样的质疑——正因如此，反对意见和FDA科学家的立场作为制衡才如此重要。值得肯定的是，该机构增补了几名具有学术与临床研究背景的临时表决成员，以冲淡这种担忧；但批评是实打实的，读上面那些8比6的票差时值得放在心上。就连投赞成票的成员，也是站在患者安全的角度：新任命者之一Haleem Mohammed医生辩称：\"作为医生，我必须尽力让患者尽可能安全。这是我的职责，对吧？首先，不造成伤害。\"这两种想法可以同时成立：动机也许是真诚的，冲突也依然可能扭曲结果。",{"type":23,"tag":35,"props":3548,"children":3550},{"id":3549},"最先动的是钱",[3551],{"type":28,"value":3549},{"type":23,"tag":24,"props":3553,"children":3554},{},[3555],{"type":28,"value":3556},"一个值得留意的信号：BPC-157投票之后，Hims & Hers——一家有望从更广泛的配制肽类渠道中获益的远程医疗公司——股价上涨超过10%。法律没有改变。没有任何一种肽获批。没有任何一家药房拿到新权利。委员会只是向FDA提了个建议，市场却在一天之内让一只股票涨了两位数。真正发生的（一项不具约束力的建议）与被外界解读成的（放行）之间的这道落差，正是我们要冷静下笔的全部理由。市场能抢在事实前面，一封冲着你来的营销邮件也一样。",{"type":23,"tag":35,"props":3558,"children":3560},{"id":3559},"对患者和诊所改变了什么又没改变什么",[3561],{"type":28,"value":3562},"对患者和诊所改变了什么，又没改变什么",{"type":23,"tag":24,"props":3564,"children":3565},{},[3566],{"type":28,"value":3567},"我们把话说准，因为这一段最容易被扭曲。",{"type":23,"tag":24,"props":3569,"children":3570},{},[3571,3573,3577,3579,3584,3586,3591],{"type":28,"value":3572},"7月23日",{"type":23,"tag":162,"props":3574,"children":3575},{},[3576],{"type":28,"value":257},{"type":28,"value":3578},"改变的：这些肽中任何一种的法律地位。BPC-157、TB-500、KPV和MOTS-c今天的合法程度——无论合法与否——都和投票前一天一模一样。没有一种成了获批药物。没有一种因为这次投票就成了药房当下可以配制的东西。此刻有人卖给你、贴着\"BPC-157\"或\"TB-500\"标签的任何东西，不论是包装成保健品还是标着\"仅供研究\"，仍然是未获批的灰色市场货，其真伪与纯度都无从核实。委员会的一句意见，既不能让一支西林瓶变干净，也不能替你核验瓶里到底装了什么。完整的法律图景，可读我们的支柱文章",{"type":23,"tag":273,"props":3580,"children":3581},{"href":1580},[3582],{"type":28,"value":3583},"肽类合法吗",{"type":28,"value":3585},"；而",{"type":23,"tag":273,"props":3587,"children":3588},{"href":436},[3589],{"type":28,"value":3590},"经FDA批准的肽",{"type":28,"value":3592},"会告诉你哪些肽真正通过了批准——那是一份很不一样、也短得多的清单。",{"type":23,"tag":24,"props":3594,"children":3595},{},[3596,3601],{"type":23,"tag":664,"props":3597,"children":3598},{},[3599],{"type":28,"value":3600},"以后",{"type":28,"value":3602},"可能改变的：如果FDA采纳建议，这些肽就会获得一条合法的配制途径。久而久之，这通常意味着凭处方、更稳定、药房级别的产品，也意味着更少理由去碰灰色市场。这是乐观的一面，而且真实存在。但这只是一种尚未发生的可能，前提是FDA点头——而这个决定还没做出。",{"type":23,"tag":35,"props":3604,"children":3606},{"id":3605},"接下来会怎样",[3607],{"type":28,"value":3605},{"type":23,"tag":24,"props":3609,"children":3610},{},[3611],{"type":28,"value":3612},"委员会提建议，FDA作决定。眼下该机构在权衡这项建议，决定是否启动正式的立法程序，把其中某些肽列入503A清单——这个过程实际上会持续许多个月，可能一直拖到2027年。它可以采纳建议、否决建议，也可以逐个肽地落在两者之间。第二天关于艾米地肽、Semax和Epitalon的投票会补齐其余画面；结果一经公开，我们就会用确认过的票数更新本文。",{"type":23,"tag":24,"props":3614,"children":3615},{},[3616],{"type":28,"value":3617},"诚实的结论既不是\"肽类回来了\"，也不是\"肽类被禁了\"。而是：7月23日，少数几种具体的肽，其处境确实开始松动——朝着最终合法配制的方向——但截至今天，它们仍停在原地：未获批、未受监管、灰色市场。盯住这一动向是明智的；把它当成已经尘埃落定，则不然。",{"type":23,"tag":24,"props":3619,"children":3620},{},[3621,3623,3627,3629,3633,3635,3640,3642,3648],{"type":28,"value":3622},"如果你本就在记录肽类，把自己有什么、浓度多少、什么时候用的记清楚——这正是",{"type":23,"tag":273,"props":3624,"children":3625},{"href":1625},[3626],{"type":28,"value":1628},{"type":28,"value":3628},"的用途——远比任何论坛对一次委员会投票的解读更有价值。想从头理解这一类物质，先看",{"type":23,"tag":273,"props":3630,"children":3631},{"href":449},[3632],{"type":28,"value":452},{"type":28,"value":3634},"；想了解这次会议之前的来龙去脉，看",{"type":23,"tag":273,"props":3636,"children":3637},{"href":3292},[3638],{"type":28,"value":3639},"FDA听证会解读",{"type":28,"value":3641},"；至于如何冷静地读一个大标题，我们那篇关于",{"type":23,"tag":273,"props":3643,"children":3645},{"href":3644},"\u002Fblog\u002Fretatrutide-triumph-1-results",[3646],{"type":28,"value":3647},"瑞他鲁肽TRIUMPH-1",{"type":28,"value":3649},"的姊妹文，讲的正是同一种冷静的读法，只不过换到了另一种药上。",{"type":23,"tag":35,"props":3651,"children":3653},{"id":3652},"结语",[3654],{"type":28,"value":3652},{"type":23,"tag":24,"props":3656,"children":3657},{},[3658],{"type":28,"value":3659},"FDA一个咨询委员会以微弱多数建议将BPC-157、KPV、TB-500和MOTS-c纳入配制范围，越过了自己的科学家——与此同时，谁在投票是个真问题，而支持任何一种肽有效的人体证据都很单薄。建议不是批准，FDA尚未定夺，投票当天购买这些肽既没有变得更安全，也没有变得更合法。把这个结果读作规则\"可能改变\"的信号，而不是读作它\"已经改变\"的许可。",{"type":23,"tag":35,"props":3661,"children":3662},{"id":464},[3663],{"type":28,"value":464},{"type":23,"tag":175,"props":3665,"children":3666},{},[3667,3679,3691,3703,3715,3727],{"type":23,"tag":179,"props":3668,"children":3669},{},[3670,3672],{"type":28,"value":3671},"FDA，",{"type":23,"tag":273,"props":3673,"children":3676},{"href":3674,"rel":3675},"https:\u002F\u002Fwww.fda.gov\u002Fadvisory-committees\u002Fadvisory-committee-calendar\u002Fjuly-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026",[479],[3677],{"type":28,"value":3678},"药房配制咨询委员会会议，2026年7月23日至24日",{"type":23,"tag":179,"props":3680,"children":3681},{},[3682,3684],{"type":28,"value":3683},"TIME，",{"type":23,"tag":273,"props":3685,"children":3688},{"href":3686,"rel":3687},"https:\u002F\u002Ftime.com\u002Farticle\u002F2026\u002F07\u002F23\u002Ffda-committee-peptides\u002F",[479],[3689],{"type":28,"value":3690},"An FDA committee just voted in favor of peptides — despite the agency's opposition",{"type":23,"tag":179,"props":3692,"children":3693},{},[3694,3696],{"type":28,"value":3695},"STAT，",{"type":23,"tag":273,"props":3697,"children":3700},{"href":3698,"rel":3699},"https:\u002F\u002Fwww.statnews.com\u002F2026\u002F07\u002F23\u002Ffda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv\u002F",[479],[3701],{"type":28,"value":3702},"FDA panel backs compounded BPC-157, KPV peptides in win for RFK Jr.",{"type":23,"tag":179,"props":3704,"children":3705},{},[3706,3708],{"type":28,"value":3707},"RAPS，",{"type":23,"tag":273,"props":3709,"children":3712},{"href":3710,"rel":3711},"https:\u002F\u002Fwww.raps.org\u002Fresource\u002Ffda-advisory-committee-backs-two-controversial-peptides.html",[479],[3713],{"type":28,"value":3714},"FDA advisory committee backs two controversial peptides",{"type":23,"tag":179,"props":3716,"children":3717},{},[3718,3720],{"type":28,"value":3719},"BioPharma Dive，",{"type":23,"tag":273,"props":3721,"children":3724},{"href":3722,"rel":3723},"https:\u002F\u002Fwww.biopharmadive.com\u002Fnews\u002Ffda-peptides-advisory-committee-vote-bpc-kpv-tb-mots\u002F826062\u002F",[479],[3725],{"type":28,"value":3726},"FDA panel endorses broader use of certain peptides",{"type":23,"tag":179,"props":3728,"children":3729},{},[3730,3732],{"type":28,"value":3731},"The Hill，",{"type":23,"tag":273,"props":3733,"children":3736},{"href":3734,"rel":3735},"https:\u002F\u002Fthehill.com\u002Fhomenews\u002F5987510-fda-committee-votes-peptides\u002F",[479],[3737],{"type":28,"value":3738},"FDA committee votes to add peptides to permitted compounding list despite opposition from agency scientists",{"title":8,"searchDepth":556,"depth":556,"links":3740},[3741,3742,3743,3744,3745,3746,3747,3748],{"id":3300,"depth":556,"text":3300},{"id":3506,"depth":556,"text":3509},{"id":3534,"depth":556,"text":3534},{"id":3549,"depth":556,"text":3549},{"id":3559,"depth":556,"text":3562},{"id":3605,"depth":556,"text":3605},{"id":3652,"depth":556,"text":3652},{"id":464,"depth":556,"text":464},"content:blog:zh:fda-peptides-503a-vote.md","blog\u002Fzh\u002Ffda-peptides-503a-vote.md","blog\u002Fzh\u002Ffda-peptides-503a-vote",{"_path":3753,"_dir":6,"_draft":7,"_partial":7,"_locale":8,"title":3754,"description":3755,"cat":11,"icon":3756,"accent":3757,"date":3758,"dateLabel":2369,"read":3759,"author":17,"image":3760,"body":3761,"_type":568,"_id":4073,"_source":570,"_file":4074,"_stem":4075,"_extension":573},"\u002Fblog\u002Fzh\u002Fretatrutide-triumph-2-3-results","Retatrutide TRIUMPH-2 与 TRIUMPH-3：糖尿病与心脏病人群的三期数据","本文属于一般性科普，不是医疗建议，也不是鼓励你去获取或使用任何东西。Retatrutide 仍处于试验阶段，尚未获批。下面这些数字，是一家公司从自己的试验里报出来的结果，既不是对任何疗效的承诺，也不是用药指导。","tabler:chart-line","#4C9F70","2026-07-23","6 min","\u002Fassets\u002Freta_triumph_hero.png",{"type":20,"children":3762,"toc":4064},[3763,3767,3772,3778,3783,3843,3848,3853,3861,3867,3872,3916,3921,3926,3931,3936,3941,3960,3966,3997,4002,4007,4011,4022,4026],{"type":23,"tag":24,"props":3764,"children":3765},{},[3766],{"type":28,"value":3755},{"type":23,"tag":24,"props":3768,"children":3769},{},[3770],{"type":28,"value":3771},"一句话版本：2026 年 7 月 23 日，礼来公布了旗下三重激动剂 Retatrutide 另外两项三期试验的顶线结果。TRIUMPH-2 面向 2 型糖尿病成年人，TRIUMPH-3 面向重度肥胖合并已确诊心血管疾病的成年人。两项都达到了各自的减重目标，糖尿病那项里血糖控制也一并改善了。数据很硬。而要泼的这盆冷水，和 TRIUMPH-1 时一模一样：这只是公司的一份新闻稿，不是经过完整同行评审的数据集；Retatrutide 至今仍未获批；今天任何打着这个名号卖的东西，都是未获批的灰色市场货。",{"type":23,"tag":35,"props":3773,"children":3775},{"id":3774},"triumph-22-型糖尿病人群的数字",[3776],{"type":28,"value":3777},"TRIUMPH-2：2 型糖尿病人群的数字",{"type":23,"tag":24,"props":3779,"children":3780},{},[3781],{"type":28,"value":3782},"TRIUMPH-2 招募了 1,152 名成年人，他们除了肥胖或超重，还患有 2 型糖尿病；试验在 80 周里测试了这款每周一次注射剂的三种剂量。",{"type":23,"tag":46,"props":3784,"children":3785},{},[3786,3802],{"type":23,"tag":50,"props":3787,"children":3788},{},[3789],{"type":23,"tag":54,"props":3790,"children":3791},{},[3792,3797],{"type":23,"tag":58,"props":3793,"children":3794},{},[3795],{"type":28,"value":3796},"每周剂量",{"type":23,"tag":58,"props":3798,"children":3799},{},[3800],{"type":28,"value":3801},"80 周平均减重",{"type":23,"tag":69,"props":3803,"children":3804},{},[3805,3818,3830],{"type":23,"tag":54,"props":3806,"children":3807},{},[3808,3813],{"type":23,"tag":76,"props":3809,"children":3810},{},[3811],{"type":28,"value":3812},"4 mg",{"type":23,"tag":76,"props":3814,"children":3815},{},[3816],{"type":28,"value":3817},"约 12.7%（约 13.5 公斤 \u002F 29.8 磅）",{"type":23,"tag":54,"props":3819,"children":3820},{},[3821,3825],{"type":23,"tag":76,"props":3822,"children":3823},{},[3824],{"type":28,"value":1270},{"type":23,"tag":76,"props":3826,"children":3827},{},[3828],{"type":28,"value":3829},"约 19.1%（约 20.6 公斤 \u002F 45.4 磅）",{"type":23,"tag":54,"props":3831,"children":3832},{},[3833,3838],{"type":23,"tag":76,"props":3834,"children":3835},{},[3836],{"type":28,"value":3837},"12 mg",{"type":23,"tag":76,"props":3839,"children":3840},{},[3841],{"type":28,"value":3842},"约 20.8%（约 22.5 公斤 \u002F 49.6 磅）",{"type":23,"tag":24,"props":3844,"children":3845},{},[3846],{"type":28,"value":3847},"除了减重，HbA1c——衡量三个月血糖控制的常用指标——平均最多降了 1.6 个百分点，安慰剂组只降了 0.2。对一款在糖尿病领域研发的药来说，同时管住体重和血糖，正是它的意义所在。",{"type":23,"tag":24,"props":3849,"children":3850},{},[3851],{"type":28,"value":3852},"Retatrutide 是一款三重激动剂：一个分子同时作用于 GIP、GLP-1 和胰高血糖素三种受体。正是胰高血糖素这第三个靶点，被认为让它比之前的 GLP-1 以及 GLP-1\u002FGIP 药物\"下手更狠\"。",{"type":23,"tag":24,"props":3854,"children":3855},{},[3856],{"type":23,"tag":2949,"props":3857,"children":3860},{"alt":3858,"src":3859},"减重曲线一路向下，旁边是逐渐纤细的身形剪影","\u002Fassets\u002Freta_triumph_chart.png",[],{"type":23,"tag":35,"props":3862,"children":3864},{"id":3863},"triumph-3更难啃的人群",[3865],{"type":28,"value":3866},"TRIUMPH-3：更难啃的人群",{"type":23,"tag":24,"props":3868,"children":3869},{},[3870],{"type":28,"value":3871},"TRIUMPH-3 挑的是一批更棘手的人：1,949 名重度肥胖并已确诊心血管疾病的成年人，无论是否合并 2 型糖尿病，都用两种较高剂量随访了 80 周。",{"type":23,"tag":46,"props":3873,"children":3874},{},[3875,3889],{"type":23,"tag":50,"props":3876,"children":3877},{},[3878],{"type":23,"tag":54,"props":3879,"children":3880},{},[3881,3885],{"type":23,"tag":58,"props":3882,"children":3883},{},[3884],{"type":28,"value":3796},{"type":23,"tag":58,"props":3886,"children":3887},{},[3888],{"type":28,"value":3801},{"type":23,"tag":69,"props":3890,"children":3891},{},[3892,3904],{"type":23,"tag":54,"props":3893,"children":3894},{},[3895,3899],{"type":23,"tag":76,"props":3896,"children":3897},{},[3898],{"type":28,"value":1270},{"type":23,"tag":76,"props":3900,"children":3901},{},[3902],{"type":28,"value":3903},"约 21.6%",{"type":23,"tag":54,"props":3905,"children":3906},{},[3907,3911],{"type":23,"tag":76,"props":3908,"children":3909},{},[3910],{"type":28,"value":3837},{"type":23,"tag":76,"props":3912,"children":3913},{},[3914],{"type":28,"value":3915},"约 22.6%（约 25.3 公斤 \u002F 55.8 磅）",{"type":23,"tag":24,"props":3917,"children":3918},{},[3919],{"type":28,"value":3920},"礼来还报告这一组在心血管代谢指标上的改善——血压和甘油三酯都在其中——而对已经患有心脏病的人群来说，这恰恰是最有分量的那类数据。和这里的一切一样，在完整数据集出来之前，都请把它当作顶线数字看待。",{"type":23,"tag":35,"props":3922,"children":3924},{"id":3923},"冷水还得泼",[3925],{"type":28,"value":3923},{"type":23,"tag":24,"props":3927,"children":3928},{},[3929],{"type":28,"value":3930},"有三件事给这份兴奋降降温，和第一项试验时说的是同样三件。",{"type":23,"tag":24,"props":3932,"children":3933},{},[3934],{"type":28,"value":3935},"它没获批。三期顶线数据是申报路上的一个里程碑，不是终点线。在监管机构审完整个材料包之前，不存在合法、凭处方开出的 Retatrutide——无论是用于糖尿病还是减重。",{"type":23,"tag":24,"props":3937,"children":3938},{},[3939],{"type":28,"value":3940},"\"顶线\"不等于完整数据集。新闻稿给你的，是挑得最好看的那几个数字。完整结果、安全性细节，以及那份永远最关键的脱落率与不良事件明细，都得等到后面——在某场医学大会上、在某本期刊里才会揭晓。",{"type":23,"tag":24,"props":3942,"children":3943},{},[3944,3946,3951,3953,3958],{"type":28,"value":3945},"而最实际的一点：眼下市面上流通的全是灰色市场货。正因为真正的药还没获批，网上打着\"retatrutide\"名号卖的，是不受监管的研究级原料，成分和纯度都成谜。试验里那些数字，是用一种成分明确的化合物、在临床环境下按剂量给药并全程监测得来的；它们完全说明不了论坛上某人卖的那支西林瓶到底是什么。这些我们在 ",{"type":23,"tag":273,"props":3947,"children":3948},{"href":3644},[3949],{"type":28,"value":3950},"TRIUMPH-1 解读",{"type":28,"value":3952},"和 ",{"type":23,"tag":273,"props":3954,"children":3955},{"href":275},[3956],{"type":28,"value":3957},"Retatrutide 肝损伤事实核查",{"type":28,"value":3959},"里都聊得很透。",{"type":23,"tag":35,"props":3961,"children":3963},{"id":3962},"你即将到处看到的剂量以及它们不是什么",[3964],{"type":28,"value":3965},"你即将到处看到的剂量，以及它们不是什么",{"type":23,"tag":24,"props":3967,"children":3968},{},[3969,3971,3976,3978,3984,3986,3990,3992,3996],{"type":28,"value":3970},"试验剂量——每周 4 mg、9 mg 和 12 mg——如今出现在每一篇报道里，而这也正是有人开始拿灰色市场西林瓶反推一张\"Retatrutide 剂量表\"的地方。这张表我们不会给你：上面那些剂量是礼来在临床监督下给的，不是拿来照抄的方案。工具能替你做的，只是中立的那一部分——算术。如果你已经知道一支西林瓶的浓度、又往里加了多少抑菌注射用水，我们的 ",{"type":23,"tag":273,"props":3972,"children":3973},{"href":1633},[3974],{"type":28,"value":3975},"Retatrutide 复溶计算器",{"type":28,"value":3977},"会把目标剂量换算成注射器上确切的单位数；要是让你犯难的是配制这一步，",{"type":23,"tag":273,"props":3979,"children":3981},{"href":3980},"\u002Fcalculator\u002Fbac-water",[3982],{"type":28,"value":3983},"该加多少抑菌注射用水",{"type":28,"value":3985},"就专门做这一道计算。因为它是每周一次注射，药物在体内的水平会在两针之间起起落落——Retatrutide 半衰期的这条曲线，你可以在",{"type":23,"tag":273,"props":3987,"children":3988},{"href":1641},[3989],{"type":28,"value":3139},{"type":28,"value":3991},"里看到。想了解已发表文献里报告的剂量，以及这款分子的基础知识，可以看我们的 ",{"type":23,"tag":273,"props":3993,"children":3994},{"href":1494},[3995],{"type":28,"value":2903},{"type":28,"value":370},{"type":23,"tag":35,"props":3998,"children":4000},{"id":3999},"接下来会发生什么",[4001],{"type":28,"value":3999},{"type":23,"tag":24,"props":4003,"children":4004},{},[4005],{"type":28,"value":4006},"礼来表示，计划在 2027 年第一季度之前把 Retatrutide 递交给 FDA。正是这一步，才把一份顶线新闻稿变成一份可以审查的申请；而在监管机构真正看过完整的安全性与有效性材料之前，不存在获批、凭处方开出的 Retatrutide。TRIUMPH-2 和 TRIUMPH-3 的完整数据也会在医学大会和期刊上亮相，届时独立研究者就能核对新闻稿略过的那些细节。",{"type":23,"tag":35,"props":4008,"children":4009},{"id":3144},[4010],{"type":28,"value":3144},{"type":23,"tag":24,"props":4012,"children":4013},{},[4014,4016,4020],{"type":28,"value":4015},"又是两场三期胜利：2 型糖尿病人群最高减重 20.8%、HbA1c 下降 1.6 个百分点，已确诊心脏病人群最高达 22.6%。就现有进展看，Retatrutide 仍像是在研管线里最强的那款肠促胰素类药物。但它同样尚未获批，目前也只公布了顶线数据，今天更不可能通过受监管的渠道买到。读一份试验数据，和读一个卖货页面，完全是两码事。想从零开始搞懂这一类药，先从",{"type":23,"tag":273,"props":4017,"children":4018},{"href":449},[4019],{"type":28,"value":452},{"type":28,"value":4021},"看起。",{"type":23,"tag":35,"props":4023,"children":4024},{"id":464},[4025],{"type":28,"value":464},{"type":23,"tag":175,"props":4027,"children":4028},{},[4029,4041,4053],{"type":23,"tag":179,"props":4030,"children":4031},{},[4032,4034],{"type":28,"value":4033},"礼来（投资者新闻稿），2026 年 7 月 23 日，",{"type":23,"tag":273,"props":4035,"children":4038},{"href":4036,"rel":4037},"https:\u002F\u002Finvestor.lilly.com\u002Fnews-releases\u002Fnews-release-details\u002Flillys-triple-agonist-retatrutide-successful-two-additional",[479],[4039],{"type":28,"value":4040},"Lilly's triple agonist retatrutide successful in two additional phase-3 obesity trials",{"type":23,"tag":179,"props":4042,"children":4043},{},[4044,4046],{"type":28,"value":4045},"PharmExec，",{"type":23,"tag":273,"props":4047,"children":4050},{"href":4048,"rel":4049},"https:\u002F\u002Fwww.pharmexec.com\u002Fview\u002Fretatrutide-delivers-22-weight-loss-two-phase-iii-trials",[479],[4051],{"type":28,"value":4052},"Retatrutide delivers up to 22.6% weight loss in two new phase-III trials",{"type":23,"tag":179,"props":4054,"children":4055},{},[4056,4057],{"type":28,"value":3243},{"type":23,"tag":273,"props":4058,"children":4061},{"href":4059,"rel":4060},"https:\u002F\u002Fwww.hcplive.com\u002Fview\u002Fretatrutide-meets-phase-3-weight-loss-endpoints-in-2-obesity-trials",[479],[4062],{"type":28,"value":4063},"Retatrutide meets phase-3 weight-loss endpoints in two obesity trials",{"title":8,"searchDepth":556,"depth":556,"links":4065},[4066,4067,4068,4069,4070,4071,4072],{"id":3774,"depth":556,"text":3777},{"id":3863,"depth":556,"text":3866},{"id":3923,"depth":556,"text":3923},{"id":3962,"depth":556,"text":3965},{"id":3999,"depth":556,"text":3999},{"id":3144,"depth":556,"text":3144},{"id":464,"depth":556,"text":464},"content:blog:zh:retatrutide-triumph-2-3-results.md","blog\u002Fzh\u002Fretatrutide-triumph-2-3-results.md","blog\u002Fzh\u002Fretatrutide-triumph-2-3-results",{"_path":4077,"_dir":6,"_draft":7,"_partial":7,"_locale":8,"title":4078,"description":4079,"cat":3267,"icon":3268,"accent":3269,"date":4080,"dateLabel":2369,"read":3759,"author":17,"image":3271,"body":4081,"_type":568,"_id":4304,"_source":570,"_file":4305,"_stem":4306,"_extension":573},"\u002Fblog\u002Fzh\u002Ffda-peptide-review-2026","2026年7月，FDA就BPC-157、TB-500等七种肽召开听证会","以下内容属于一般性科普，不构成医疗建议，也不是在建议你去获取或使用任何物质。它只是在解释一个监管流程，仅此而已。下文提到的几种物质并未获批用于人体。","2026-07-01",{"type":20,"children":4082,"toc":4296},[4083,4087,4099,4105,4110,4158,4163,4170,4176,4181,4186,4191,4196,4201,4206,4224,4229,4234,4250,4255,4259],{"type":23,"tag":24,"props":4084,"children":4085},{},[4086],{"type":28,"value":4079},{"type":23,"tag":24,"props":4088,"children":4089},{},[4090,4092,4098],{"type":28,"value":4091},"一句话概括：2026年7月23日和24日，FDA下属的药房配制咨询委员会（PCAC）将开会，商定要就七种早已被很多人挂在嘴边的肽——包括BPC-157和TB-500——提出什么建议。问题本身范围很窄，但份量不轻：这些物质该不该被列入503A条款下的\"原料药清单\"，而正是这份清单，决定了配制药房能否合法地为患者制备它们。委员会只负责提建议，最终拍板的还是FDA。更多细节可见",{"type":23,"tag":273,"props":4093,"children":4095},{"href":3674,"rel":4094},[479],[4096],{"type":28,"value":4097},"FDA官方的会议页面",{"type":28,"value":370},{"type":23,"tag":35,"props":4100,"children":4102},{"id":4101},"有哪几种肽什么时候审",[4103],{"type":28,"value":4104},"有哪几种肽，什么时候审",{"type":23,"tag":24,"props":4106,"children":4107},{},[4108],{"type":28,"value":4109},"议程分成两天。",{"type":23,"tag":46,"props":4111,"children":4112},{},[4113,4129],{"type":23,"tag":50,"props":4114,"children":4115},{},[4116],{"type":23,"tag":54,"props":4117,"children":4118},{},[4119,4124],{"type":23,"tag":58,"props":4120,"children":4121},{},[4122],{"type":28,"value":4123},"日期",{"type":23,"tag":58,"props":4125,"children":4126},{},[4127],{"type":28,"value":4128},"审议的肽",{"type":23,"tag":69,"props":4130,"children":4131},{},[4132,4145],{"type":23,"tag":54,"props":4133,"children":4134},{},[4135,4140],{"type":23,"tag":76,"props":4136,"children":4137},{},[4138],{"type":28,"value":4139},"2026年7月23日",{"type":23,"tag":76,"props":4141,"children":4142},{},[4143],{"type":28,"value":4144},"BPC-157、KPV、TB-500、MOTS-c",{"type":23,"tag":54,"props":4146,"children":4147},{},[4148,4153],{"type":23,"tag":76,"props":4149,"children":4150},{},[4151],{"type":28,"value":4152},"2026年7月24日",{"type":23,"tag":76,"props":4154,"children":4155},{},[4156],{"type":28,"value":4157},"Emideltide（DSIP）、Semax、Epitalon",{"type":23,"tag":24,"props":4159,"children":4160},{},[4161],{"type":28,"value":4162},"如果你觉得这些名字很眼熟，那是因为它们正是\"科研用肽\"以及恢复\u002F抗衰圈子的招牌角色。到目前为止，其中大多数都卡在一个不上不下的法律灰色地带里——而这场会议要谈的，恰恰就是这个。",{"type":23,"tag":24,"props":4164,"children":4165},{},[4166],{"type":23,"tag":2949,"props":4167,"children":4169},{"alt":4168,"src":3502},"放大镜下的七支西林瓶，旁边放着一块审查用的记录板",[],{"type":23,"tag":35,"props":4171,"children":4173},{"id":4172},"_503a清单到底是什么",[4174],{"type":28,"value":4175},"503A清单到底是什么",{"type":23,"tag":24,"props":4177,"children":4178},{},[4179],{"type":28,"value":4180},"配制药房为个别患者定制药物。但它们不能拿随便什么原料就上手配。对于那些还不是已获批药物成分的原料药来说，一般都得先进入FDA的503A原料药清单，药剂师才能合法地拿它来配药。上了清单，就意味着有一条合法途径，可以由持牌药房来制备它。没上清单，就没有这条路；于是在市面上流通的，就变成了那些贴着\"仅供科研使用\"标签的灰色市场货——既没有合法途径，也没有任何质量保证。",{"type":23,"tag":24,"props":4182,"children":4183},{},[4184],{"type":28,"value":4185},"所以这场讨论不是在争这些肽到底有没有用。它要回答的，是一个窄得多的行政问题：从安全性和标准来看，是否有足够充分的理由，让受监管的药房去配制它们。",{"type":23,"tag":35,"props":4187,"children":4189},{"id":4188},"当初它们为什么会被点名",[4190],{"type":28,"value":4188},{"type":23,"tag":24,"props":4192,"children":4193},{},[4194],{"type":28,"value":4195},"这七种肽走到今天这一步并非偶然。它们此前被FDA归进了\"第二类\"（Category 2）那一档，意思是监管方对它们存有明显的安全疑虑，或者掌握的信息不足。被送到PCAC这一步，是把这些问题摆到台面上公开讨论的正式程序：呈报数据、请专家投票给出建议。结果两头都有可能，而且委员会的投票只是建议，不是最终定论。",{"type":23,"tag":35,"props":4197,"children":4199},{"id":4198},"结果会改变什么",[4200],{"type":28,"value":4198},{"type":23,"tag":24,"props":4202,"children":4203},{},[4204],{"type":28,"value":4205},"大体上，对任何一种肽而言，可能出现三种走向：",{"type":23,"tag":175,"props":4207,"children":4208},{},[4209,4214,4219],{"type":23,"tag":179,"props":4210,"children":4211},{},[4212],{"type":28,"value":4213},"建议列入清单。一条合法的配制途径就此打开，长期来看，这往往意味着产品更稳定、达到药房级水准，也让人少了几分去碰灰色市场的理由。",{"type":23,"tag":179,"props":4215,"children":4216},{},[4217],{"type":28,"value":4218},"不予列入。维持现状：没有合法的配制途径，网上卖的那些依旧是未获批、不受监管的货。",{"type":23,"tag":179,"props":4220,"children":4221},{},[4222],{"type":28,"value":4223},"暂缓，等更多数据。当正反两边的证据都不足时，这种情况很常见。",{"type":23,"tag":24,"props":4225,"children":4226},{},[4227],{"type":28,"value":4228},"对读者来说，真正该记住的不是\"赶紧买\"或\"离远点\"，而是：这几种肽脚下的法律地基，可能在几周之内就发生变化，值得盯着看，别想当然地以为今天的局面会一直不变。这一轮还多了一层政治因素：委员会的人员构成，再加上一股要求放宽准入的更大声浪，已经引来公众争论——读这类报道时，最好用你对待任何游说时的那种怀疑眼光去看。",{"type":23,"tag":35,"props":4230,"children":4232},{"id":4231},"该盯着看什么",[4233],{"type":28,"value":4231},{"type":23,"tag":24,"props":4235,"children":4236},{},[4237,4239,4243,4245,4249],{"type":28,"value":4238},"会议在7月23到24日举行。建议通常很快就会出来；FDA真正的决定则可能要等更久。等投票结果和任何决定公开后，我们会更新这篇文章。如果你想先搞清楚背后的法律背景，可以看",{"type":23,"tag":273,"props":4240,"children":4241},{"href":1580},[4242],{"type":28,"value":3108},{"type":28,"value":4244},"；如果你还不清楚这些化合物到底是什么，那就从",{"type":23,"tag":273,"props":4246,"children":4247},{"href":449},[4248],{"type":28,"value":452},{"type":28,"value":4021},{"type":23,"tag":24,"props":4251,"children":4252},{},[4253],{"type":28,"value":4254},"不管委员会最后怎么决定，\"仅供科研使用\"这个标签，改变不了一种物质本身到底是什么，本文也绝不是在建议你去用它。这篇文章讲的是规则，不是放行的绿灯。",{"type":23,"tag":35,"props":4256,"children":4257},{"id":464},[4258],{"type":28,"value":464},{"type":23,"tag":175,"props":4260,"children":4261},{},[4262,4272,4284],{"type":23,"tag":179,"props":4263,"children":4264},{},[4265,4266],{"type":28,"value":3671},{"type":23,"tag":273,"props":4267,"children":4269},{"href":3674,"rel":4268},[479],[4270],{"type":28,"value":4271},"药房配制咨询委员会会议，2026年7月23–24日",{"type":23,"tag":179,"props":4273,"children":4274},{},[4275,4277],{"type":28,"value":4276},"Drug Topics，",{"type":23,"tag":273,"props":4278,"children":4281},{"href":4279,"rel":4280},"https:\u002F\u002Fwww.drugtopics.com\u002Fview\u002Ffda-set-to-review-peptide-access-for-compounding-pharmacies",[479],[4282],{"type":28,"value":4283},"FDA将审议配制药房的肽类获取问题",{"type":23,"tag":179,"props":4285,"children":4286},{},[4287,4289],{"type":28,"value":4288},"Lengea Law，",{"type":23,"tag":273,"props":4290,"children":4293},{"href":4291,"rel":4292},"https:\u002F\u002Flengealaw.com\u002Ffda-puts-bpc-157-tb-500-and-5-other-peptides-under-the-microscope-what-prescribers-need-to-know-about-the-503a-review\u002F",[479],[4294],{"type":28,"value":4295},"FDA把BPC-157、TB-500等七种肽送上503A的显微镜",{"title":8,"searchDepth":556,"depth":556,"links":4297},[4298,4299,4300,4301,4302,4303],{"id":4101,"depth":556,"text":4104},{"id":4172,"depth":556,"text":4175},{"id":4188,"depth":556,"text":4188},{"id":4198,"depth":556,"text":4198},{"id":4231,"depth":556,"text":4231},{"id":464,"depth":556,"text":464},"content:blog:zh:fda-peptide-review-2026.md","blog\u002Fzh\u002Ffda-peptide-review-2026.md","blog\u002Fzh\u002Ffda-peptide-review-2026",{"_path":4308,"_dir":6,"_draft":7,"_partial":7,"_locale":8,"title":4309,"description":4310,"cat":1811,"icon":4311,"accent":1813,"date":4080,"dateLabel":4312,"read":4313,"author":17,"image":4314,"body":4315,"_type":568,"_id":4601,"_source":570,"_file":4602,"_stem":4603,"_extension":573},"\u002Fblog\u002Fzh\u002Fglp1-dosing-errors","GLP-1 用药出错：中毒热线电话为何猛增","这里说的只是科普内容，不是医疗建议，也不是给药指导。它讲的是一项研究发现了什么、错误都扎堆在哪些环节，好让你能提前看出这些坑。凡是涉及你自己治疗的事，还是去问最了解你情况的开方医生和药师。","tabler:alert-triangle","2026 年 7 月","7 分钟","\u002Fassets\u002Fglp1_errors_hero.png",{"type":20,"children":4316,"toc":4592},[4317,4321,4335,4340,4345,4350,4358,4364,4463,4468,4473,4478,4483,4489,4516,4521,4526,4531,4535,4550,4554],{"type":23,"tag":24,"props":4318,"children":4319},{},[4320],{"type":28,"value":4310},{"type":23,"tag":24,"props":4322,"children":4323},{},[4324,4326,4333],{"type":28,"value":4325},"先说结论：自 2019 年以来，美国各地中毒控制中心接到的 GLP-1 电话大约涨了 1,500%。德州大学圣安东尼奥分校（UT San Antonio）的一项新分析（由 ",{"type":23,"tag":273,"props":4327,"children":4330},{"href":4328,"rel":4329},"https:\u002F\u002Fwww.usnews.com\u002Fnews\u002Fhealth-news\u002Farticles\u002F2026-06-25\u002Fglp-1-weight-loss-boom-linked-to-surge-in-poison-control-calls",[479],[4331],{"type":28,"value":4332},"U.S. News\u002FHealthDay，2026 年 6 月 25 日",{"type":28,"value":4334}," 报道）发现，约 91% 的病例都属于治疗性差错——不是那种耸人听闻的“服药过量”，而是有人把剂量或时间点弄错了。大多数都很轻。但严重到得跑一趟诊所的比例，在研究观察的这段时间里，从 23% 一点点爬到了约 33%。而这些几乎无一例外都是本可以避免的。",{"type":23,"tag":35,"props":4336,"children":4338},{"id":4337},"这些数字到底在说什么",[4339],{"type":28,"value":4337},{"type":23,"tag":24,"props":4341,"children":4342},{},[4343],{"type":28,"value":4344},"在司美格鲁肽（semaglutide）2021 年拿到减重适应症之前，中毒中心每年记录的 GLP-1 病例大约在 1,000 到 1,500 例上下。到了 2023 年，这个数字已经飙到 8,000 以上。光司美格鲁肽一种就占了约 64% 的来电——这也不奇怪，毕竟它是用的人最多的那一款。",{"type":23,"tag":24,"props":4346,"children":4347},{},[4348],{"type":28,"value":4349},"比起这个绝对数量，背后的规律更值得琢磨。这些人大多并不是想多打。他们只是没记住自己的用药节奏，或者把某个数字搞混了。这类问题是能解决的，所以搞清楚到底是哪一步容易让人犯糊涂，很有价值。",{"type":23,"tag":24,"props":4351,"children":4352},{},[4353],{"type":23,"tag":2949,"props":4354,"children":4357},{"alt":4355,"src":4356},"带单位刻度的胰岛素注射器，旁边放着一个放大镜和一张周历","\u002Fassets\u002Fglp1_errors_units.png",[],{"type":23,"tag":35,"props":4359,"children":4361},{"id":4360},"一而再再而三出现的四种差错",[4362],{"type":28,"value":4363},"一而再、再而三出现的四种差错",{"type":23,"tag":46,"props":4365,"children":4366},{},[4367,4388],{"type":23,"tag":50,"props":4368,"children":4369},{},[4370],{"type":23,"tag":54,"props":4371,"children":4372},{},[4373,4378,4383],{"type":23,"tag":58,"props":4374,"children":4375},{},[4376],{"type":28,"value":4377},"差错",{"type":23,"tag":58,"props":4379,"children":4380},{},[4381],{"type":28,"value":4382},"具体情况",{"type":23,"tag":58,"props":4384,"children":4385},{},[4386],{"type":28,"value":4387},"为什么会这样",{"type":23,"tag":69,"props":4389,"children":4390},{},[4391,4409,4427,4445],{"type":23,"tag":54,"props":4392,"children":4393},{},[4394,4399,4404],{"type":23,"tag":76,"props":4395,"children":4396},{},[4397],{"type":28,"value":4398},"把每周一次打成每天一次",{"type":23,"tag":76,"props":4400,"children":4401},{},[4402],{"type":28,"value":4403},"本该一周注射一次的剂量，天天都打",{"type":23,"tag":76,"props":4405,"children":4406},{},[4407],{"type":28,"value":4408},"“药得按天吃”这个习惯根深蒂固；按周给药太少见",{"type":23,"tag":54,"props":4410,"children":4411},{},[4412,4417,4422],{"type":23,"tag":76,"props":4413,"children":4414},{},[4415],{"type":28,"value":4416},"一上来就顶格用",{"type":23,"tag":76,"props":4418,"children":4419},{},[4420],{"type":28,"value":4421},"直接从高剂量起步，而不是逐步加量",{"type":23,"tag":76,"props":4423,"children":4424},{},[4425],{"type":28,"value":4426},"漏看或没当回事——这类药本来就设计了一套爬坡方案",{"type":23,"tag":54,"props":4428,"children":4429},{},[4430,4435,4440],{"type":23,"tag":76,"props":4431,"children":4432},{},[4433],{"type":28,"value":4434},"重复给药",{"type":23,"tag":76,"props":4436,"children":4437},{},[4438],{"type":28,"value":4439},"两针挨得太近",{"type":23,"tag":76,"props":4441,"children":4442},{},[4443],{"type":28,"value":4444},"记不清上一针到底打没打",{"type":23,"tag":54,"props":4446,"children":4447},{},[4448,4453,4458],{"type":23,"tag":76,"props":4449,"children":4450},{},[4451],{"type":28,"value":4452},"药瓶与注射器的换算",{"type":23,"tag":76,"props":4454,"children":4455},{},[4456],{"type":28,"value":4457},"从多剂量药瓶里抽错了单位数",{"type":23,"tag":76,"props":4459,"children":4460},{},[4461],{"type":28,"value":4462},"咖啡还没喝够，就靠手算把毫克剂量换成注射器上的单位",{"type":23,"tag":24,"props":4464,"children":4465},{},[4466],{"type":28,"value":4467},"最后一种是本站最在意的，因为它纯粹是道算术题，而纯算术恰恰是一个累坏了的人坐在餐桌前最容易翻车的地方。注射笔会替你把剂量量好，药瓶可不会：你得自己把“这么多毫克”变成“药筒上的这么多单位”，而只要药瓶里的浓度跟你以为的对不上，你抽出来的那个数就错了。",{"type":23,"tag":35,"props":4469,"children":4471},{"id":4470},"为什么用药瓶的人更容易中招",[4472],{"type":28,"value":4470},{"type":23,"tag":24,"props":4474,"children":4475},{},[4476],{"type":28,"value":4477},"这波激增，几乎和两件事同步发生：远程医疗的普及，以及复方 GLP-1 药物的兴起——后者往往以多剂量药瓶、而不是预填充注射笔的形式供应。注射笔是个带刻度盘的封闭系统；药瓶却把整套计算原封不动甩给了你。这样确实更灵活、往往也更便宜，可与此同时，那道安全护栏也没了。报告里提到的“重复给药”“两针间隔太近”，很多其实就是有人拿不准上周那一针到底打进去没有，要么就是把药筒刻度看错了。",{"type":23,"tag":24,"props":4479,"children":4480},{},[4481],{"type":28,"value":4482},"这并不是说药瓶不好。而是说“量取”这一步值得你认真对待。两个习惯就能顶大半的活：只留一份清清楚楚的记录，写明上一次是什么时候打的；以及，用你那颗累坏了的脑袋以外的东西，去核对毫克换单位的这道算术。",{"type":23,"tag":35,"props":4484,"children":4486},{"id":4485},"让算术靠谱同时又不算建议",[4487],{"type":28,"value":4488},"让算术靠谱（同时又不算“建议”）",{"type":23,"tag":24,"props":4490,"children":4491},{},[4492,4494,4499,4501,4507,4509,4515],{"type":28,"value":4493},"我们不会告诉你该往身上打哪个数字，那是你和临床医生之间的事。工具能做的是中性的那一半：把你手上已经有的数值换算出来。只要你知道药瓶规格、自己加了多少抑菌水、以及开方医生定下的剂量，",{"type":23,"tag":273,"props":4495,"children":4496},{"href":1633},[4497],{"type":28,"value":4498},"复溶计算器",{"type":28,"value":4500}," 就能把它们换算成注射器上确切的单位——这样一来，早上 6 点就不用靠脑子现算了。它不给任何推荐，只是把你原本要手算的那道题替你做掉。要是连配药这一步本身都还没弄明白，可以先看看 ",{"type":23,"tag":273,"props":4502,"children":4504},{"href":4503},"\u002Freconstitute-peptides",[4505],{"type":28,"value":4506},"复溶到底是怎么回事",{"type":28,"value":4508}," 和 ",{"type":23,"tag":273,"props":4510,"children":4512},{"href":4511},"\u002Fbacteriostatic-vs-sterile-water",[4513],{"type":28,"value":4514},"抑菌水和灭菌水有什么区别",{"type":28,"value":370},{"type":23,"tag":24,"props":4517,"children":4518},{},[4519],{"type":28,"value":4520},"另一半又枯燥又管用：把每次给药的日期记下来。大多数“重复给药”的求助电话，追根究底都是那句“我实在想不起来打没打过”。一份带日期的记录，就能让你不用再靠猜。",{"type":23,"tag":35,"props":4522,"children":4524},{"id":4523},"更大的背景",[4525],{"type":28,"value":4523},{"type":23,"tag":24,"props":4527,"children":4528},{},[4529],{"type":28,"value":4530},"中毒热线的这波激增并不是孤立现象。同一时期，涉及这些药物、上报给 FDA 的用药错误也在大幅增加，而贯穿始终的那条线索是：从诊所里由医护打的针，转成了在家自己打，而且往往是从药瓶里抽。人更多了，自己动手的更多了，可人读错数字的老毛病一点没变。研究作者说得很直白：这些事件里的大多数，只要患者教育做得更到位就能预防。而这，正是我们在这儿讲它的全部意义。",{"type":23,"tag":35,"props":4532,"children":4533},{"id":3144},[4534],{"type":28,"value":3144},{"type":23,"tag":24,"props":4536,"children":4537},{},[4538,4540,4544,4545,4549],{"type":28,"value":4539},"那个吓人的标题（“中毒热线电话暴涨 1,500%”）底下藏着的东西其实相当平淡：大多很轻，大多能避免，大多不过是用药节奏或单位换算出了岔子。如果你是从药瓶给药，那么能让你不成为这组统计数字之一的，就两样东西：每一针都有带日期的记录，以及一个靠得住的办法，把毫克换成单位。这俩都不是医疗建议。它们无非是——别再凭记忆去做那些要紧的算术。想了解具体药物的背景，可以看看 ",{"type":23,"tag":273,"props":4541,"children":4542},{"href":457},[4543],{"type":28,"value":460},{"type":28,"value":4508},{"type":23,"tag":273,"props":4546,"children":4547},{"href":886},[4548],{"type":28,"value":889},{"type":28,"value":370},{"type":23,"tag":35,"props":4551,"children":4552},{"id":2271},[4553],{"type":28,"value":2271},{"type":23,"tag":175,"props":4555,"children":4556},{},[4557,4568,4580],{"type":23,"tag":179,"props":4558,"children":4559},{},[4560,4562],{"type":28,"value":4561},"U.S. News \u002F HealthDay，2026 年 6 月 25 日，",{"type":23,"tag":273,"props":4563,"children":4565},{"href":4328,"rel":4564},[479],[4566],{"type":28,"value":4567},"GLP-1 weight-loss boom linked to surge in poison-control calls",{"type":23,"tag":179,"props":4569,"children":4570},{},[4571,4573],{"type":28,"value":4572},"News-Medical，2026 年 6 月 26 日，",{"type":23,"tag":273,"props":4574,"children":4577},{"href":4575,"rel":4576},"https:\u002F\u002Fwww.news-medical.net\u002Fnews\u002F20260626\u002FSemaglutide-approval-drove-a-surge-in-GLP-1-poison-center-exposures.aspx",[479],[4578],{"type":28,"value":4579},"Semaglutide approval drove a surge in GLP-1 poison-center exposures",{"type":23,"tag":179,"props":4581,"children":4582},{},[4583,4585],{"type":28,"value":4584},"Bioengineer，2026 年 6 月，",{"type":23,"tag":273,"props":4586,"children":4589},{"href":4587,"rel":4588},"https:\u002F\u002Fbioengineer.org\u002Ffda-approval-of-semaglutide-for-weight-loss-spurs-surge-in-u-s-poison-control-calls-ut-san-antonio-study-finds\u002F",[479],[4590],{"type":28,"value":4591},"UT San Antonio study on the semaglutide-era poison-control surge",{"title":8,"searchDepth":556,"depth":556,"links":4593},[4594,4595,4596,4597,4598,4599,4600],{"id":4337,"depth":556,"text":4337},{"id":4360,"depth":556,"text":4363},{"id":4470,"depth":556,"text":4470},{"id":4485,"depth":556,"text":4488},{"id":4523,"depth":556,"text":4523},{"id":3144,"depth":556,"text":3144},{"id":2271,"depth":556,"text":2271},"content:blog:zh:glp1-dosing-errors.md","blog\u002Fzh\u002Fglp1-dosing-errors.md","blog\u002Fzh\u002Fglp1-dosing-errors",{"_path":4605,"_dir":6,"_draft":7,"_partial":7,"_locale":8,"title":4606,"description":4607,"cat":11,"icon":3756,"accent":3757,"date":4080,"dateLabel":2369,"read":4608,"author":17,"image":3760,"body":4609,"_type":568,"_id":4836,"_source":570,"_file":4837,"_stem":4838,"_extension":573},"\u002Fblog\u002Fzh\u002Fretatrutide-triumph-1-results","Retatrutide TRIUMPH-1:三期数据,和那个不能忽略的星号","本文属于一般性科普,不是医疗建议,也不是鼓励你去获取或使用任何东西。Retatrutide 仍处于试验阶段,尚未获批。下面这些数字,是一家公司从自己的试验里报告出来的结果,既不是对任何疗效的承诺,也不是用药指导。","7 min",{"type":20,"children":4610,"toc":4828},[4611,4615,4620,4625,4630,4703,4708,4715,4720,4725,4730,4735,4740,4745,4756,4760,4765,4769,4785,4789],{"type":23,"tag":24,"props":4612,"children":4613},{},[4614],{"type":28,"value":4607},{"type":23,"tag":24,"props":4616,"children":4617},{},[4618],{"type":28,"value":4619},"一句话版本:2026 年 5 月 21 日,礼来公布了 TRIUMPH-1 的顶线结果——这是 Retatrutide 针对肥胖的首个三期试验。最抢眼的一条是:在最高的 12 mg 剂量下、历时 80 周,平均减重达到 28.3%,并且有 45.3% 的受试者减掉了至少 30% 的体重——这个幅度过去只属于减重手术。数字是真的,也确实很大。而那个星号是:Retatrutide 至今仍未获批,这只是公司的一份新闻稿,而不是经过完整同行评审的数据集;今天任何打着这个名号卖的东西,都是未获批的灰色市场货。",{"type":23,"tag":35,"props":4621,"children":4623},{"id":4622},"礼来报告的那些数字",[4624],{"type":28,"value":4622},{"type":23,"tag":24,"props":4626,"children":4627},{},[4628],{"type":28,"value":4629},"TRIUMPH-1 招募了 2,339 名成年人,他们要么肥胖,要么超重并伴有与体重相关的疾病;试验在 80 周里测试了这款每周一次注射剂的三种剂量。",{"type":23,"tag":46,"props":4631,"children":4632},{},[4633,4648],{"type":23,"tag":50,"props":4634,"children":4635},{},[4636],{"type":23,"tag":54,"props":4637,"children":4638},{},[4639,4644],{"type":23,"tag":58,"props":4640,"children":4641},{},[4642],{"type":28,"value":4643},"指标(顶线)",{"type":23,"tag":58,"props":4645,"children":4646},{},[4647],{"type":28,"value":67},{"type":23,"tag":69,"props":4649,"children":4650},{},[4651,4664,4677,4690],{"type":23,"tag":54,"props":4652,"children":4653},{},[4654,4659],{"type":23,"tag":76,"props":4655,"children":4656},{},[4657],{"type":28,"value":4658},"12 mg、80 周平均减重",{"type":23,"tag":76,"props":4660,"children":4661},{},[4662],{"type":28,"value":4663},"约 28.3%(约 70 磅)",{"type":23,"tag":54,"props":4665,"children":4666},{},[4667,4672],{"type":23,"tag":76,"props":4668,"children":4669},{},[4670],{"type":28,"value":4671},"减掉体重 ≥30% 的受试者比例",{"type":23,"tag":76,"props":4673,"children":4674},{},[4675],{"type":28,"value":4676},"45.3%",{"type":23,"tag":54,"props":4678,"children":4679},{},[4680,4685],{"type":23,"tag":76,"props":4681,"children":4682},{},[4683],{"type":28,"value":4684},"高 BMI 组延长至 104 周",{"type":23,"tag":76,"props":4686,"children":4687},{},[4688],{"type":28,"value":4689},"最高约 30.3%(约 85 磅)",{"type":23,"tag":54,"props":4691,"children":4692},{},[4693,4698],{"type":23,"tag":76,"props":4694,"children":4695},{},[4696],{"type":28,"value":4697},"试验规模",{"type":23,"tag":76,"props":4699,"children":4700},{},[4701],{"type":28,"value":4702},"2,339 名成年人",{"type":23,"tag":24,"props":4704,"children":4705},{},[4706],{"type":28,"value":4707},"Retatrutide 是一款三重激动剂:一个分子同时作用于 GIP、GLP-1 和胰高血糖素三种受体。正是胰高血糖素这第三个靶点,被认为让它比之前的 GLP-1 以及 GLP-1\u002FGIP 药物\"下手更狠\"。就目前这些顶线数据而言,它是迄今公布三期数据的减重药里最有效的一款。",{"type":23,"tag":24,"props":4709,"children":4710},{},[4711],{"type":23,"tag":2949,"props":4712,"children":4714},{"alt":4713,"src":3859},"减重曲线一路向下,旁边是逐渐纤细的身形剪影",[],{"type":23,"tag":35,"props":4716,"children":4718},{"id":4717},"没人写进标题的那个星号",[4719],{"type":28,"value":4717},{"type":23,"tag":24,"props":4721,"children":4722},{},[4723],{"type":28,"value":4724},"有三件事会给这份兴奋降降温,也正是我们选择冷静报道它的原因。",{"type":23,"tag":24,"props":4726,"children":4727},{},[4728],{"type":28,"value":4729},"第一,它没获批。三期顶线数据是申报路上的一个里程碑,而不是终点线。礼来还得递交申请,FDA 还得审,现实点看,这些都要往后拖。在那之前,不存在合法的、凭处方开出的减重 Retatrutide。",{"type":23,"tag":24,"props":4731,"children":4732},{},[4733],{"type":28,"value":4734},"第二,\"顶线\"不等于完整数据集。新闻稿给你的是包装得最漂亮的那几个头条数字。完整结果、安全性细节,以及那份永远最关键的脱落率与不良事件明细,都得等到后面——在某场医学大会上、在某本期刊里才会揭晓。把这 28.3% 当成\"有希望但仍是初步\"的结论,而不是板上钉钉的定论。",{"type":23,"tag":24,"props":4736,"children":4737},{},[4738],{"type":28,"value":4739},"第三,也是最实际的一点:眼下市面上流通的全是灰色市场货。正因为真正的药还没获批,网上打着 \"retatrutide\" 名头卖的,是不受监管的研究级原料,成分和纯度都成谜。试验里那些数字,是用一种成分明确的化合物、在临床环境下按剂量给药并全程监测得出的。它们完全说明不了论坛上某人卖的那支西林瓶到底是什么。",{"type":23,"tag":35,"props":4741,"children":4743},{"id":4742},"数字没覆盖到的那些部分",[4744],{"type":28,"value":4742},{"type":23,"tag":24,"props":4746,"children":4747},{},[4748,4750,4754],{"type":28,"value":4749},"疗效只是一款药的一半。这一类药物已知的那些取舍,在这里同样适用。副作用主要集中在肠胃:恶心、呕吐、腹泻、便秘,和剂量相关,而且在加量阶段最难受。此外,在这些药上快速掉秤,减掉的不只有脂肪,还有瘦体重;掉的体重里相当一部分可能是肌肉——这也是为什么\"蛋白质\"和\"抗阻训练\"会被反复提起。关于掉肌肉这一点,以及二期和三期数据之间的区别,我们在",{"type":23,"tag":273,"props":4751,"children":4752},{"href":275},[4753],{"type":28,"value":3957},{"type":28,"value":4755},"里聊得更透。",{"type":23,"tag":35,"props":4757,"children":4758},{"id":3999},[4759],{"type":28,"value":3999},{"type":23,"tag":24,"props":4761,"children":4762},{},[4763],{"type":28,"value":4764},"TRIUMPH-1 只是一个更大项目的第一批数据。礼来已经预告,2026 年晚些时候还会有更多:面向 2 型糖尿病人群的 TRIUMPH-2,以及面向已确诊心血管疾病人群的 TRIUMPH-3。这两项很关键,因为糖尿病和心脏结局数据,才能把一个减重数字撑成一个更全面的论据。等 TRIUMPH-1 的完整数据在大会上亮相,独立研究者也就能亲自去抠它的安全性和持久性,而不必对着一份新闻稿照单全收。",{"type":23,"tag":35,"props":4766,"children":4767},{"id":3144},[4768],{"type":28,"value":3144},{"type":23,"tag":24,"props":4770,"children":4771},{},[4772,4774,4778,4780,4784],{"type":28,"value":4773},"28.3% 确实是个大数字,就现有数据看,Retatrutide 像是目前最强的一款肠促胰素类药物。但它同样没获批,目前也只公布了顶线数据,今天更不可能通过受监管的渠道买到。看数据,和看一个购买页面,是两件截然不同的事。想了解已发表文献里报告的剂量,可以看我们的 ",{"type":23,"tag":273,"props":4775,"children":4776},{"href":1494},[4777],{"type":28,"value":2903},{"type":28,"value":4779},";想从零开始搞懂这一类药,先从",{"type":23,"tag":273,"props":4781,"children":4782},{"href":449},[4783],{"type":28,"value":452},{"type":28,"value":4021},{"type":23,"tag":35,"props":4786,"children":4787},{"id":464},[4788],{"type":28,"value":464},{"type":23,"tag":175,"props":4790,"children":4791},{},[4792,4804,4816],{"type":23,"tag":179,"props":4793,"children":4794},{},[4795,4797],{"type":28,"value":4796},"礼来(投资者新闻稿),2026 年 5 月 21 日,",{"type":23,"tag":273,"props":4798,"children":4801},{"href":4799,"rel":4800},"https:\u002F\u002Finvestor.lilly.com\u002Fnews-releases\u002Fnews-release-details\u002Flillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",[479],[4802],{"type":28,"value":4803},"Retatrutide delivered powerful weight loss in pivotal phase-3 obesity trial",{"type":23,"tag":179,"props":4805,"children":4806},{},[4807,4809],{"type":28,"value":4808},"AJMC,",{"type":23,"tag":273,"props":4810,"children":4813},{"href":4811,"rel":4812},"https:\u002F\u002Fwww.ajmc.com\u002Fview\u002Fretatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trial",[479],[4814],{"type":28,"value":4815},"Retatrutide achieves up to 30.3% average weight loss in phase-3 TRIUMPH-1",{"type":23,"tag":179,"props":4817,"children":4818},{},[4819,4821],{"type":28,"value":4820},"BioPharma Dive,",{"type":23,"tag":273,"props":4822,"children":4825},{"href":4823,"rel":4824},"https:\u002F\u002Fwww.biopharmadive.com\u002Fnews\u002Flillys-retatrutide-tripleG-phase3-obesity-data\u002F820851\u002F",[479],[4826],{"type":28,"value":4827},"Lilly's triple-acting obesity drug hits goal in phase-3 trial",{"title":8,"searchDepth":556,"depth":556,"links":4829},[4830,4831,4832,4833,4834,4835],{"id":4622,"depth":556,"text":4622},{"id":4717,"depth":556,"text":4717},{"id":4742,"depth":556,"text":4742},{"id":3999,"depth":556,"text":3999},{"id":3144,"depth":556,"text":3144},{"id":464,"depth":556,"text":464},"content:blog:zh:retatrutide-triumph-1-results.md","blog\u002Fzh\u002Fretatrutide-triumph-1-results.md","blog\u002Fzh\u002Fretatrutide-triumph-1-results",{"_path":4840,"_dir":6,"_draft":7,"_partial":7,"_locale":8,"title":4841,"description":8,"cat":4842,"icon":4843,"accent":4844,"date":4845,"dateLabel":4846,"read":4847,"author":17,"image":4848,"body":4849,"_type":568,"_id":7163,"_source":570,"_file":7164,"_stem":7165,"_extension":573},"\u002Fblog\u002Fzh\u002Fretatrutide-liver-damage-myths","瑞它鲁肽伤肝？一次彻底的事实核查","事实核查","tabler:microscope","#F2A93B","2026-06-27","2026年6月","20 min","\u002Fassets\u002Freta_hero.png",{"type":20,"children":4850,"toc":7142},[4851,4947,4951,4956,5119,5124,5130,5135,5140,5148,5199,5218,5224,5256,5275,5281,5286,5294,5330,5356,5362,5367,5375,5395,5453,5459,5464,5472,5498,5503,5508,5551,5556,5561,5566,5570,5575,5580,5586,5606,5627,5632,5653,5688,5694,5727,5767,5773,5825,5846,5879,5897,5982,5999,6093,6098,6104,6123,6170,6176,6188,6213,6219,6251,6257,6271,6276,6301,6326,6331],{"type":23,"tag":4852,"props":4853,"children":4854},"disclaimer",{},[4855,4865,4896,4906,4924,4939],{"type":23,"tag":24,"props":4856,"children":4857},{},[4858,4863],{"type":23,"tag":664,"props":4859,"children":4860},{},[4861],{"type":28,"value":4862},"本文属于观点表达与科学评论——不是医疗建议，除有出处支撑的内容外，也不构成对任何人的事实陈述。",{"type":28,"value":4864}," 出于公共利益和公允评论的立场，本文讨论的是一位公众人物选择向大量受众发布的医疗类说法。",{"type":23,"tag":24,"props":4866,"children":4867},{},[4868,4873,4875,4880,4882,4887,4889,4894],{"type":23,"tag":162,"props":4869,"children":4870},{},[4871],{"type":28,"value":4872},"事实与观点之分。",{"type":28,"value":4874}," 凡是我们陈述可查证的事实之处——执业资质状态、企业归属、公开记录和视频里的原话——我们都附上一手出处，方便你自己去核对。凡是我们标明为",{"type":23,"tag":664,"props":4876,"children":4877},{},[4878],{"type":28,"value":4879},"评估",{"type":28,"value":4881},"、",{"type":23,"tag":664,"props":4883,"children":4884},{},[4885],{"type":28,"value":4886},"对数据的解读",{"type":28,"value":4888},"或",{"type":23,"tag":664,"props":4890,"children":4891},{},[4892],{"type":28,"value":4893},"我们的看法",{"type":28,"value":4895},"的地方，都是针对公开言论的观点与公允评论。我们并不声称掌握任何人的私人动机；凡涉及动机或效果之处，我们说的是我们所见，而非既定事实。",{"type":23,"tag":24,"props":4897,"children":4898},{},[4899,4904],{"type":23,"tag":162,"props":4900,"children":4901},{},[4902],{"type":28,"value":4903},"出处可能并不完整。",{"type":28,"value":4905}," 本文所有信息均取自公开来源，并本着善意、以我们撰稿时所掌握的最好认知如实呈现。公开记录和第三方报道可能不完整、可能有变、也可能被后续信息取代；我们或许遗漏了某些背景，在细节上也可能出错。",{"type":23,"tag":24,"props":4907,"children":4908},{},[4909,4914,4916,4922],{"type":23,"tag":162,"props":4910,"children":4911},{},[4912],{"type":28,"value":4913},"答辩与更正权。",{"type":28,"value":4915}," 如果你在本文中被提及，且认为任何事实陈述有误或已过时——或者你希望补充自己的立场——请通过我们的",{"type":23,"tag":273,"props":4917,"children":4919},{"href":4918},"\u002Flegal-notice",[4920],{"type":28,"value":4921},"法律声明",{"type":28,"value":4923},"与我们联系，我们会在合理范围内审阅并更正或更新文章。我们欢迎有据可查的更正。",{"type":23,"tag":24,"props":4925,"children":4926},{},[4927,4932,4934],{"type":23,"tag":162,"props":4928,"children":4929},{},[4930],{"type":28,"value":4931},"不是医疗建议——也不是在推荐你去用任何东西。",{"type":28,"value":4933}," 本文没有任何一句是在告诉你该拿自己的身体怎么办，也没有任何一句是在背书或指导你去获取、给药或使用瑞它鲁肽或其他任何物质——其中好几种还是在研药物，在许多地方并未获批用于人体。我们引用的试验数字描述的是已发表研究里报告的结果；它们不是任何疗效的承诺，也不是给药指导。如果你正在考虑或正在使用这些物质中的任何一种，",{"type":23,"tag":162,"props":4935,"children":4936},{},[4937],{"type":28,"value":4938},"在照着网上（无论这里还是别处）读到的东西行动之前，先去当面找一位你最不那么信不过的医生。",{"type":23,"tag":24,"props":4940,"children":4941},{},[4942],{"type":23,"tag":664,"props":4943,"children":4944},{},[4945],{"type":28,"value":4946},"最后更新：2026年6月27日。本文为观点与评论，可能随着新信息出现而修订。",{"type":23,"tag":35,"props":4948,"children":4949},{"id":3144},[4950],{"type":28,"value":3144},{"type":23,"tag":24,"props":4952,"children":4953},{},[4954],{"type":28,"value":4955},"一段45分钟、标题为*《瑞它鲁肽大剂量 vs 微剂量：哪种更伤你的肝？》*的视频宣称，除非你照着某套特定的给药方案来，否则瑞它鲁肽会悄悄损伤你的肝脏和胰腺——而讲这套话的人，随后就把这套方案连同肽本身一起卖给你。我们查证了一番。长话短说：",{"type":23,"tag":175,"props":4957,"children":4958},{},[4959,4993,5043,5068,5100],{"type":23,"tag":179,"props":4960,"children":4961},{},[4962,4967,4969,4974,4976,4983,4985,4992],{"type":23,"tag":162,"props":4963,"children":4964},{},[4965],{"type":28,"value":4966},"传话的人。",{"type":28,"value":4968}," “Trevor Bachmeyer 博士”并不是医生。他曾是脊椎按摩师，连这个执照都已经没了：加州执照（DC 29377）",{"type":23,"tag":162,"props":4970,"children":4971},{},[4972],{"type":28,"value":4973},"已于2020年7月8日起被吊销",{"type":28,"value":4975},"，这一点",{"type":23,"tag":273,"props":4977,"children":4980},{"href":4978,"rel":4979},"https:\u002F\u002Fwww.chiro.ca.gov\u002Fabout_us\u002Fmeetings\u002F20201029_materials.pdf",[479],[4981],{"type":28,"value":4982},"加州脊椎按摩师考核委员会",{"type":28,"value":4984},"有案可查。同一段视频还把观众导流到他的付费辅导，以及他自己的科研肽商店 ",{"type":23,"tag":273,"props":4986,"children":4989},{"href":4987,"rel":4988},"https:\u002F\u002Felitebiogenix.com\u002F",[479],[4990],{"type":28,"value":4991},"EliteBiogenix",{"type":28,"value":370},{"type":23,"tag":179,"props":4994,"children":4995},{},[4996,5001,5003,5008,5010,5015,5017,5024,5026,5033,5034,5041],{"type":23,"tag":162,"props":4997,"children":4998},{},[4999],{"type":28,"value":5000},"“胰高血糖素让脂肪淹没全身。”",{"type":28,"value":5002}," 误导。在人体内，生理浓度的胰高血糖素",{"type":23,"tag":162,"props":5004,"children":5005},{},[5006],{"type":28,"value":5007},"并不会",{"type":28,"value":5009},"直接分解身体（白色脂肪组织）里的脂肪——它驱动的是",{"type":23,"tag":664,"props":5011,"children":5012},{},[5013],{"type":28,"value":5014},"肝脏内部",{"type":28,"value":5016},"的脂肪氧化（",{"type":23,"tag":273,"props":5018,"children":5021},{"href":5019,"rel":5020},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F32132708\u002F",[479],[5022],{"type":28,"value":5023},"Perry 等，Nature 2020",{"type":28,"value":5025},"；",{"type":23,"tag":273,"props":5027,"children":5030},{"href":5028,"rel":5029},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC9576180\u002F",[479],[5031],{"type":28,"value":5032},"Vasileva 等，2022",{"type":28,"value":5025},{"type":23,"tag":273,"props":5035,"children":5038},{"href":5036,"rel":5037},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F11344211\u002F",[479],[5039],{"type":28,"value":5040},"Gravholt 等，2001",{"type":28,"value":5042},"）。",{"type":23,"tag":179,"props":5044,"children":5045},{},[5046,5051,5053,5058,5060,5067],{"type":23,"tag":162,"props":5047,"children":5048},{},[5049],{"type":28,"value":5050},"“脂肪酶升高意味着你的胰腺在衰竭。”",{"type":28,"value":5052}," 基本是错的。轻度、无症状的酶升高很常见，也无害；大型试验数据显示",{"type":23,"tag":162,"props":5054,"children":5055},{},[5056],{"type":28,"value":5057},"急性胰腺炎并没有增加",{"type":28,"value":5059},"（",{"type":23,"tag":273,"props":5061,"children":5064},{"href":5062,"rel":5063},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F28476871\u002F",[479],[5065],{"type":28,"value":5066},"Steinberg 等，Diabetes Care 2017",{"type":28,"value":5042},{"type":23,"tag":179,"props":5069,"children":5070},{},[5071,5076,5078,5083,5085,5090,5091,5098],{"type":23,"tag":162,"props":5072,"children":5073},{},[5074],{"type":28,"value":5075},"“瑞它鲁肽让肝脏不堪重负、受到损伤。”",{"type":28,"value":5077}," 数据恰恰相反。在二期肝脂肪试验里，它",{"type":23,"tag":162,"props":5079,"children":5080},{},[5081],{"type":28,"value":5082},"让肝脏脂肪最多减少了86%",{"type":28,"value":5084},"，而且",{"type":23,"tag":162,"props":5086,"children":5087},{},[5088],{"type":28,"value":5089},"用最高剂量的患者中约93%的人肝脂肪恢复了正常",{"type":28,"value":5059},{"type":23,"tag":273,"props":5092,"children":5095},{"href":5093,"rel":5094},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11271400\u002F",[479],[5096],{"type":28,"value":5097},"Sanyal 等，Nature Medicine 2024",{"type":28,"value":5099},"）。瑞它鲁肽恰恰是作为脂肪肝的治疗药物来开发的。",{"type":23,"tag":179,"props":5101,"children":5102},{},[5103,5108,5110,5117],{"type":23,"tag":162,"props":5104,"children":5105},{},[5106],{"type":28,"value":5107},"他说对的部分。",{"type":28,"value":5109}," 有两点：别为了一个孤立的脂肪酶数值就慌慌张张停药；快速减重确实会赔上肌肉（",{"type":23,"tag":273,"props":5111,"children":5114},{"href":5112,"rel":5113},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC12471476\u002F",[479],[5115],{"type":28,"value":5116},"Koceva 等，2025",{"type":28,"value":5118},"）。有道理的观点，被裹进了一套站不住脚的吓人叙事里。",{"type":23,"tag":24,"props":5120,"children":5121},{},[5122],{"type":28,"value":5123},"更完整的图景，以及上面每一句背后的科学，都在下文。文末的深挖是一份带出处的入门读物，讲的是整个这一类药——写出来就是让你能核对我们，而不只是相信我们。",{"type":23,"tag":5125,"props":5126,"children":5129},"youtube",{"id":5127,"title":5128},"gb-XEtsMr-w","The video this article examines — Bachmeyer on retatrutide dosing",[],{"type":23,"tag":35,"props":5131,"children":5133},{"id":5132},"是谁在这么说",[5134],{"type":28,"value":5132},{"type":23,"tag":24,"props":5136,"children":5137},{},[5138],{"type":28,"value":5139},"在看科学之前，先看来源。他给自己贴的标签是“Trevor Bachmeyer 博士，斯巴达人”和“全球第一健康权威”，面对的是数十万观众。有两个可查证的事实很关键。",{"type":23,"tag":24,"props":5141,"children":5142},{},[5143],{"type":23,"tag":2949,"props":5144,"children":5147},{"alt":5145,"src":5146},"健康恐慌是如何被一步步引向商品销售的","\u002Fassets\u002Freta_funnel.png",[],{"type":23,"tag":24,"props":5149,"children":5150},{},[5151,5153,5158,5160,5165,5167,5172,5174,5180,5181,5188,5190,5197],{"type":28,"value":5152},"第一，",{"type":23,"tag":162,"props":5154,"children":5155},{},[5156],{"type":28,"value":5157},"他不是医生。",{"type":28,"value":5159}," 他曾是",{"type":23,"tag":162,"props":5161,"children":5162},{},[5163],{"type":28,"value":5164},"脊椎按摩师",{"type":28,"value":5166},"，而连这个执照都没了：加州执照 DC 29377 ",{"type":23,"tag":162,"props":5168,"children":5169},{},[5170],{"type":28,"value":5171},"已于2020年7月8日起被加州脊椎按摩师考核委员会吊销",{"type":28,"value":5173},"。这一处分在委员会自己的文件里有据可查（",{"type":23,"tag":273,"props":5175,"children":5177},{"href":4978,"rel":5176},[479],[5178],{"type":28,"value":5179},"2020年10月29日会议材料",{"type":28,"value":5025},{"type":23,"tag":273,"props":5182,"children":5185},{"href":5183,"rel":5184},"https:\u002F\u002Fwww.chiro.ca.gov\u002Fenforcement\u002Factions.shtml",[479],[5186],{"type":28,"value":5187},"最终纪律处分",{"type":28,"value":5189},"），也可以通过州里的",{"type":23,"tag":273,"props":5191,"children":5194},{"href":5192,"rel":5193},"https:\u002F\u002Fsearch.dca.ca.gov\u002F",[479],[5195],{"type":28,"value":5196},"执照查询",{"type":28,"value":5198},"自行核实——读者可以查阅所附记录，了解具体的认定内容。他至今仍以“博士”自居，在我们看来，这种用法会诱导读者以为他持有一份其实并不具备的现行医疗资质。",{"type":23,"tag":24,"props":5200,"children":5201},{},[5202,5204,5209,5211,5216],{"type":28,"value":5203},"第二，",{"type":23,"tag":162,"props":5205,"children":5206},{},[5207],{"type":28,"value":5208},"他卖的正是他自己在建议的那个东西。",{"type":28,"value":5210}," 视频把观众引向一个付费的“黑卡”辅导会员，以及他的商店 ",{"type":23,"tag":273,"props":5212,"children":5214},{"href":4987,"rel":5213},[479],[5215],{"type":28,"value":4991},{"type":28,"value":5217},"——那里卖的是科研肽和 SARM，标注“仅供体外研究”。所以，那个警告你“瑞它鲁肽会伤你，除非你剂量用对”的人，同时也在卖那套剂量指导和那些肽。这本身并不能一票否决他——但这恰恰是一个谨慎的观众应当记在心里的利益冲突，也正是本文存在的理由。",{"type":23,"tag":35,"props":5219,"children":5221},{"id":5220},"平心而论他到底在主张什么",[5222],{"type":28,"value":5223},"平心而论，他到底在主张什么",{"type":23,"tag":24,"props":5225,"children":5226},{},[5227,5229,5234,5236,5241,5243,5247,5249,5254],{"type":28,"value":5228},"要把他树成一个稻草人来打很容易，所以我们要说得准确。他自己的视频简介写道：",{"type":23,"tag":664,"props":5230,"children":5231},{},[5232],{"type":28,"value":5233},"“瑞它鲁肽本身并不直接造成肝脏或胰腺损伤；是不负责任的给药和糟糕的监测造成了生物学损伤。”",{"type":28,"value":5235}," 他的章节列表是*“胰高血糖素脂肪洪流 → 胰腺超载 → 脂肪肝级联 → 胰岛素抵抗漩涡”",{"type":23,"tag":664,"props":5237,"children":5238},{},[5239],{"type":28,"value":5240},"，接着话锋一转，转到",{"type":28,"value":5242},"“损伤控制方案”",{"type":23,"tag":664,"props":5244,"children":5245},{},[5246],{"type":28,"value":4881},{"type":28,"value":5248},"“安全给药规则”",{"type":23,"tag":664,"props":5250,"children":5251},{},[5252],{"type":28,"value":5253},"和",{"type":28,"value":5255},"“负责任地使用”*。",{"type":23,"tag":24,"props":5257,"children":5258},{},[5259,5261,5266,5268,5273],{"type":28,"value":5260},"所以他的论点",{"type":23,"tag":162,"props":5262,"children":5263},{},[5264],{"type":28,"value":5265},"并不是",{"type":28,"value":5267},"“这药是毒药，别碰”。而是“这药会伤你，",{"type":23,"tag":664,"props":5269,"children":5270},{},[5271],{"type":28,"value":5272},"除非你按我的方式给药",{"type":28,"value":5274},"”。这更微妙、听起来更可信、也远比前者好卖——而这正是我们要核查的。问题不在于他编造假研究。而在于他用一堆真实的术语，搭起了一台吓人的机器，可试验数据并不支持那个吓人的部分。",{"type":23,"tag":35,"props":5276,"children":5278},{"id":5277},"说法一胰高血糖素脂肪洪流",[5279],{"type":28,"value":5280},"说法一：“胰高血糖素脂肪洪流”",{"type":23,"tag":24,"props":5282,"children":5283},{},[5284],{"type":28,"value":5285},"他这台机器的引擎，是瑞它鲁肽里的胰高血糖素成分：据说它会掀起一场脂肪的洪水——游离脂肪酸从你的身体脂肪里倾泻而出，把肝脏和胰腺给淹没。",{"type":23,"tag":24,"props":5287,"children":5288},{},[5289],{"type":23,"tag":2949,"props":5290,"children":5293},{"alt":5291,"src":5292},"胰高血糖素驱动的是肝脏里的脂肪氧化，而非身体脂肪","\u002Fassets\u002Freta_glucagon.png",[],{"type":23,"tag":24,"props":5295,"children":5296},{},[5297,5299,5304,5306,5312,5314,5320,5321,5328],{"type":28,"value":5298},"这是胰高血糖素生理学里最古老的一个误解。没错，胰高血糖素是一个强力的燃脂信号——",{"type":23,"tag":162,"props":5300,"children":5301},{},[5302],{"type":28,"value":5303},"但是在肝脏里，不是在你的身体脂肪里。",{"type":28,"value":5305}," 胰高血糖素受体在肝细胞上密集表达，在人的脂肪细胞上却几乎不存在。当研究者专门把小鼠脂肪组织里的胰高血糖素受体敲除后，它们的脂肪代谢、体重、循环游离脂肪酸——什么都没变（",{"type":23,"tag":273,"props":5307,"children":5309},{"href":5028,"rel":5308},[479],[5310],{"type":28,"value":5311},"Vasileva 等，AJP-Endocrinology 2022",{"type":28,"value":5313},"）。在人体里，把胰高血糖素升到生理水平，压根不会增加腹部脂肪的脂解（",{"type":23,"tag":273,"props":5315,"children":5317},{"href":5036,"rel":5316},[479],[5318],{"type":28,"value":5319},"Gravholt 等，JCEM 2001",{"type":28,"value":5025},{"type":23,"tag":273,"props":5322,"children":5325},{"href":5323,"rel":5324},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F1991802\u002F",[479],[5326],{"type":28,"value":5327},"Jensen 等，JCEM 1991",{"type":28,"value":5329},"）。脂解效应只有在试管里、在血液里根本达不到的超生理浓度下才会出现。",{"type":23,"tag":24,"props":5331,"children":5332},{},[5333,5335,5339,5341,5346,5347,5354],{"type":28,"value":5334},"胰高血糖素真正做的，是驱动",{"type":23,"tag":162,"props":5336,"children":5337},{},[5338],{"type":28,"value":5014},{"type":28,"value":5340},"的脂肪氧化——通过 cAMP\u002FPKA 和钙通路激活肝脏的脂肪分解（",{"type":23,"tag":273,"props":5342,"children":5344},{"href":5019,"rel":5343},[479],[5345],{"type":28,"value":5023},{"type":28,"value":5025},{"type":23,"tag":273,"props":5348,"children":5351},{"href":5349,"rel":5350},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F38300523\u002F",[479],[5352],{"type":28,"value":5353},"Kajani 等，Physiological Reviews 2024",{"type":28,"value":5355},"）——并提高全身能量消耗。至于胰高血糖素“融化”你的肚子脂肪、再让它涌进你各个器官的画面，那是体外实验的假象，不是人体生理。他那场“洪水”的地基，从第一章就裂了。",{"type":23,"tag":35,"props":5357,"children":5359},{"id":5358},"说法二胰腺超载",[5360],{"type":28,"value":5361},"说法二：胰腺“超载”",{"type":23,"tag":24,"props":5363,"children":5364},{},[5365],{"type":28,"value":5366},"接下来，他把脂肪酶升高当成你的胰腺正被逼向衰竭的证据。",{"type":23,"tag":24,"props":5368,"children":5369},{},[5370],{"type":23,"tag":2949,"props":5371,"children":5374},{"alt":5372,"src":5373},"轻度脂肪酶升高反映的是无害的酶渗漏，而不是胰腺被摧毁","\u002Fassets\u002Freta_pancreas.png",[],{"type":23,"tag":24,"props":5376,"children":5377},{},[5378,5380,5385,5387,5394],{"type":28,"value":5379},"平淡的真相是：在这一类药上，轻度、无症状的脂肪酶和淀粉酶升高",{"type":23,"tag":162,"props":5381,"children":5382},{},[5383],{"type":28,"value":5384},"很常见，而且通常无害",{"type":28,"value":5386},"。这反映的是被刺激但依然完好的腺泡细胞往血里渗出一点点酶——一种生理性的“渗漏”，而不是器官在自我消化。我们甚至知道其中的受体机制：GLP-1 受体位于胰腺腺泡细胞上，会推动它们释放酶，这发生在健康组织里，不造成损伤（",{"type":23,"tag":273,"props":5388,"children":5391},{"href":5389,"rel":5390},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC4698438\u002F",[479],[5392],{"type":28,"value":5393},"Hou…Williams 等，AJP-GI 2016",{"type":28,"value":5042},{"type":23,"tag":24,"props":5396,"children":5397},{},[5398,5400,5405,5406,5411,5413,5420,5422,5427,5428,5435,5437,5442,5444,5451],{"type":28,"value":5399},"而那些硬终点指标令人放心。在大型利拉鲁肽试验项目里，淀粉酶和脂肪酶有轻度升高，",{"type":23,"tag":162,"props":5401,"children":5402},{},[5403],{"type":28,"value":5404},"却并不预示急性胰腺炎",{"type":28,"value":5059},{"type":23,"tag":273,"props":5407,"children":5409},{"href":5062,"rel":5408},[479],[5410],{"type":28,"value":5066},{"type":28,"value":5412},"）。一项2026年持续更新的系统综述（living systematic review），汇总了31项安慰剂对照试验、超过4万名患者，发现用药组与安慰剂组的胰腺炎发生率基本一模一样（比值比 ≈ 0.99）——不过平心而论，这一项目前还是",{"type":23,"tag":273,"props":5414,"children":5417},{"href":5415,"rel":5416},"https:\u002F\u002Fwww.medrxiv.org\u002Fcontent\u002F10.64898\u002F2026.03.19.26348844v1",[479],[5418],{"type":28,"value":5419},"预印本",{"type":28,"value":5421},"，尚未经过同行评审。一项2024年的分析甚至报告，在高风险患者中，用 GLP-1 类药物后复发性胰腺炎发作",{"type":23,"tag":162,"props":5423,"children":5424},{},[5425],{"type":28,"value":5426},"更少",{"type":28,"value":5059},{"type":23,"tag":273,"props":5429,"children":5432},{"href":5430,"rel":5431},"https:\u002F\u002Fwww.endocrine.org\u002Fnews-and-advocacy\u002Fnews-room\u002F2024\u002Fendo-2024-press-nassar",[479],[5433],{"type":28,"value":5434},"Nassar 等，ENDO 2024 —— 会议摘要",{"type":28,"value":5436},"），可能是因为这些药物纠正了根本诱因。关键在于，急性胰腺炎是一个临床诊断——修订版亚特兰大标准要求同时满足真实的疼痛、脂肪酶超过正常上限三倍、",{"type":23,"tag":664,"props":5438,"children":5439},{},[5440],{"type":28,"value":5441},"以及",{"type":28,"value":5443},"影像学证据（",{"type":23,"tag":273,"props":5445,"children":5448},{"href":5446,"rel":5447},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F23100216\u002F",[479],[5449],{"type":28,"value":5450},"Banks 等，Gut 2013",{"type":28,"value":5452},"）。光凭一个孤立的化验数值还不足以确诊，而从“你的脂肪酶升高了”直接跳到“你的胰腺正超载走向衰竭”，是没有依据的。",{"type":23,"tag":35,"props":5454,"children":5456},{"id":5455},"说法三脂肪肝级联",[5457],{"type":28,"value":5458},"说法三：“脂肪肝级联”",{"type":23,"tag":24,"props":5460,"children":5461},{},[5462],{"type":28,"value":5463},"这是最核心的一处颠倒，也是最值得弄清楚的一处。",{"type":23,"tag":24,"props":5465,"children":5466},{},[5467],{"type":23,"tag":2949,"props":5468,"children":5471},{"alt":5469,"src":5470},"在临床试验中，瑞它鲁肽大幅降低肝脏脂肪","\u002Fassets\u002Freta_liverfat.png",[],{"type":23,"tag":24,"props":5473,"children":5474},{},[5475,5477,5482,5484,5489,5491,5496],{"type":28,"value":5476},"他把瑞它鲁肽描述成让肝脏不堪重负、受到损伤——一场“脂肪肝级联”、一次“肝脏超载”。试验数据显示的恰恰相反。在二期肝脂肪研究里，瑞它鲁肽以剂量依赖的方式减少肝脏脂肪：在第48周，8 mg 组为**−81.7%",{"type":23,"tag":162,"props":5478,"children":5479},{},[5480],{"type":28,"value":5481},"，12 mg 组为",{"type":28,"value":5483},"−86.0%**，而安慰剂组只有 −4.6%。在最高剂量组里，",{"type":23,"tag":162,"props":5485,"children":5486},{},[5487],{"type":28,"value":5488},"约93%的患者肝脂肪降到了5%的阈值以下",{"type":28,"value":5490},"——这在医学意义上等于他们的脂肪肝已经恢复了正常（",{"type":23,"tag":273,"props":5492,"children":5494},{"href":5093,"rel":5493},[479],[5495],{"type":28,"value":5097},{"type":28,"value":5497},"）。这是迄今为止该药临床开发中报告过的最大幅度的肝脂肪下降之一。瑞它鲁肽不是什么潜伏的肝脏杀手；它恰恰是作为脂肪肝（MASLD）的治疗药物在研发的。在对照试验里，它对肝脏的净效应是强烈的保护——与他所描述的那套级联正好相反。",{"type":23,"tag":35,"props":5499,"children":5501},{"id":5500},"他说对的地方",[5502],{"type":28,"value":5500},{"type":23,"tag":24,"props":5504,"children":5505},{},[5506],{"type":28,"value":5507},"一次公道的事实核查，不能只挑错，也得承认他说对的地方——他的立论背后有两点是站得住脚的。",{"type":23,"tag":24,"props":5509,"children":5510},{},[5511,5513,5518,5520,5525,5527,5532,5533,5540,5542,5549],{"type":28,"value":5512},"他说对了：你",{"type":23,"tag":162,"props":5514,"children":5515},{},[5516],{"type":28,"value":5517},"不应该",{"type":28,"value":5519},"为了一个孤立、无症状的脂肪酶升高就慌张停药；这确实符合消化科指南所暗示的做法。他也说对了：在这类药上快速减重会赔上",{"type":23,"tag":162,"props":5521,"children":5522},{},[5523],{"type":28,"value":5524},"瘦体重",{"type":28,"value":5526},"——减掉的体重里，大约四分之一到接近一半可能是无脂肪质量，其中很大一部分是肌肉（",{"type":23,"tag":273,"props":5528,"children":5530},{"href":5112,"rel":5529},[479],[5531],{"type":28,"value":5116},{"type":28,"value":5025},{"type":23,"tag":273,"props":5534,"children":5537},{"href":5535,"rel":5536},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11450469\u002F",[479],[5538],{"type":28,"value":5539},"Tinsley 等，2024",{"type":28,"value":5541},"），这正是为什么蛋白质摄入和抗阻训练理应出现在任何一份认真的方案里（",{"type":23,"tag":273,"props":5543,"children":5546},{"href":5544,"rel":5545},"https:\u002F\u002Fdiabetesjournals.org\u002Fcare\u002Farticle\u002F47\u002F10\u002F1718\u002F154535\u002F",[479],[5547],{"type":28,"value":5548},"Locatelli 等，Diabetes Care 2024",{"type":28,"value":5550},"）。这些道理都是成立的。问题出在包裹它们的那层外壳上。",{"type":23,"tag":35,"props":5552,"children":5554},{"id":5553},"这套路数",[5555],{"type":28,"value":5553},{"type":23,"tag":24,"props":5557,"children":5558},{},[5559],{"type":28,"value":5560},"在我们看来，这里的结构是一种很眼熟的套路：用真实术语来营造权威感；拼装出一个吓人的“损伤级联”，而按我们对试验数据的解读，证据并不支持它；把别人的声音打上“虚假信息”的标签；然后端出来的解药，是一套付费方案和从作者自家商店买来的肽。我们并不声称掌握他的动机——我们描述的是我们所见到的效果，而其中的商业背景，读者可以自行掂量。",{"type":23,"tag":24,"props":5562,"children":5563},{},[5564],{"type":28,"value":5565},"瑞它鲁肽是一款严肃的在研药物，有真实的副作用谱（大多是胃肠道的、剂量依赖的、在加量阶段最严重），关于长期使用和肌肉流失也有真正尚未解答的问题。它值得谨慎对待，也需要一位开处方的临床医生。但它不该被一个卖着“解药”的人，硬扣上一个人为制造的“器官衰竭”叙事。",{"type":23,"tag":5567,"props":5568,"children":5569},"hr",{},[],{"type":23,"tag":35,"props":5571,"children":5573},{"id":5572},"完整的科学图景",[5574],{"type":28,"value":5572},{"type":23,"tag":24,"props":5576,"children":5577},{},[5578],{"type":28,"value":5579},"上面那一节是结论。这一部分是功课：一份带出处的入门读物，讲的是这些药真正在做什么，好让你能自己去判断那些说法，而不是听信任何人的一面之词——无论是我们的还是他的。这部分是故意写得密的。",{"type":23,"tag":35,"props":5581,"children":5583},{"id":5582},"从-nafld-到-masld",[5584],{"type":28,"value":5585},"从 NAFLD 到 MASLD",{"type":23,"tag":24,"props":5587,"children":5588},{},[5589,5591,5596,5598,5605],{"type":28,"value":5590},"几十年来，肝脏在没有大量饮酒的情况下堆积脂肪，被称为非酒精性脂肪性肝病（NAFLD）——如今它是地球上最常见的慢性肝病，影响着大约30%到38%的成年人。2023年，一项国际共识把它改名为 ",{"type":23,"tag":162,"props":5592,"children":5593},{},[5594],{"type":28,"value":5595},"MASLD——代谢功能障碍相关脂肪性肝病",{"type":28,"value":5597},"——为的是把代谢这一根本病因摆到台前，而不是用“它不是什么”来定义这个病（",{"type":23,"tag":273,"props":5599,"children":5602},{"href":5600,"rel":5601},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC10653297\u002F",[479],[5603],{"type":28,"value":5604},"Rinella 等，2023",{"type":28,"value":5042},{"type":23,"tag":24,"props":5607,"children":5608},{},[5609,5611,5625],{"type":28,"value":5610},"这一进展可以用一个**“多重打击”模型",{"type":23,"tag":162,"props":5612,"children":5613},{},[5614,5616,5623],{"type":28,"value":5615},"来描述：第一击是脂肪在肝细胞里积累，这让肝脏变得容易受到进一步的伤害——氧化应激、线粒体功能障碍、肠肝菌群失调、炎症（",{"type":23,"tag":273,"props":5617,"children":5620},{"href":5618,"rel":5619},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F26823198\u002F",[479],[5621],{"type":28,"value":5622},"Buzzetti 等，2016",{"type":28,"value":5624},"）。这个谱系从单纯性脂肪变，经过带有炎症和细胞损伤的脂肪性肝炎（MASH），一直发展到纤维化、肝硬化和肝癌。推动这一进展的是",{"type":28,"value":5626},"脂毒性**——不是惰性的甘油三酯本身，而是像神经酰胺和二酰甘油这样有毒的脂质中间产物，它们损坏细胞机器，并激活炎症通路。",{"type":23,"tag":35,"props":5628,"children":5630},{"id":5629},"选择性肝脏胰岛素抵抗",[5631],{"type":28,"value":5629},{"type":23,"tag":24,"props":5633,"children":5634},{},[5635,5637,5644,5645,5652],{"type":28,"value":5636},"这里最重要的观念之一，主要由 Samuel 和 Shulman 提出，解决了一个悖论：为什么一个糖尿病患者的肝脏无视胰岛素“停止造糖”的信号，却依然听从胰岛素“去造脂肪”的信号（",{"type":23,"tag":273,"props":5638,"children":5641},{"href":5639,"rel":5640},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC4701542\u002F",[479],[5642],{"type":28,"value":5643},"Samuel & Shulman，JCI 2016",{"type":28,"value":5025},{"type":23,"tag":273,"props":5646,"children":5649},{"href":5647,"rel":5648},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC5762395\u002F",[479],[5650],{"type":28,"value":5651},"Cell Metabolism 2018",{"type":28,"value":5042},{"type":23,"tag":24,"props":5654,"children":5655},{},[5656,5658,5663,5665,5670,5672,5679,5681,5686],{"type":28,"value":5657},"机制是这样的：随着脂肪在肝脏里积累，",{"type":23,"tag":162,"props":5659,"children":5660},{},[5661],{"type":28,"value":5662},"二酰甘油",{"type":28,"value":5664},"堆积起来，激活一种酶（PKCε），它卡住了近端的胰岛素信号。胰岛素再也无法抑制葡萄糖输出——于是血糖上升——但造脂肪的机器却靠着现成的底物和高胰岛素水平继续运转。再加上产生抵抗的脂肪组织把游离脂肪酸直接倾入肝脏，一个脂肪堆积的自我强化循环就此形成。同位素研究给这股流入量标出了具体数字：在脂肪肝患者体内，储存于肝脏的甘油三酯里，约",{"type":23,"tag":162,"props":5666,"children":5667},{},[5668],{"type":28,"value":5669},"59%来自循环中的游离脂肪酸",{"type":28,"value":5671},"（外周脂解），约26%来自新生脂肪生成，约15%来自饮食（",{"type":23,"tag":273,"props":5673,"children":5676},{"href":5674,"rel":5675},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC1087172\u002F",[479],[5677],{"type":28,"value":5678},"Donnelly 等，JCI 2005",{"type":28,"value":5680},"）。这才是那段视频含糊其辞地指向的真实生物学——而这也恰恰是为什么，一种",{"type":23,"tag":664,"props":5682,"children":5683},{},[5684],{"type":28,"value":5685},"减少",{"type":28,"value":5687},"那股脂肪流入的药物是帮忙而非帮倒忙。",{"type":23,"tag":35,"props":5689,"children":5691},{"id":5690},"胰高血糖素真正做的事以及那个白脂肪误解",[5692],{"type":28,"value":5693},"胰高血糖素真正做的事——以及那个白脂肪误解",{"type":23,"tag":24,"props":5695,"children":5696},{},[5697,5699,5704,5705,5710,5711,5718,5719,5725],{"type":28,"value":5698},"胰高血糖素长期被塑造成只是胰岛素的对立面，如今则被视为能量和脂质代谢的一个作用广泛的调节者。它的主要靶点是肝脏，在那里它触发葡萄糖释放，而且很重要的是，通过 cAMP\u002FPKA 通路和一个激活肝脏脂肪分解的钙释放机制，",{"type":23,"tag":162,"props":5700,"children":5701},{},[5702],{"type":28,"value":5703},"驱动脂肪氧化并抑制新脂肪的合成",{"type":28,"value":5059},{"type":23,"tag":273,"props":5706,"children":5708},{"href":5019,"rel":5707},[479],[5709],{"type":28,"value":5023},{"type":28,"value":5025},{"type":23,"tag":273,"props":5712,"children":5715},{"href":5713,"rel":5714},"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fphysiology\u002Farticles\u002F10.3389\u002Ffphys.2019.00413\u002Ffull",[479],[5716],{"type":28,"value":5717},"Galsgaard 等，2019",{"type":28,"value":5025},{"type":23,"tag":273,"props":5720,"children":5722},{"href":5349,"rel":5721},[479],[5723],{"type":28,"value":5724},"Kajani 等，2024",{"type":28,"value":5726},"）。正是这种肝脏“燃脂”，才让药物开发者把一个胰高血糖素信号嫁接到了瑞它鲁肽上。",{"type":23,"tag":24,"props":5728,"children":5729},{},[5730,5732,5737,5739,5744,5746,5751,5752,5758,5760,5765],{"type":28,"value":5731},"但是——这就是那处要纠正的误解——这个作用是",{"type":23,"tag":162,"props":5733,"children":5734},{},[5735],{"type":28,"value":5736},"肝脏的，不是外周的。",{"type":28,"value":5738}," 早年的体外实验显示，孤立的脂肪细胞浸在胰高血糖素里时能够分解脂肪，可那浓度比身体所能产生的高出10到100倍。现代研究把这事定了论：把脂肪组织里的胰高血糖素受体敲掉，脂质代谢毫无变化（",{"type":23,"tag":273,"props":5740,"children":5742},{"href":5028,"rel":5741},[479],[5743],{"type":28,"value":5032},{"type":28,"value":5745},"）；给人注入生理浓度的胰高血糖素，腹部脂肪的脂解纹丝不动（",{"type":23,"tag":273,"props":5747,"children":5749},{"href":5036,"rel":5748},[479],[5750],{"type":28,"value":5040},{"type":28,"value":5025},{"type":23,"tag":273,"props":5753,"children":5755},{"href":5323,"rel":5754},[479],[5756],{"type":28,"value":5757},"Jensen 等，1991",{"type":28,"value":5759},"）。含胰高血糖素的药物带来的减重，来自食欲抑制、能量消耗提高，以及",{"type":23,"tag":162,"props":5761,"children":5762},{},[5763],{"type":28,"value":5764},"肝脏",{"type":28,"value":5766},"脂肪氧化——不是胰高血糖素把你的肚子脂肪化开、再灌满你的器官。",{"type":23,"tag":35,"props":5768,"children":5770},{"id":5769},"多重激动剂的跃迁从司美格鲁肽到瑞它鲁肽",[5771],{"type":28,"value":5772},"多重激动剂的跃迁：从司美格鲁肽到瑞它鲁肽",{"type":23,"tag":24,"props":5774,"children":5775},{},[5776,5778,5799,5800,5807,5809,5816,5817,5824],{"type":28,"value":5777},"肠促胰素类药物是肠道激素的模拟物，经过改造以抵抗快速降解，从而作用更持久。第一波是 GLP-1 单激动剂：司美格鲁肽在其关键性肥胖试验里带来了约",{"type":23,"tag":162,"props":5779,"children":5780},{},[5781,5783,5797],{"type":28,"value":5782},"14.9%",{"type":23,"tag":162,"props":5784,"children":5785},{},[5786,5788,5795],{"type":28,"value":5787},"的平均减重（",{"type":23,"tag":273,"props":5789,"children":5792},{"href":5790,"rel":5791},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F33567185\u002F",[479],[5793],{"type":28,"value":5794},"STEP 1，Wilding 等，NEJM 2021",{"type":28,"value":5796},"）。接着是 GLP-1\u002FGIP 双激动：替尔泊肽达到了最高",{"type":28,"value":5798},"20.9%",{"type":28,"value":5059},{"type":23,"tag":273,"props":5801,"children":5804},{"href":5802,"rel":5803},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F35658024\u002F",[479],[5805],{"type":28,"value":5806},"SURMOUNT-1，Jastreboff 等，NEJM 2022",{"type":28,"value":5808},"）。关于这些激素如何协同作用的生理学，可参见 ",{"type":23,"tag":273,"props":5810,"children":5813},{"href":5811,"rel":5812},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F39160334\u002F",[479],[5814],{"type":28,"value":5815},"Holst，Nature Metabolism 2024",{"type":28,"value":4508},{"type":23,"tag":273,"props":5818,"children":5821},{"href":5819,"rel":5820},"https:\u002F\u002Fdom-pubs.onlinelibrary.wiley.com\u002Fdoi\u002F10.1111\u002Fdom.14496",[479],[5822],{"type":28,"value":5823},"Nauck 等，2021",{"type":28,"value":370},{"type":23,"tag":24,"props":5826,"children":5827},{},[5828,5830,5835,5837,5844],{"type":28,"value":5829},"瑞它鲁肽（LY3437943）更进一步：一个分子同时作用于 ",{"type":23,"tag":162,"props":5831,"children":5832},{},[5833],{"type":28,"value":5834},"GLP-1、GIP 和胰高血糖素",{"type":28,"value":5836},"三种受体（",{"type":23,"tag":273,"props":5838,"children":5841},{"href":5839,"rel":5840},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT04881760",[479],[5842],{"type":28,"value":5843},"试验 NCT04881760",{"type":28,"value":5845},"）。胰高血糖素这一路增加肝脏脂肪氧化和能量消耗；GLP-1 和 GIP 两路则提供食欲抑制、胰岛素支持，以及——最关键的——抵消胰高血糖素升高血糖的倾向。",{"type":23,"tag":24,"props":5847,"children":5848},{},[5849,5851,5855,5857,5864,5865,5871,5873,5877],{"type":28,"value":5850},"关于命名的一点提醒：下面的",{"type":23,"tag":162,"props":5852,"children":5853},{},[5854],{"type":28,"value":1482},{"type":28,"value":5856},"数据来自 ",{"type":23,"tag":273,"props":5858,"children":5861},{"href":5859,"rel":5860},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F37366315\u002F",[479],[5862],{"type":28,"value":5863},"Jastreboff 等，NEJM 2023",{"type":28,"value":4508},{"type":23,"tag":273,"props":5866,"children":5868},{"href":5093,"rel":5867},[479],[5869],{"type":28,"value":5870},"MASLD 子研究，Sanyal 等，Nature Medicine 2024",{"type":28,"value":5872},"。“TRIUMPH”是后来的",{"type":23,"tag":664,"props":5874,"children":5875},{},[5876],{"type":28,"value":1512},{"type":28,"value":5878},"项目——所以别让任何人把二期的数字当成 TRIUMPH-1 的结果来呈现。",{"type":23,"tag":24,"props":5880,"children":5881},{},[5882,5887,5889,5895],{"type":23,"tag":162,"props":5883,"children":5884},{},[5885],{"type":28,"value":5886},"第48周的体重变化",{"type":28,"value":5888},"（二期，n=338；",{"type":23,"tag":273,"props":5890,"children":5892},{"href":5859,"rel":5891},[479],[5893],{"type":28,"value":5894},"Jastreboff 等，2023",{"type":28,"value":5896},"）：",{"type":23,"tag":46,"props":5898,"children":5899},{},[5900,5915],{"type":23,"tag":50,"props":5901,"children":5902},{},[5903],{"type":23,"tag":54,"props":5904,"children":5905},{},[5906,5910],{"type":23,"tag":58,"props":5907,"children":5908},{},[5909],{"type":28,"value":3796},{"type":23,"tag":58,"props":5911,"children":5912},{},[5913],{"type":28,"value":5914},"平均体重变化",{"type":23,"tag":69,"props":5916,"children":5917},{},[5918,5930,5943,5956,5969],{"type":23,"tag":54,"props":5919,"children":5920},{},[5921,5925],{"type":23,"tag":76,"props":5922,"children":5923},{},[5924],{"type":28,"value":1296},{"type":23,"tag":76,"props":5926,"children":5927},{},[5928],{"type":28,"value":5929},"−2.1%",{"type":23,"tag":54,"props":5931,"children":5932},{},[5933,5938],{"type":23,"tag":76,"props":5934,"children":5935},{},[5936],{"type":28,"value":5937},"瑞它鲁肽 1 mg",{"type":23,"tag":76,"props":5939,"children":5940},{},[5941],{"type":28,"value":5942},"−8.7%",{"type":23,"tag":54,"props":5944,"children":5945},{},[5946,5951],{"type":23,"tag":76,"props":5947,"children":5948},{},[5949],{"type":28,"value":5950},"瑞它鲁肽 4 mg",{"type":23,"tag":76,"props":5952,"children":5953},{},[5954],{"type":28,"value":5955},"−17.1%",{"type":23,"tag":54,"props":5957,"children":5958},{},[5959,5964],{"type":23,"tag":76,"props":5960,"children":5961},{},[5962],{"type":28,"value":5963},"瑞它鲁肽 8 mg",{"type":23,"tag":76,"props":5965,"children":5966},{},[5967],{"type":28,"value":5968},"−22.8%",{"type":23,"tag":54,"props":5970,"children":5971},{},[5972,5977],{"type":23,"tag":76,"props":5973,"children":5974},{},[5975],{"type":28,"value":5976},"瑞它鲁肽 12 mg",{"type":23,"tag":76,"props":5978,"children":5979},{},[5980],{"type":28,"value":5981},"−24.2%",{"type":23,"tag":24,"props":5983,"children":5984},{},[5985,5990,5992,5998],{"type":23,"tag":162,"props":5986,"children":5987},{},[5988],{"type":28,"value":5989},"第48周的肝脂肪变化",{"type":28,"value":5991},"（MASLD 子研究，n=98；",{"type":23,"tag":273,"props":5993,"children":5995},{"href":5093,"rel":5994},[479],[5996],{"type":28,"value":5997},"Sanyal 等，2024",{"type":28,"value":5896},{"type":23,"tag":46,"props":6000,"children":6001},{},[6002,6022],{"type":23,"tag":50,"props":6003,"children":6004},{},[6005],{"type":23,"tag":54,"props":6006,"children":6007},{},[6008,6012,6017],{"type":23,"tag":58,"props":6009,"children":6010},{},[6011],{"type":28,"value":3796},{"type":23,"tag":58,"props":6013,"children":6014},{},[6015],{"type":28,"value":6016},"肝脂肪相对变化",{"type":23,"tag":58,"props":6018,"children":6019},{},[6020],{"type":28,"value":6021},"肝脂肪恢复正常（\u003C5%）",{"type":23,"tag":69,"props":6023,"children":6024},{},[6025,6042,6059,6076],{"type":23,"tag":54,"props":6026,"children":6027},{},[6028,6032,6037],{"type":23,"tag":76,"props":6029,"children":6030},{},[6031],{"type":28,"value":1296},{"type":23,"tag":76,"props":6033,"children":6034},{},[6035],{"type":28,"value":6036},"−4.6%",{"type":23,"tag":76,"props":6038,"children":6039},{},[6040],{"type":28,"value":6041},"0%",{"type":23,"tag":54,"props":6043,"children":6044},{},[6045,6049,6054],{"type":23,"tag":76,"props":6046,"children":6047},{},[6048],{"type":28,"value":5937},{"type":23,"tag":76,"props":6050,"children":6051},{},[6052],{"type":28,"value":6053},"−51.3%",{"type":23,"tag":76,"props":6055,"children":6056},{},[6057],{"type":28,"value":6058},">50%",{"type":23,"tag":54,"props":6060,"children":6061},{},[6062,6066,6071],{"type":23,"tag":76,"props":6063,"children":6064},{},[6065],{"type":28,"value":5963},{"type":23,"tag":76,"props":6067,"children":6068},{},[6069],{"type":28,"value":6070},"−81.7%",{"type":23,"tag":76,"props":6072,"children":6073},{},[6074],{"type":28,"value":6075},"—",{"type":23,"tag":54,"props":6077,"children":6078},{},[6079,6083,6088],{"type":23,"tag":76,"props":6080,"children":6081},{},[6082],{"type":28,"value":5976},{"type":23,"tag":76,"props":6084,"children":6085},{},[6086],{"type":28,"value":6087},"−86.0%",{"type":23,"tag":76,"props":6089,"children":6090},{},[6091],{"type":28,"value":6092},"~93%",{"type":23,"tag":24,"props":6094,"children":6095},{},[6096],{"type":28,"value":6097},"不到一年就减掉接近四分之一的体重，达到了以往只有减重手术才能触及的量级——而且在最高剂量下，超过九成患者的脂肪肝恢复了正常。这些正是一个“肝脏超载”叙事不得不无视的数据。",{"type":23,"tag":35,"props":6099,"children":6101},{"id":6100},"胃肠道反应以及麻醉这个问题",[6102],{"type":28,"value":6103},"胃肠道反应，以及麻醉这个问题",{"type":23,"tag":24,"props":6105,"children":6106},{},[6107,6109,6114,6116,6121],{"type":28,"value":6108},"这份疗效的代价，主要落在胃肠道上。胃排空减慢加上脑干的恶心信号，使得",{"type":23,"tag":162,"props":6110,"children":6111},{},[6112],{"type":28,"value":6113},"恶心、呕吐、腹泻和便秘",{"type":28,"value":6115},"成为常见副作用——剂量依赖、在加量阶段最重、通常是一过性的（",{"type":23,"tag":273,"props":6117,"children":6119},{"href":5859,"rel":6118},[479],[6120],{"type":28,"value":5894},{"type":28,"value":6122},"）。缓慢滴定（从低剂量起步）是标准的缓解办法。",{"type":23,"tag":24,"props":6124,"children":6125},{},[6126,6128,6135,6136,6143,6145,6152,6154,6161,6163,6168],{"type":28,"value":6127},"有一个现实后果引发了真正的医学讨论：因为这些药减慢胃排空，食物会在胃里滞留更久，从而增加麻醉前胃内容物残留的可能，带来理论上的误吸风险。荟萃分析确实发现用药者的胃内残留物明显更多（",{"type":23,"tag":273,"props":6129,"children":6132},{"href":6130,"rel":6131},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11264430\u002F",[479],[6133],{"type":28,"value":6134},"do Nascimento 等，2024",{"type":28,"value":5025},{"type":23,"tag":273,"props":6137,"children":6140},{"href":6138,"rel":6139},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F40133086\u002F",[479],[6141],{"type":28,"value":6142},"Tan 等，2025",{"type":28,"value":6144},"），尽管实际的误吸事件依然罕见（",{"type":23,"tag":273,"props":6146,"children":6149},{"href":6147,"rel":6148},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11651700\u002F",[479],[6150],{"type":28,"value":6151},"Jalleh 等，JCEM 2024",{"type":28,"value":6153},"）。麻醉学会现在建议在择期手术前暂停用药（",{"type":23,"tag":273,"props":6155,"children":6158},{"href":6156,"rel":6157},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F37982170\u002F",[479],[6159],{"type":28,"value":6160},"ASA 指南，2024",{"type":28,"value":6162},"）。这是一个合理、且已被充分研究的注意事项——而值得注意的是，这",{"type":23,"tag":664,"props":6164,"children":6165},{},[6166],{"type":28,"value":6167},"恰恰不是",{"type":28,"value":6169},"那段视频所聚焦的那个。",{"type":23,"tag":35,"props":6171,"children":6173},{"id":6172},"胰腺它是怎么工作的以及脂肪酶这个问题",[6174],{"type":28,"value":6175},"胰腺：它是怎么工作的，以及脂肪酶这个问题",{"type":23,"tag":24,"props":6177,"children":6178},{},[6179,6181,6187],{"type":28,"value":6180},"胰腺90%以上是外分泌组织——制造消化酶的腺泡细胞。它们储存无活性的酶前体，一收到信号就释放；而酶在细胞内部提前被激活，才是真正胰腺炎的定义。GLP-1 受体存在于这些腺泡细胞上，所以这些药推动酶释放，属于一种正常的、受体介导的效应（",{"type":23,"tag":273,"props":6182,"children":6184},{"href":5389,"rel":6183},[479],[6185],{"type":28,"value":6186},"Hou…Williams 等，2016",{"type":28,"value":5042},{"type":23,"tag":24,"props":6189,"children":6190},{},[6191,6193,6198,6200,6206,6208,6212],{"type":28,"value":6192},"这正是为什么用药时轻度的脂肪酶和淀粉酶升高如此常见——也正是为什么它们通常没有意义。它们是被刺激的酶",{"type":23,"tag":664,"props":6194,"children":6195},{},[6196],{"type":28,"value":6197},"渗漏",{"type":28,"value":6199},"，不是组织被破坏。上文的试验证据显示，这些升高并不预示胰腺炎（",{"type":23,"tag":273,"props":6201,"children":6203},{"href":5062,"rel":6202},[479],[6204],{"type":28,"value":6205},"Steinberg 等，2017",{"type":28,"value":6207},"），而汇总数据显示，相较于安慰剂并没有额外的胰腺炎风险。确实存在的那点背景风险，是跟着人群走的——肥胖和2型糖尿病人群本身就因为胆结石和高甘油三酯而带有更高的基线胰腺炎风险，与任何药物无关。而正是因为治好了这些诱因，才有可能解释为什么某些数据显示用 GLP-1 治疗后复发",{"type":23,"tag":162,"props":6209,"children":6210},{},[6211],{"type":28,"value":5426},{"type":28,"value":370},{"type":23,"tag":35,"props":6214,"children":6216},{"id":6215},"真正的警示瘦体重的流失",[6217],{"type":28,"value":6218},"真正的警示：瘦体重的流失",{"type":23,"tag":24,"props":6220,"children":6221},{},[6222,6224,6229,6231,6236,6237,6242,6244,6250],{"type":28,"value":6223},"如果说有哪一条警告，配得上视频花在幻想中的器官损伤上的那些时长，那就是这一条。在各项肠促胰素试验中，减掉的体重里有相当一部分是",{"type":23,"tag":162,"props":6225,"children":6226},{},[6227],{"type":28,"value":6228},"无脂肪质量",{"type":28,"value":6230},"——大约25%到40%，其中很大一部分是骨骼肌（",{"type":23,"tag":273,"props":6232,"children":6234},{"href":5112,"rel":6233},[479],[6235],{"type":28,"value":5116},{"type":28,"value":5025},{"type":23,"tag":273,"props":6238,"children":6240},{"href":5535,"rel":6239},[479],[6241],{"type":28,"value":5539},{"type":28,"value":6243},"）。这并不是这些药独有的——任何大幅、快速的减重都会这样——但流失肌肉会降低代谢率（为停药后的反弹埋下伏笔）、降低胰岛素敏感性，并提高老年人的衰弱和跌倒风险。有循证依据的对策一点也不光鲜：在用药的同时，保证充足的蛋白质和渐进式的抗阻训练（",{"type":23,"tag":273,"props":6245,"children":6247},{"href":5544,"rel":6246},[479],[6248],{"type":28,"value":6249},"Locatelli 等，2024",{"type":28,"value":5042},{"type":23,"tag":35,"props":6252,"children":6254},{"id":6253},"新的前沿免疫代谢与癌症",[6255],{"type":28,"value":6256},"新的前沿：免疫代谢与癌症",{"type":23,"tag":24,"props":6258,"children":6259},{},[6260,6262,6269],{"type":28,"value":6261},"最后，瞥一眼科学正走向何方。肥胖驱动慢性炎症，并让那些对抗肿瘤的免疫细胞在代谢上“精疲力竭”。早期研究提示 GLP-1 类药物或许能部分逆转这一点：在肥胖的肺癌小鼠模型里，一种 GLP-1 激动剂减缓了肿瘤生长，并改善了抗肿瘤的免疫环境——而这种效应只在肥胖动物身上见到（",{"type":23,"tag":273,"props":6263,"children":6266},{"href":6264,"rel":6265},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F40857107\u002F",[479],[6267],{"type":28,"value":6268},"Pachimatla…Sanghvi 等，JCI Insight 2025",{"type":28,"value":6270},"）。这还是临床前的、很早期的研究，但它暗示，纠正代谢功能障碍的好处，可能远远超出体重秤上的那个数字。",{"type":23,"tag":35,"props":6272,"children":6274},{"id":6273},"诚实的结论",[6275],{"type":28,"value":6273},{"type":23,"tag":24,"props":6277,"children":6278},{},[6279,6281,6286,6288,6293,6295,6299],{"type":28,"value":6280},"把证据拼到一起，得到的图景与那段视频正好相反。在对照试验里，瑞它鲁肽大幅",{"type":23,"tag":162,"props":6282,"children":6283},{},[6284],{"type":28,"value":6285},"降低",{"type":28,"value":6287},"肝脂肪，",{"type":23,"tag":162,"props":6289,"children":6290},{},[6291],{"type":28,"value":6292},"不会",{"type":28,"value":6294},"提高胰腺炎风险，也",{"type":23,"tag":162,"props":6296,"children":6297},{},[6298],{"type":28,"value":6292},{"type":28,"value":6300},"通过什么胰高血糖素洪流把你的身体脂肪化开。而那些真正需要注意的地方——肌肉流失、胃肠道反应、麻醉这一相互作用，以及一个直白的事实：灰色市场的产品未受监管，可能根本不是标签上写的那个东西——恰恰是一个卖肽给你的商家最没有动力去多谈的。",{"type":23,"tag":24,"props":6302,"children":6303},{},[6304,6306,6311,6313,6318,6320,6324],{"type":28,"value":6305},"如果你正在考虑、或者已经在用这些东西，正确的做法不是一段45分钟的视频加一个结账按钮。而是抽血化验、一位真正的处方医生，以及诚实的预期。要是有什么感觉不对劲，",{"type":23,"tag":162,"props":6307,"children":6308},{},[6309],{"type":28,"value":6310},"在你相信一套由那个在 YouTube 上给你下诊断的人所兜售的方案之前，先去当面找一位你最不那么信不过的医生。",{"type":28,"value":6312}," 想看已发表文献里报告的试验剂量，请见我们的",{"type":23,"tag":273,"props":6314,"children":6315},{"href":1494},[6316],{"type":28,"value":6317},"瑞它鲁肽参考页",{"type":28,"value":6319},"；想先弄懂这一类药，就从",{"type":23,"tag":273,"props":6321,"children":6322},{"href":449},[6323],{"type":28,"value":452},{"type":28,"value":6325},"开始。",{"type":23,"tag":35,"props":6327,"children":6329},{"id":6328},"参考文献",[6330],{"type":28,"value":6328},{"type":23,"tag":2164,"props":6332,"children":6333},{},[6334,6367,6399,6416,6438,6460,6484,6508,6531,6553,6576,6599,6624,6654,6677,6699,6721,6743,6765,6787,6809,6832,6854,6876,6898,6920,6941,6963,6985,7006,7028,7050,7068,7084,7101,7118],{"type":23,"tag":179,"props":6335,"children":6336},{},[6337,6339,6344,6345,6350,6352,6358,6360],{"type":28,"value":6338},"Jastreboff AM, Kaplan LM, Frías JP, et al. ",{"type":23,"tag":162,"props":6340,"children":6341},{},[6342],{"type":28,"value":6343},"Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.",{"type":28,"value":2083},{"type":23,"tag":664,"props":6346,"children":6347},{},[6348],{"type":28,"value":6349},"N Engl J Med",{"type":28,"value":6351}," 2023. ",{"type":23,"tag":273,"props":6353,"children":6355},{"href":5859,"rel":6354},[479],[6356],{"type":28,"value":6357},"PubMed",{"type":28,"value":6359}," · ",{"type":23,"tag":273,"props":6361,"children":6364},{"href":6362,"rel":6363},"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2301972",[479],[6365],{"type":28,"value":6366},"NEJM",{"type":23,"tag":179,"props":6368,"children":6369},{},[6370,6372,6377,6378,6383,6385,6391,6392],{"type":28,"value":6371},"Sanyal AJ, et al. ",{"type":23,"tag":162,"props":6373,"children":6374},{},[6375],{"type":28,"value":6376},"Triple hormone receptor agonist retatrutide for MASLD: a randomized phase 2a trial.",{"type":28,"value":2083},{"type":23,"tag":664,"props":6379,"children":6380},{},[6381],{"type":28,"value":6382},"Nature Medicine",{"type":28,"value":6384}," 2024. ",{"type":23,"tag":273,"props":6386,"children":6388},{"href":5093,"rel":6387},[479],[6389],{"type":28,"value":6390},"PMC full text",{"type":28,"value":6359},{"type":23,"tag":273,"props":6393,"children":6396},{"href":6394,"rel":6395},"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41591-024-03018-2",[479],[6397],{"type":28,"value":6398},"Nature",{"type":23,"tag":179,"props":6400,"children":6401},{},[6402,6404,6409,6410],{"type":28,"value":6403},"Phase-2 retatrutide obesity trial registration. ",{"type":23,"tag":664,"props":6405,"children":6406},{},[6407],{"type":28,"value":6408},"ClinicalTrials.gov",{"type":28,"value":2083},{"type":23,"tag":273,"props":6411,"children":6413},{"href":5839,"rel":6412},[479],[6414],{"type":28,"value":6415},"NCT04881760",{"type":23,"tag":179,"props":6417,"children":6418},{},[6419,6421,6426,6427,6431,6433],{"type":28,"value":6420},"Perry RJ, et al. ",{"type":23,"tag":162,"props":6422,"children":6423},{},[6424],{"type":28,"value":6425},"Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis.",{"type":28,"value":2083},{"type":23,"tag":664,"props":6428,"children":6429},{},[6430],{"type":28,"value":6398},{"type":28,"value":6432}," 2020. ",{"type":23,"tag":273,"props":6434,"children":6436},{"href":5019,"rel":6435},[479],[6437],{"type":28,"value":6357},{"type":23,"tag":179,"props":6439,"children":6440},{},[6441,6443,6448,6449,6454,6455],{"type":28,"value":6442},"Kajani S, et al. ",{"type":23,"tag":162,"props":6444,"children":6445},{},[6446],{"type":28,"value":6447},"Hepatic glucagon action: beyond glucose mobilization.",{"type":28,"value":2083},{"type":23,"tag":664,"props":6450,"children":6451},{},[6452],{"type":28,"value":6453},"Physiological Reviews",{"type":28,"value":6384},{"type":23,"tag":273,"props":6456,"children":6458},{"href":5349,"rel":6457},[479],[6459],{"type":28,"value":6357},{"type":23,"tag":179,"props":6461,"children":6462},{},[6463,6465,6470,6471,6476,6478],{"type":28,"value":6464},"Galsgaard KD, et al. ",{"type":23,"tag":162,"props":6466,"children":6467},{},[6468],{"type":28,"value":6469},"Glucagon Receptor Signaling and Lipid Metabolism.",{"type":28,"value":2083},{"type":23,"tag":664,"props":6472,"children":6473},{},[6474],{"type":28,"value":6475},"Front Physiol",{"type":28,"value":6477}," 2019. ",{"type":23,"tag":273,"props":6479,"children":6481},{"href":5713,"rel":6480},[479],[6482],{"type":28,"value":6483},"Full text",{"type":23,"tag":179,"props":6485,"children":6486},{},[6487,6489,6494,6495,6500,6502],{"type":28,"value":6488},"Vasileva A, et al. ",{"type":23,"tag":162,"props":6490,"children":6491},{},[6492],{"type":28,"value":6493},"Glucagon receptor signaling at white adipose tissue does not regulate lipolysis.",{"type":28,"value":2083},{"type":23,"tag":664,"props":6496,"children":6497},{},[6498],{"type":28,"value":6499},"Am J Physiol Endocrinol Metab",{"type":28,"value":6501}," 2022. ",{"type":23,"tag":273,"props":6503,"children":6505},{"href":5028,"rel":6504},[479],[6506],{"type":28,"value":6507},"PMC",{"type":23,"tag":179,"props":6509,"children":6510},{},[6511,6513,6518,6519,6524,6526],{"type":28,"value":6512},"Gravholt CH, et al. ",{"type":23,"tag":162,"props":6514,"children":6515},{},[6516],{"type":28,"value":6517},"Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue.",{"type":28,"value":2083},{"type":23,"tag":664,"props":6520,"children":6521},{},[6522],{"type":28,"value":6523},"JCEM",{"type":28,"value":6525}," 2001. ",{"type":23,"tag":273,"props":6527,"children":6529},{"href":5036,"rel":6528},[479],[6530],{"type":28,"value":6357},{"type":23,"tag":179,"props":6532,"children":6533},{},[6534,6536,6541,6542,6546,6548],{"type":28,"value":6535},"Jensen MD, et al. ",{"type":23,"tag":162,"props":6537,"children":6538},{},[6539],{"type":28,"value":6540},"Effects of glucagon on free fatty acid metabolism in humans.",{"type":28,"value":2083},{"type":23,"tag":664,"props":6543,"children":6544},{},[6545],{"type":28,"value":6523},{"type":28,"value":6547}," 1991. ",{"type":23,"tag":273,"props":6549,"children":6551},{"href":5323,"rel":6550},[479],[6552],{"type":28,"value":6357},{"type":23,"tag":179,"props":6554,"children":6555},{},[6556,6558,6563,6564,6569,6571],{"type":28,"value":6557},"Hou Y, Ernst SA, Heidenreich K, Williams JA. ",{"type":23,"tag":162,"props":6559,"children":6560},{},[6561],{"type":28,"value":6562},"GLP-1 receptor is present in pancreatic acinar cells and regulates amylase secretion.",{"type":28,"value":2083},{"type":23,"tag":664,"props":6565,"children":6566},{},[6567],{"type":28,"value":6568},"Am J Physiol Gastrointest Liver Physiol",{"type":28,"value":6570}," 2016. ",{"type":23,"tag":273,"props":6572,"children":6574},{"href":5389,"rel":6573},[479],[6575],{"type":28,"value":6507},{"type":23,"tag":179,"props":6577,"children":6578},{},[6579,6581,6586,6587,6592,6594],{"type":28,"value":6580},"Steinberg WM, et al. ",{"type":23,"tag":162,"props":6582,"children":6583},{},[6584],{"type":28,"value":6585},"Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide (LEADER).",{"type":28,"value":2083},{"type":23,"tag":664,"props":6588,"children":6589},{},[6590],{"type":28,"value":6591},"Diabetes Care",{"type":28,"value":6593}," 2017. ",{"type":23,"tag":273,"props":6595,"children":6597},{"href":5062,"rel":6596},[479],[6598],{"type":28,"value":6357},{"type":23,"tag":179,"props":6600,"children":6601},{},[6602,6604,6609,6611,6616,6618],{"type":28,"value":6603},"GLP-1 receptor agonists and the risk of acute pancreatitis: a living systematic review. ",{"type":23,"tag":664,"props":6605,"children":6606},{},[6607],{"type":28,"value":6608},"medRxiv",{"type":28,"value":6610}," 2026 (",{"type":23,"tag":162,"props":6612,"children":6613},{},[6614],{"type":28,"value":6615},"预印本，尚未经过同行评审",{"type":28,"value":6617},"). ",{"type":23,"tag":273,"props":6619,"children":6621},{"href":5415,"rel":6620},[479],[6622],{"type":28,"value":6623},"Preprint",{"type":23,"tag":179,"props":6625,"children":6626},{},[6627,6629,6634,6635,6640,6642,6647,6648],{"type":28,"value":6628},"Nassar M, et al. ",{"type":23,"tag":162,"props":6630,"children":6631},{},[6632],{"type":28,"value":6633},"GLP-1 medications may lower risk of recurrent acute pancreatitis.",{"type":28,"value":2083},{"type":23,"tag":664,"props":6636,"children":6637},{},[6638],{"type":28,"value":6639},"ENDO 2024",{"type":28,"value":6641}," (",{"type":23,"tag":162,"props":6643,"children":6644},{},[6645],{"type":28,"value":6646},"会议摘要",{"type":28,"value":6617},{"type":23,"tag":273,"props":6649,"children":6651},{"href":5430,"rel":6650},[479],[6652],{"type":28,"value":6653},"Press release",{"type":23,"tag":179,"props":6655,"children":6656},{},[6657,6659,6664,6665,6670,6672],{"type":28,"value":6658},"Banks PA, et al. ",{"type":23,"tag":162,"props":6660,"children":6661},{},[6662],{"type":28,"value":6663},"Classification of acute pancreatitis — 2012: revision of the Atlanta classification.",{"type":28,"value":2083},{"type":23,"tag":664,"props":6666,"children":6667},{},[6668],{"type":28,"value":6669},"Gut",{"type":28,"value":6671}," 2013. ",{"type":23,"tag":273,"props":6673,"children":6675},{"href":5446,"rel":6674},[479],[6676],{"type":28,"value":6357},{"type":23,"tag":179,"props":6678,"children":6679},{},[6680,6682,6687,6688,6693,6694],{"type":28,"value":6681},"Rinella ME, et al. ",{"type":23,"tag":162,"props":6683,"children":6684},{},[6685],{"type":28,"value":6686},"A multisociety Delphi consensus on new fatty liver disease nomenclature (MASLD).",{"type":28,"value":2083},{"type":23,"tag":664,"props":6689,"children":6690},{},[6691],{"type":28,"value":6692},"Hepatology \u002F J Hepatol",{"type":28,"value":6351},{"type":23,"tag":273,"props":6695,"children":6697},{"href":5600,"rel":6696},[479],[6698],{"type":28,"value":6507},{"type":23,"tag":179,"props":6700,"children":6701},{},[6702,6704,6709,6710,6715,6716],{"type":28,"value":6703},"Samuel VT, Shulman GI. ",{"type":23,"tag":162,"props":6705,"children":6706},{},[6707],{"type":28,"value":6708},"The pathogenesis of insulin resistance.",{"type":28,"value":2083},{"type":23,"tag":664,"props":6711,"children":6712},{},[6713],{"type":28,"value":6714},"J Clin Invest",{"type":28,"value":6570},{"type":23,"tag":273,"props":6717,"children":6719},{"href":5639,"rel":6718},[479],[6720],{"type":28,"value":6507},{"type":23,"tag":179,"props":6722,"children":6723},{},[6724,6725,6730,6731,6736,6738],{"type":28,"value":6703},{"type":23,"tag":162,"props":6726,"children":6727},{},[6728],{"type":28,"value":6729},"NAFLD as a Nexus of Metabolic and Hepatic Diseases.",{"type":28,"value":2083},{"type":23,"tag":664,"props":6732,"children":6733},{},[6734],{"type":28,"value":6735},"Cell Metabolism",{"type":28,"value":6737}," 2018. ",{"type":23,"tag":273,"props":6739,"children":6741},{"href":5647,"rel":6740},[479],[6742],{"type":28,"value":6507},{"type":23,"tag":179,"props":6744,"children":6745},{},[6746,6748,6753,6754,6759,6760],{"type":28,"value":6747},"Buzzetti E, Pinzani M, Tsochatzis EA. ",{"type":23,"tag":162,"props":6749,"children":6750},{},[6751],{"type":28,"value":6752},"The multiple-hit pathogenesis of NAFLD.",{"type":28,"value":2083},{"type":23,"tag":664,"props":6755,"children":6756},{},[6757],{"type":28,"value":6758},"Metabolism",{"type":28,"value":6570},{"type":23,"tag":273,"props":6761,"children":6763},{"href":5618,"rel":6762},[479],[6764],{"type":28,"value":6357},{"type":23,"tag":179,"props":6766,"children":6767},{},[6768,6770,6775,6776,6780,6782],{"type":28,"value":6769},"Donnelly KL, et al. ",{"type":23,"tag":162,"props":6771,"children":6772},{},[6773],{"type":28,"value":6774},"Sources of fatty acids stored in liver and secreted via lipoproteins in NAFLD.",{"type":28,"value":2083},{"type":23,"tag":664,"props":6777,"children":6778},{},[6779],{"type":28,"value":6714},{"type":28,"value":6781}," 2005. ",{"type":23,"tag":273,"props":6783,"children":6785},{"href":5674,"rel":6784},[479],[6786],{"type":28,"value":6507},{"type":23,"tag":179,"props":6788,"children":6789},{},[6790,6792,6797,6798,6802,6803],{"type":28,"value":6791},"Locatelli JC, et al. ",{"type":23,"tag":162,"props":6793,"children":6794},{},[6795],{"type":28,"value":6796},"Incretin-Based Weight Loss and Resistance Exercise.",{"type":28,"value":2083},{"type":23,"tag":664,"props":6799,"children":6800},{},[6801],{"type":28,"value":6591},{"type":28,"value":6384},{"type":23,"tag":273,"props":6804,"children":6806},{"href":5544,"rel":6805},[479],[6807],{"type":28,"value":6808},"Article",{"type":23,"tag":179,"props":6810,"children":6811},{},[6812,6814,6819,6820,6825,6827],{"type":28,"value":6813},"Koceva A, et al. ",{"type":23,"tag":162,"props":6815,"children":6816},{},[6817],{"type":28,"value":6818},"Impact of Incretin-Based Therapy on Skeletal Muscle Health.",{"type":28,"value":2083},{"type":23,"tag":664,"props":6821,"children":6822},{},[6823],{"type":28,"value":6824},"Medicina",{"type":28,"value":6826}," 2025. ",{"type":23,"tag":273,"props":6828,"children":6830},{"href":5112,"rel":6829},[479],[6831],{"type":28,"value":6507},{"type":23,"tag":179,"props":6833,"children":6834},{},[6835,6837,6842,6843,6848,6849],{"type":28,"value":6836},"Tinsley GM, et al. ",{"type":23,"tag":162,"props":6838,"children":6839},{},[6840],{"type":28,"value":6841},"Body Composition Principles for Fat-Free and Skeletal Muscle Mass Changes.",{"type":28,"value":2083},{"type":23,"tag":664,"props":6844,"children":6845},{},[6846],{"type":28,"value":6847},"J Endocr Soc",{"type":28,"value":6384},{"type":23,"tag":273,"props":6850,"children":6852},{"href":5535,"rel":6851},[479],[6853],{"type":28,"value":6507},{"type":23,"tag":179,"props":6855,"children":6856},{},[6857,6859,6864,6865,6870,6871],{"type":28,"value":6858},"do Nascimento TS, et al. ",{"type":23,"tag":162,"props":6860,"children":6861},{},[6862],{"type":28,"value":6863},"GLP-1 receptor agonists and residual gastric content (perioperative).",{"type":28,"value":2083},{"type":23,"tag":664,"props":6866,"children":6867},{},[6868],{"type":28,"value":6869},"Perioper Med",{"type":28,"value":6384},{"type":23,"tag":273,"props":6872,"children":6874},{"href":6130,"rel":6873},[479],[6875],{"type":28,"value":6507},{"type":23,"tag":179,"props":6877,"children":6878},{},[6879,6881,6886,6887,6892,6893],{"type":28,"value":6880},"Tan Y, et al. ",{"type":23,"tag":162,"props":6882,"children":6883},{},[6884],{"type":28,"value":6885},"GLP-1 receptor agonists increase residual gastric content and aspiration risk.",{"type":28,"value":2083},{"type":23,"tag":664,"props":6888,"children":6889},{},[6890],{"type":28,"value":6891},"Dig Liver Dis",{"type":28,"value":6826},{"type":23,"tag":273,"props":6894,"children":6896},{"href":6138,"rel":6895},[479],[6897],{"type":28,"value":6357},{"type":23,"tag":179,"props":6899,"children":6900},{},[6901,6903,6908,6909,6914,6915],{"type":28,"value":6902},"Ushakumari DS, et al. ",{"type":23,"tag":162,"props":6904,"children":6905},{},[6906],{"type":28,"value":6907},"ASA Consensus-based Guidance on Preoperative Management of GLP-1 RAs.",{"type":28,"value":2083},{"type":23,"tag":664,"props":6910,"children":6911},{},[6912],{"type":28,"value":6913},"Anesthesiology",{"type":28,"value":6384},{"type":23,"tag":273,"props":6916,"children":6918},{"href":6156,"rel":6917},[479],[6919],{"type":28,"value":6357},{"type":23,"tag":179,"props":6921,"children":6922},{},[6923,6925,6930,6931,6935,6936],{"type":28,"value":6924},"Jalleh RJ, et al. ",{"type":23,"tag":162,"props":6926,"children":6927},{},[6928],{"type":28,"value":6929},"Clinical Consequences of Delayed Gastric Emptying With GLP-1 RAs.",{"type":28,"value":2083},{"type":23,"tag":664,"props":6932,"children":6933},{},[6934],{"type":28,"value":6523},{"type":28,"value":6384},{"type":23,"tag":273,"props":6937,"children":6939},{"href":6147,"rel":6938},[479],[6940],{"type":28,"value":6507},{"type":23,"tag":179,"props":6942,"children":6943},{},[6944,6946,6951,6952,6957,6958],{"type":28,"value":6945},"Pachimatla AG, … Sanghvi VR, et al. ",{"type":23,"tag":162,"props":6947,"children":6948},{},[6949],{"type":28,"value":6950},"GLP-1 receptor agonism improves lung cancer outcomes and tumor immunity (obese models).",{"type":28,"value":2083},{"type":23,"tag":664,"props":6953,"children":6954},{},[6955],{"type":28,"value":6956},"JCI Insight",{"type":28,"value":6826},{"type":23,"tag":273,"props":6959,"children":6961},{"href":6264,"rel":6960},[479],[6962],{"type":28,"value":6357},{"type":23,"tag":179,"props":6964,"children":6965},{},[6966,6968,6973,6974,6978,6980],{"type":28,"value":6967},"Wilding JPH, et al. ",{"type":23,"tag":162,"props":6969,"children":6970},{},[6971],{"type":28,"value":6972},"Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).",{"type":28,"value":2083},{"type":23,"tag":664,"props":6975,"children":6976},{},[6977],{"type":28,"value":6349},{"type":28,"value":6979}," 2021. ",{"type":23,"tag":273,"props":6981,"children":6983},{"href":5790,"rel":6982},[479],[6984],{"type":28,"value":6357},{"type":23,"tag":179,"props":6986,"children":6987},{},[6988,6990,6995,6996,7000,7001],{"type":28,"value":6989},"Jastreboff AM, et al. ",{"type":23,"tag":162,"props":6991,"children":6992},{},[6993],{"type":28,"value":6994},"Tirzepatide Once Weekly for Obesity (SURMOUNT-1).",{"type":28,"value":2083},{"type":23,"tag":664,"props":6997,"children":6998},{},[6999],{"type":28,"value":6349},{"type":28,"value":6501},{"type":23,"tag":273,"props":7002,"children":7004},{"href":5802,"rel":7003},[479],[7005],{"type":28,"value":6357},{"type":23,"tag":179,"props":7007,"children":7008},{},[7009,7011,7016,7017,7022,7023],{"type":28,"value":7010},"Holst JJ. ",{"type":23,"tag":162,"props":7012,"children":7013},{},[7014],{"type":28,"value":7015},"GLP-1 physiology in obesity and incretin-based drugs.",{"type":28,"value":2083},{"type":23,"tag":664,"props":7018,"children":7019},{},[7020],{"type":28,"value":7021},"Nature Metabolism",{"type":28,"value":6384},{"type":23,"tag":273,"props":7024,"children":7026},{"href":5811,"rel":7025},[479],[7027],{"type":28,"value":6357},{"type":23,"tag":179,"props":7029,"children":7030},{},[7031,7033,7038,7039,7044,7045],{"type":28,"value":7032},"Nauck MA, et al. ",{"type":23,"tag":162,"props":7034,"children":7035},{},[7036],{"type":28,"value":7037},"The evolving story of incretins (GIP and GLP-1).",{"type":28,"value":2083},{"type":23,"tag":664,"props":7040,"children":7041},{},[7042],{"type":28,"value":7043},"Diabetes Obes Metab",{"type":28,"value":6979},{"type":23,"tag":273,"props":7046,"children":7048},{"href":5819,"rel":7047},[479],[7049],{"type":28,"value":6808},{"type":23,"tag":179,"props":7051,"children":7052},{},[7053,7055,7060,7062],{"type":28,"value":7054},"California Board of Chiropractic Examiners. ",{"type":23,"tag":162,"props":7056,"children":7057},{},[7058],{"type":28,"value":7059},"Meeting materials, 29 Oct 2020",{"type":28,"value":7061}," (licence DC 29377, revoked 8 Jul 2020). ",{"type":23,"tag":273,"props":7063,"children":7065},{"href":4978,"rel":7064},[479],[7066],{"type":28,"value":7067},"PDF",{"type":23,"tag":179,"props":7069,"children":7070},{},[7071,7072,7077,7078],{"type":28,"value":7054},{"type":23,"tag":162,"props":7073,"children":7074},{},[7075],{"type":28,"value":7076},"Final Disciplinary Actions.",{"type":28,"value":2083},{"type":23,"tag":273,"props":7079,"children":7081},{"href":5183,"rel":7080},[479],[7082],{"type":28,"value":7083},"Page",{"type":23,"tag":179,"props":7085,"children":7086},{},[7087,7089,7094,7095],{"type":28,"value":7088},"California Department of Consumer Affairs. ",{"type":23,"tag":162,"props":7090,"children":7091},{},[7092],{"type":28,"value":7093},"License Search.",{"type":28,"value":2083},{"type":23,"tag":273,"props":7096,"children":7098},{"href":5192,"rel":7097},[479],[7099],{"type":28,"value":7100},"Lookup",{"type":23,"tag":179,"props":7102,"children":7103},{},[7104,7106,7111,7112],{"type":28,"value":7105},"EliteBiogenix. ",{"type":23,"tag":162,"props":7107,"children":7108},{},[7109],{"type":28,"value":7110},"Research peptides and SARMs vendor (in-vitro research only).",{"type":28,"value":2083},{"type":23,"tag":273,"props":7113,"children":7115},{"href":4987,"rel":7114},[479],[7116],{"type":28,"value":7117},"Site",{"type":23,"tag":179,"props":7119,"children":7120},{},[7121,7123,7128,7129,7134,7135],{"type":28,"value":7122},"Bachmeyer T. ",{"type":23,"tag":162,"props":7124,"children":7125},{},[7126],{"type":28,"value":7127},"\"Mega Dosing vs Micro Dosing Retatrutide: Which Damages Your Liver More?\"",{"type":28,"value":2083},{"type":23,"tag":664,"props":7130,"children":7131},{},[7132],{"type":28,"value":7133},"YouTube.",{"type":28,"value":2083},{"type":23,"tag":273,"props":7136,"children":7139},{"href":7137,"rel":7138},"https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=gb-XEtsMr-w",[479],[7140],{"type":28,"value":7141},"Video",{"title":8,"searchDepth":556,"depth":556,"links":7143},[7144,7145,7146,7147,7148,7149,7150,7151,7152,7153,7154,7155,7156,7157,7158,7159,7160,7161,7162],{"id":3144,"depth":556,"text":3144},{"id":5132,"depth":556,"text":5132},{"id":5220,"depth":556,"text":5223},{"id":5277,"depth":556,"text":5280},{"id":5358,"depth":556,"text":5361},{"id":5455,"depth":556,"text":5458},{"id":5500,"depth":556,"text":5500},{"id":5553,"depth":556,"text":5553},{"id":5572,"depth":556,"text":5572},{"id":5582,"depth":556,"text":5585},{"id":5629,"depth":556,"text":5629},{"id":5690,"depth":556,"text":5693},{"id":5769,"depth":556,"text":5772},{"id":6100,"depth":556,"text":6103},{"id":6172,"depth":556,"text":6175},{"id":6215,"depth":556,"text":6218},{"id":6253,"depth":556,"text":6256},{"id":6273,"depth":556,"text":6273},{"id":6328,"depth":556,"text":6328},"content:blog:zh:retatrutide-liver-damage-myths.md","blog\u002Fzh\u002Fretatrutide-liver-damage-myths.md","blog\u002Fzh\u002Fretatrutide-liver-damage-myths",{"_path":7167,"_dir":6,"_draft":7,"_partial":7,"_locale":8,"title":7168,"description":8,"cat":7169,"icon":7170,"accent":7171,"date":7172,"dateLabel":7173,"updated":7174,"read":7175,"author":17,"image":7176,"faq":7177,"body":7187,"_type":568,"_id":7383,"_source":570,"_file":7384,"_stem":7385,"_extension":573},"\u002Fblog\u002Fzh\u002Frecovery-duo","BPC-157 与 TB-500：它们是什么，处于什么状态","化合物","tabler:file-description","#4CAF50","2026-06-05","2026年6月5日","2026-09-04","3 分钟阅读","\u002Fassets\u002Fbpc157_tb500_status_hero.png",[7178,7181,7184],{"q":7179,"a":7180},"BPC-157 和 TB-500 是什么？","BPC-157 是一种由 15 个氨基酸构成的人工合成肽，序列取自胃液中发现的一段结构；TB-500 是胸腺素 β4 的人工合成片段。两者都不是获批药物。",{"q":7182,"a":7183},"BPC-157 和 TB-500 在体育运动中被禁用吗？","两者在任何时候都被禁用，不只是在赛内。BPC-157 归入 S0，也就是收纳「尚无任何人用治疗用途监管批准」之物质的那一类，2026 年版清单在该类的举例中点了它的名；胸腺素 β4 及其衍生物则被明确列在 S2.3（生长因子）之下，TB-500 就在其中。",{"q":7185,"a":7186},"BPC-157 的法律地位是怎样的？","它在美国、欧盟和澳大利亚都不是获批药物；澳大利亚将其列入《毒物标准》附表 4，即凭处方供应。持有和使用是否合法，取决于你所在地的法律。",{"type":20,"children":7188,"toc":7371},[7189,7197,7202,7207,7212,7217,7229,7234,7239,7256,7261,7267,7271,7276,7280,7285,7289,7293],{"type":23,"tag":4852,"props":7190,"children":7191},{},[7192],{"type":23,"tag":24,"props":7193,"children":7194},{},[7195],{"type":28,"value":7196},"本文仅为一般性信息——不构成医疗建议，不是给药或使用建议，也不是在建议谁去获取或使用任何物质。这两种肽都不是获批药物；在澳大利亚，BPC-157 属于凭处方供应。持有和使用是否合法，取决于你所在国家的法律，责任也在你自己。健康方面的问题，请咨询有执业资格的医生或药师。",{"type":23,"tag":24,"props":7198,"children":7199},{},[7200],{"type":28,"value":7201},"这两个名字几乎从不单独出现，久而久之，人们很容易把它们当成同一样东西。下面是一份中立的梳理：各自是什么、研究做到了哪一步、如今处于什么状态。",{"type":23,"tag":35,"props":7203,"children":7205},{"id":7204},"两者各自是什么",[7206],{"type":28,"value":7204},{"type":23,"tag":24,"props":7208,"children":7209},{},[7210],{"type":28,"value":7211},"BPC-157 是一种人工合成的十五肽，由 15 个氨基酸串成，其序列取自胃液中发现的一段结构。TB-500 则是胸腺素 β4 的人工合成片段——胸腺素 β4 是一种蛋白，文献里常把它与肌动蛋白结合、细胞迁移联系在一起。把两者绑成一对，是网络讨论养出来的习惯，而不是药理学上的分类。",{"type":23,"tag":35,"props":7213,"children":7215},{"id":7214},"研究做到了哪一步",[7216],{"type":28,"value":7214},{"type":23,"tag":24,"props":7218,"children":7219},{},[7220,7222,7227],{"type":28,"value":7221},"两者的研究几乎全部停在临床前阶段：细胞培养和动物模型。公开的临床试验注册平台上，BPC-157 没有一项已完成的人体疗效对照试验；围绕胸腺素 β4 衍生物登记在案的人体研究也很有限。2026 年，FDA 的审评科学家在梳理证据后报告说，关于 BPC-157，他们基本上只找到一篇小型试验的摘要——受试者约 46 人，而且给药方式并非注射；同一份审评还指出，免疫原性，也就是身体对注射进来的肽产生免疫反应的可能，在这一类物质上大体尚未评估。这份审评的细节，写在我们对 ",{"type":23,"tag":273,"props":7223,"children":7224},{"href":2258},[7225],{"type":28,"value":7226},"503A 那场投票",{"type":28,"value":7228},"的解读里。",{"type":23,"tag":35,"props":7230,"children":7232},{"id":7231},"监管地位与反兴奋剂状态",[7233],{"type":28,"value":7231},{"type":23,"tag":24,"props":7235,"children":7236},{},[7237],{"type":28,"value":7238},"在美国、欧盟和澳大利亚，两者都不是获批药物；澳大利亚的《毒物标准》把 BPC-157 列入附表 4，即凭处方供应。在体育领域，两者在任何时候都被禁用，不只是在赛内：BPC-157 归入 S0——世界反兴奋剂机构《禁用清单》中专门收纳「尚无任何人用治疗用途监管批准」之物质的那一类，2026 年版在该类的举例里点了它的名；胸腺素 β4 及其衍生物则被明确写在 S2.3（生长因子）之下，TB-500 就在其中。",{"type":23,"tag":24,"props":7240,"children":7241},{},[7242,7244,7249,7251,7255],{"type":28,"value":7243},"在美国，FDA 的审评科学家对受审的全部七种肽都给出了否定意见；2026 年 7 月 23 日，药房配制咨询委员会逐个品种投票，建议把 BPC-157 和 TB-500 纳入 503A 条款清单，两次的票型都是 8 票赞成、6 票反对、1 票弃权。所谓 503A 条款清单，是一份原料药清单：一种原料药必须先列入其中，药房才可以用它配制。委员会的投票是一项建议，不是批准。更大的图景：",{"type":23,"tag":273,"props":7245,"children":7246},{"href":1625},[7247],{"type":28,"value":7248},"附批准状态的肽类清单",{"type":28,"value":7250},"，以及",{"type":23,"tag":273,"props":7252,"children":7253},{"href":1580},[7254],{"type":28,"value":3583},{"type":28,"value":370},{"type":23,"tag":35,"props":7257,"children":7259},{"id":7258},"常见问题",[7260],{"type":28,"value":7258},{"type":23,"tag":7262,"props":7263,"children":7265},"h3",{"id":7264},"bpc-157-和-tb-500-是什么",[7266],{"type":28,"value":7179},{"type":23,"tag":24,"props":7268,"children":7269},{},[7270],{"type":28,"value":7180},{"type":23,"tag":7262,"props":7272,"children":7274},{"id":7273},"bpc-157-和-tb-500-在体育运动中被禁用吗",[7275],{"type":28,"value":7182},{"type":23,"tag":24,"props":7277,"children":7278},{},[7279],{"type":28,"value":7183},{"type":23,"tag":7262,"props":7281,"children":7283},{"id":7282},"bpc-157-的法律地位是怎样的",[7284],{"type":28,"value":7185},{"type":23,"tag":24,"props":7286,"children":7287},{},[7288],{"type":28,"value":7186},{"type":23,"tag":35,"props":7290,"children":7291},{"id":464},[7292],{"type":28,"value":464},{"type":23,"tag":175,"props":7294,"children":7295},{},[7296,7310,7324,7337,7349],{"type":23,"tag":179,"props":7297,"children":7298},{},[7299,7301,7308],{"type":28,"value":7300},"WADA，",{"type":23,"tag":273,"props":7302,"children":7305},{"href":7303,"rel":7304},"https:\u002F\u002Fwww.wada-ama.org\u002Fen\u002Fprohibited-list",[479],[7306],{"type":28,"value":7307},"禁用清单",{"type":28,"value":7309},"——S0（未获批准的物质）在举例中点名 BPC-157；S2.3（生长因子）列出胸腺素 β4 及其衍生物，例如 TB-500",{"type":23,"tag":179,"props":7311,"children":7312},{},[7313,7315,7322],{"type":28,"value":7314},"TGA，",{"type":23,"tag":273,"props":7316,"children":7319},{"href":7317,"rel":7318},"https:\u002F\u002Fwww.tga.gov.au\u002Fproducts\u002Funapproved-therapeutic-goods\u002Fpoisons-standard-susmp",[479],[7320],{"type":28,"value":7321},"毒物标准（SUSMP）",{"type":28,"value":7323},"——BPC-157 列于附表 4",{"type":23,"tag":179,"props":7325,"children":7326},{},[7327,7328,7335],{"type":28,"value":3671},{"type":23,"tag":273,"props":7329,"children":7332},{"href":7330,"rel":7331},"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Fbulk-drug-substances-used-compounding-under-section-503a-fdc-act",[479],[7333],{"type":28,"value":7334},"503A 条款下用于配制的原料药",{"type":28,"value":7336},"——针对被提名用于配制之原料药的过渡期政策",{"type":23,"tag":179,"props":7338,"children":7339},{},[7340,7341,7347],{"type":28,"value":3671},{"type":23,"tag":273,"props":7342,"children":7344},{"href":3674,"rel":7343},[479],[7345],{"type":28,"value":7346},"药房配制咨询委员会会议，2026 年 7 月 23–24 日",{"type":28,"value":7348},"——对 BPC-157、KPV、TB-500 和 MOTS-c 的投票",{"type":23,"tag":179,"props":7350,"children":7351},{},[7352,7354,7360,7362,7369],{"type":28,"value":7353},"ClinicalTrials.gov，针对 ",{"type":23,"tag":273,"props":7355,"children":7358},{"href":7356,"rel":7357},"https:\u002F\u002Fclinicaltrials.gov\u002Fsearch?intr=BPC-157",[479],[7359],{"type":28,"value":2253},{"type":28,"value":7361}," 与",{"type":23,"tag":273,"props":7363,"children":7366},{"href":7364,"rel":7365},"https:\u002F\u002Fclinicaltrials.gov\u002Fsearch?intr=Thymosin+beta-4",[479],[7367],{"type":28,"value":7368},"胸腺素 β4",{"type":28,"value":7370},"的注册平台检索",{"title":8,"searchDepth":556,"depth":556,"links":7372},[7373,7374,7375,7376,7382],{"id":7204,"depth":556,"text":7204},{"id":7214,"depth":556,"text":7214},{"id":7231,"depth":556,"text":7231},{"id":7258,"depth":556,"text":7258,"children":7377},[7378,7380,7381],{"id":7264,"depth":7379,"text":7179},3,{"id":7273,"depth":7379,"text":7182},{"id":7282,"depth":7379,"text":7185},{"id":464,"depth":556,"text":464},"content:blog:zh:recovery-duo.md","blog\u002Fzh\u002Frecovery-duo.md","blog\u002Fzh\u002Frecovery-duo"]